0001493152-23-028259.txt : 20230814 0001493152-23-028259.hdr.sgml : 20230814 20230814140953 ACCESSION NUMBER: 0001493152-23-028259 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230814 DATE AS OF CHANGE: 20230814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NovelStem International Corp. CENTRAL INDEX KEY: 0000912544 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-RETAIL STORES, NEC [5990] IRS NUMBER: 650385686 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14332 FILM NUMBER: 231168539 BUSINESS ADDRESS: STREET 1: 2255 GLADES RD STREET 2: STE 237 W CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 5619988000 MAIL ADDRESS: STREET 1: 2255 GLADES RD STREET 2: STE 237 W CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: NovelStem International Corp DATE OF NAME CHANGE: 20220802 FORMER COMPANY: FORMER CONFORMED NAME: HOLLYWOOD MEDIA CORP DATE OF NAME CHANGE: 20001215 FORMER COMPANY: FORMER CONFORMED NAME: HOLLYWOOD COM INC DATE OF NAME CHANGE: 20000511 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________ to _________________

Commission file number: 001-14322

NOVELSTEM INTERNATIONAL CORP.

(Exact name of registrant as specified in its charter)

Florida

65-0385686

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

2255 Glades Road, Suite 221A, Boca Raton, FL		33431
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code

(410) 598-9024

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filed, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer  ☒	Smaller reporting company  ☒
	Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at August 14, 2023
Common Stock, $0.01 par value per share		46,881,475

NOVELSTEM INTERNATIONAL CORP.

Quarterly Report on Form 10-Q

for the Quarterly Period Ended June 30, 2023

TABLE OF CONTENTS

	PAGE

Part I Financial Information

Item 1. Financial Statements:

Condensed Balance Sheets as of June 30, 2023 (unaudited) and December 31, 2022	3

Condensed Statements of Operations (unaudited) for the three and six months ended June 30, 2023 and 2022	4

Condensed Statements of Changes in Shareholders’ Equity (Deficit) (unaudited) for the three and six months ended June 30, 2023 and 2022	5

Condensed Statements of Cash Flows (unaudited) for the six months ended June 30, 2023 and 2022	6

Notes to Condensed Financial Statements	7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3. Quantitative and Qualitative Disclosures About Market Risk	17

Item 4. Controls and Procedures	17

Part II Other Information

Item 1. Legal Proceedings	17

Item 1A. Risk Factors	17

Item 6. Exhibits	17

Signatures	18

PART I

ITEM 1. UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOVELSTEM INTERNATIONAL CORP.

CONDENSED BALANCE SHEETS

	June 30,			December 31,
	As of
	June 30,			December 31,
	2023			2022
	(Unaudited)

ASSETS
Current assets:
Cash	$	34,325		$	6,346
Accounts receivable, administrative fees		-			12,000
Prepaid expenses		26,067			40,561
Total current assets		60,392			58,907
Investment in Netco Partners		137,011			137,011
Investment in NewStem Ltd		1,905,264			2,090,286
Total assets	$	2,102,667		$	2,286,204

LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	17,098		$	21,203
Current portion of long-term notes payable		962,464			-
Accrued expenses		92,650			43,673
Total current liabilities		1,072,212			64,876
Long-term liabilities:
Long-term notes payable, including accrued interest, net		1,761,004			288,450
Derivative liability, guarantee		204,795			-
Total long-term liabilities		1,965,799			288,450
Total liabilities		3,038,011			353,326
Commitments and contingencies (see Note 7)		-			-
Shareholders’ (deficit) equity:
Common stock, $.01 par value, 100,000,000 shares authorized, 50,316,672 shares issued, and 46,881,475 shares outstanding as of June 30, 2023 and December 31, 2022		468,815			468,815
Additional paid-in capital		290,879,686			290,604,327
Accumulated deficit		(292,084,091	)		(288,940,510	)
Treasury stock, at cost, 3,435,197 shares as of June 30, 2023 and December 31, 2022		(199,754	)		(199,754	)
Total shareholders’ (deficit) equity		(935,344	)		1,932,878
Total liabilities and shareholders’ equity (deficit)	$	2,102,667		$	2,286,204

The accompanying notes are an integral part of these condensed financial statements.

NOVELSTEM INTERNATIONAL CORP.

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

	2023			2022			2023			2022
	Six Months Ended						Three Months Ended
	June 30,						June 30,
	2023			2022			2023			2022

Operating expenses:
General and administrative expenses	$	551,153		$	368,531		$	386,361		$	229,575
Litigation expenses (contra expenses) (Note 7)		2,332,663			(310,000	)		2,332,663			-
Total operating expenses		2,883,816			58,531			2,719,024			229,575
Loss from operations		(2,883,816	)		(58,531	)		(2,719,024	)		(229,575	)
Other expenses:
Loss on derivative instrument		54,795			-			54,795			-
Interest expense		27,823			2,012			20,510			407
Total other expenses		82,618			2,012			75,305			407
Loss before income taxes		(2,966,434	)		(60,543	)		(2,794,329	)		(229,982	)
Provision for income tax		-			-			-			-
Loss before equity in net income of equity method investees		(2,966,434	)		(60,543	)		(2,794,329	)		(229,982	)
Equity in net loss of equity method investees		(177,147	)		(326,256	)		(80,431	)		60,647
Net loss	$	(3,143,581	)	$	(386,799	)	$	(2,874,760	)	$	(169,335	)

Basic and diluted net loss per share:
Net loss per share - basic and diluted	$	(0.07	)	$	(0.01	)	$	(0.06	)	$	-
Weighted average number of shares outstanding - basic and diluted		46,881,475			46,881,475			46,881,475			46,881,475

The accompanying notes are an integral part of these unaudited condensed financial statements.

NOVELSTEM INTERNATIONAL CORP.

CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY (DEFICIT)

(UNAUDITED)

	Shares		Stock		Capital		Deficit			Shares		Stock			Equity
	Number of		Common		Additional Paid-In		Accumulated			Number of Treasury		Treasury			Total Shareholders’ Equity
	Shares		Stock		Capital		Deficit			Shares		Stock			(Deficit)

Balance, January 1, 2023		46,881,475	$	468,815	$	290,604,327	$	(288,940,510	)		3,435,197	$	(199,754	)	$	1,932,878
Net loss		-		-		-		(268,821	)		-		-			(268,821	)
Stock option compensation		-		-		15,077		-			-		-			15,077

Balance, March 31, 2023		46,881,475	$	468,815	$	290,619,404	$	(289,209,331	)		3,435,197	$	(199,754	)	$	1,679,134
Net loss		-		-		-		(2,874,760	)		-		-			(2,874,760	)
Stock option compensation		-		-		260,282		-			-		-			260,282

Balance, June 30, 2023		46,881,475	$	468,815	$	290,879,686	$	(292,084,091	)		3,435,197	$	(199,754	)	$	(935,344	)

					Additional					Number of					Total
	Number of		Common		Paid-In		Accumulated			Treasury		Treasury			Shareholders’
	Shares		Stock		Capital		Deficit			Shares		Stock			Equity

Balance, January 1, 2022		46,881,475	$	468,815	$	290,321,665	$	(288,174,780	)		3,435,197	$	(199,754	)	$	2,415,946
Net loss		-		-		-		(217,464	)		-		-			(217,464	)
Stock option compensation		-		-		49,011		-			-		-			49,011

Balance, March 31, 2022		46,881,475	$	468,815	$	290,370,676	$	(288,392,244	)		3,435,197	$	(199,754	)	$	2,247,493
Net loss		-		-		-		(169,335	)		-		-			(169,335	)
Stock option compensation		-		-		74,333		-			-		-			74,333

Balance, June 30, 2022		46,881,475	$	468,815	$	290,445,009	$	(288,561,579	)		3,435,197	$	(199,754	)	$	2,152,491

The accompanying notes are an integral part of these condensed financial statements.

NOVELSTEM INTERNATIONAL CORP.

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	2023			2022
	Six Months Ended
	June 30,
	2023			2022

Cash flows from operating activities:
Net loss	$	(3,143,581	)	$	(386,799	)
Equity in loss of equity method investees		177,147			326,256
Distribution from NetCo Partners		7,875			-
Accretion of discount on note payable		11,507			-
Loss on derivative instrument		54,795			-
Legal fees and litigation funding fees funded by litigation funding agreement		2,332,663			-
Accrued interest added to long-term note payable		15,848			-
Stock-based compensation		275,359			123,344
Change in operating assets and liabilities:
Accounts receivable, administrative fees		12,000			-
Prepaid expenses		14,494			(1,173	)
Accounts payable		(4,105	)		(40,397	)
Accrued expenses		48,977			49,248
Net cash (used in) provided by operating activities		(197,021	)		70,479

Cash flows from financing activities:
Repayment of short term note payable		-			(100,000	)
Proceeds from long term notes payable		225,000			100,000
Net cash from financing activities		225,000			-

Net change in cash		27,979			70,479
Cash at the beginning of the period		6,346			8,666
Cash at the end of the period	$	34,325		$	79,145

Supplemental cash flow information:
Cash paid during the period for:
Interest	$	468		$	7,764

The accompanying notes are an integral part of these condensed financial statements.

NOVELSTEM INTERNATIONAL CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1—NATURE OF OPERATIONS

Description of Business

NovelStem International Corp. (“NovelStem” or the “Company”) is a holding company whose principal assets are a 30.58% equity interest in NewStem Ltd, an Israeli biotech company (“NewStem”), and a 50% equity interest in NetCo Partners (“NetCo”). NovelStem was formerly known as Hollywood Media Corp. The Company was incorporated in the State of Florida on January 22, 1993 and changed its name to NovelStem International Corp. in September 2018 as a result of its business focus shift from a media business to biotech.

NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is collaborating with life sciences companies for the development of drugs and reagents. NetCo is a legacy media business interest which owns “Net Force”, a book publishing franchise.

Going Concern, Liquidity and Management’s Plans

Management believes the accompanying condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern. Since inception, the Company has accumulated a deficit of approximately $292,000,000. The accumulated deficit of the Company subsequent to its business focus shift and name change in September 2018 is approximately $5,400,000 which is comprised primarily of allocated losses from equity method investments and general and administrative costs incurred by the Company.

The Company will need to obtain additional funds to continue its operations. Management’s plans with regard to these matters include additional financing and fundraising until its equity investment in NewStem is profitable. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that NewStem will become profitable.

The Company has in place a financing agreement with related parties to borrow up to $600,000 for working capital needs (see Note 4). Additionally, in May 2023, the Company entered into a financing agreement with a shareholder to borrow $300,000 consisting of advances of $150,000 in May 2023 and $150,000 in October 2023 (see Note 9). Following this financing, the Company believes that its cash resources are sufficient for the operations of the Company until April 2024.

In view of the matters described above, the Company’s ability to meet financing requirements is dependent upon the ability to complete additional fundraising or obtain additional financing, and/or monetize its investment in NetCo, along with NewStem continuing as a going concern. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.

The accompanying unaudited condensed financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed financial statements have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 31, 2023, from which the Company derived the balance sheet data at December 31, 2022.

Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations for interim reporting. The Company believes that the disclosures contained herein are adequate to make the information presented not misleading.

Equity Investments

Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an investee depends on an evaluation of several factors, including, among others, representation on the investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the investee company. Under the equity method of accounting, an investee company’s accounts are not reflected within the Company’s balance sheets or statements of operations; however, the Company’s share of the earnings or losses of the investee company is reflected in the caption “Equity in net income (loss) of investee company” in the statements of operations. The Company’s carrying value in an equity method investee company is reflected in the caption “Investment in investee company’ in the Company’s balance sheets.

The Company reviews equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable.

The Company holds a minority investment in an entity, NewStem, which is accounted for pursuant to the equity method of accounting. Additionally, the Company is a 50% partner in NetCo (which is accounted for pursuant to the equity method of accounting). See Note 3.

Basic and Diluted Net Loss Per Share

Basic net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding during the period, excluding treasury stock. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding plus the dilutive potential of common shares which would result from the exercise of stock options and warrants. The dilutive effects of stock options and warrants are excluded from the computation of diluted net income (loss) per share if the effect of doing so would be antidilutive.

The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited):

	2023			2022			2023			2022
	Six Months Ended June 30,						Three Months Ended June 30,
	2023			2022			2023			2022
Net loss available to common shareholders	$	(3,143,581	)	$	(386,799	)	$	(2,874,760	)	$	(169,335	)

Weighted average shares outstanding:
-Basic		46,881,475			46,881,475			46,881,475			46,881,475
Add: Warrants		-			-			-			-
Add: Stock options		-			-			-			-
-Diluted		46,881,475			46,881,475			46,881,475			46,881,475

Basic and diluted net loss per share	$	(0.07	)	$	(0.01	)	$	(0.06	)	$	(-	)

Warrants and stock options excluded from the above calculations are as follows:

SCHEDULE OF WARRANTS AND STOCK OPTIONS

	2023		2022		2023		2022
	Six Months Ended June 30,				Three Months Ended March 31,
	2023		2022		2023		2022
Warrants		3,000,000		3,000,000		3,000,000		3,000,000
Stock options		5,760,000		5,400,000		5,760,000		5,400,000

NOTE 3—EQUITY METHOD INVESTMENTS

Investment in NewStem

In 2018, the Company entered into a Share Purchase Agreement with NewStem and other related parties to provide aggregate funding of up to $4,000,000 to NewStem. This funding was to be provided through the sale of up to 50,000 common shares of NewStem to the Company representing 33% of New Stem’s outstanding shares. In 2018, the Company purchased 25,000 shares of NewStem for $2,000,000 acquiring an ownership interest of 20%. The Company made additional investments in 2019 and 2020 purchasing 12,500 shares each year for a $1,000,000 investment each year. NewStem sold and issued shares to third party investors in 2021 and 2022 resulting in the Company recognizing a gain on dilution of equity method investment. These transactions resulted in the Company having an ownership interest of 30.58% as of June 30, 2023 and December 31, 2022.

The Company accounts for its investment in NewStem under the equity method. At June 30, 2023 and December 31, 2022, the carrying value of the investment in NewStem exceeded the underlying net assets of NewStem by $1,905,264 and $2,090,286, respectively. The excess relates to identified intangible assets including license agreements, specialized work force (goodwill) and two separate projects of in process research and development (“IPR&D”) related to stem cell-based diagnostics and therapeutics for cancer chemotherapies.

NewStem is in the development stage and has incurred losses since its inception and has yet to generate revenues sufficient to support operations. NewStem will need to obtain additional funds to continue its operations. NewStem management’s plans with regard to these matters include continued development, marketing, and licensing of its products, as well as seeking additional financing arrangements. Although NewStem’s management continues to pursue these plans, there is no assurance that the NewStem will be successful in obtaining sufficient cash from sales of products or financing on terms acceptable to NewStem’s management. NewStem obtained additional funding of approximately $1,450,000 in 2022 through the sale of shares of ordinary stock.

The following table represents the Company’s investment in NewStem:

SCHEDULE OF INVESTMENTS

	Six Months Ended June 30, 2023			Year Ended December 31, 2022
	(Unaudited)
Investment in NewStem, beginning	$	2,090,286		$	2,435,155
Allocation of net loss from NewStem, Ltd.		(185,022	)		(732,393	)
Gain on dilution of equity method investment		-			387,524
Investment in NewStem, ending	$	1,905,264		$	2,090,286

The results of operations of the Company’s investment in NewStem is summarized below (unaudited):

	2023			2022			2023			2022
	Six Months Ended June 30,						Three Months Ended June 30,
	2023			2022			2023			2022
Condensed income statement information:
Net revenues	$	95,000		$	-		$	95,000		$	-
Gross margin	$	84,000		$	-		$	84,000		$	-
Net loss	$	(605,000	)	$	(1,659,000	)	$	(342,000	)	$	(431,000	)
Company’s allocation of net loss from NewStem, Ltd.	$	(185,022	)	$	(326,256	)	$	(80,431	)	$	(60,647	)

The financial position of the Company’s investment in NewStem is summarized below:

	June 30,		December 31,
	As of
	June 30,		December 31,
	2023		2022
	(Unaudited)
Condensed balance sheet information:
Current assets	$	444,000	$	911,000
Non-current assets	$	15,000	$	23,000
Current liabilities	$	76,000	$	97,000
Non-current liabilities	$	126,000	$	121,000

Investment in NetCo

NovelStem owns a 50% interest in NetCo, a joint venture that owns the Net Force publishing franchise. The Company accounts for its investment in NetCo under the equity method and recognizes nominal royalties from this arrangement. The Company assesses its investment in NetCo for impairment on an annual basis.

The following table represents the Company’s investment in NetCo:

SCHEDULE OF INVESTMENTS

	Six Months Ended June 30, 2023			Year Ended December 31, 2022
		(Unaudited)
Investment in NetCo, beginning	$	137,011		$	137,011
Allocation of net income from NetCo		7,875			12,591
Distribution from NetCo		(7,875	)		(12,591	)
Investment in NetCo, ending	$	137,011		$	137,011

The results of operations of the Company’s investment in NetCo is summarized below (unaudited):

	2023		2022		2023		2022
	Six Months Ended June 30,				Three Months Ended June 30,
	2023		2022		2023		2022
Condensed income statement information:
Net sales	$	15,750	$	-	$	-	$	-
Gross margin	$	15,750	$	-	$	-	$	-
Net income	$	15,750	$	-	$	-	$	-
Net income (loss)	$	15,750	$	-	$	-	$	-
Company’s allocation of net income from NetCo	$	7,875	$	-	$	-	$	-

The financial position of the Company’s investment in NetCo is summarized below:

	June 30,		December 31,
	As of
	June 30,		December 31,
	2023		2022
	(Unaudited)
Condensed balance sheet information:
Current assets	$	4,197	$	13,475
Non-current assets	$	272,799	$	272,799
Current liabilities	$	2,974	$	12,252
Non-current liabilities	$	-	$	-

NOTE 4—NOTES PAYABLE

Notes payable are summarized as follows:

SCHEDULE OF NOTES PAYABLE

	As of
	June 30,			December 31,
	2023			2022
	(Unaudited)
Notes payable related parties:
Notes payable director and Executive Chairman	$	355,000		$	280,000
Accrued interest added to note balance		24,298			8,450
Total notes payable director and Executive Chairman		379,298			288,450
Note payable shareholder, principal amount		150,000			-
Less unamortized discount		(138,493	)		-
Total note payable shareholder		11,507			-
Note payable, litigation funding agreement:
Note payable Omni Bridgeway (Fund 4) Invt. 3 L.P.		2,332,663			-
Total notes payable		2,723,468			288,450
Less current portion		(962,464	)		-
Long-term notes payable	$	1,761,004		$	288,450

Notes Payable Related Parties

On April 12, 2021, the Company entered into a promissory note (the “Note”) with a related party (individual) for $100,000. The Note accrued interest at 8% per annum and matured on April 12, 2022. The proceeds of this Note were used to pay operating expenses of the Company. Interest expense related to this Note was $1,198 for the six months ended June 30, 2022. The Note and accrued interest of $6,752 were paid in full on February 16, 2022.

In May 2022, the Company entered into long-term notes payable in the form of finance agreements (the “Agreements”) with two individuals who are related parties, which were amended in July 2022, to borrow up to $600,000 for working capital needs. One of the individuals is a director and shareholder, the other is our Executive Chairman who is also a shareholder. These agreements provide for funding through January 31, 2024, provide for interest at a rate of 8% per annum through November 11, 2022, at which time the interest rate increased to 10% per annum for subsequent advances. The Agreements mature the earlier of January 31, 2024 or twenty months from the date of the first funded amount (May 2022) unless the shareholders agree to extend the due date at that time. The Company received advances of $355,000 and $280,000, respectively, pursuant to this agreement through June 30, 2023 and December 31, 2022. Interest expense related to the agreements was $15,847 and $8,768, respectively, for the six and three months ended June 30, 2023. Pursuant to the Agreements, accrued interest is added to the note balances.

On May 5, 2023, the Company entered into a long term note payable with a shareholder for $300,000 in financing to be funded $150,000 at inception and $150,000 no later than October 5, 2023. This note bears interest at zero percent (0%) and matures on May 5, 2025. The note includes a guarantee which has been identified as an embedded derivative with a fair value of a liability of $204,795 at June 30, 2023 which is reported separately on the condensed balance sheet. The fair value of the note exceeds the proceeds, and the note has been discounted at inception so that the net liability is the fair value of the derivative. Accretion of the note discount of $11,507 has been reflected as part of interest expense in the condensed statements of operations for the six and three months ended June 30, 2023.

Note Payable, Litigation Funding Agreement

On February 11, 2022, the Company entered into a nonrecourse litigation funding agreement (the “Agreement”) with Omni Bridgeway (Fund 4) Invt. 3 L.P. (“Omni”) related to an arbitration proceeding disclosed in Note 7. The Agreement provides for Omni to fund all costs related to the arbitration up to $1,000,000 in exchange for an assignment of a certain portion of rights to and interest in claims related to this arbitration. The agreement provides for specific calculations of the portion of any claims collected to be received by Omni with the remainder collectible by the Company. Additionally, the agreement provides for repayment of funded costs pursuant to the same multiple calculations in the event of a favorable outcome that does not include the collection of claims. During the six months ended June 30, 2022, the Company received $310,000 pursuant to this agreement for the reimbursement of legal costs and working capital expenditures, including previously incurred general and administrative costs.

During July 2023, the arbitration was settled with a favorable outcome for the Company. As a result of the favorable ruling disclosed in Note 7, the liability became probable and reasonably estimable, and the Company has recorded the full liability due to Omni as of June 30, 2023. This liability consists of expenses funded by Omni of $933,065, including $310,000 advanced for working capital, and related fees or investment return to Omni calculated as contractual multiples of funding totaling $1,399,598 as of June 30, 2023 for a total liability of $2,333,663. An additional fee or investment return of $466,533 is due to Omni effective August 11, 2023 as payment of the liability was not made by that date. This agreement bears interest at 5% per annum beginning January 2024 and is payable in four quarterly installments beginning April 4, 2024.

NOTE 5—EQUITY (DEFICIT)

(a) General

At June 30, 2023 and December 31, 2022, the Company had issued and outstanding 46,881,475 shares of its common stock, par value $0.01 per share. Holders of outstanding common stock are entitled to receive dividends when, as and if declared by the Board and to share ratably in the assets of the Company legally available for distribution in the event of a liquidation, dissolution or winding up of the Company.

(b) Summary Employee Option Information

The Company’s stock option plan provides for the grant to officers, directors, third party contractors and other future key employees of options to purchase shares of common stock. The purchase price may be paid in cash or, if the option is “in-the-money”, it is automatically exercised “net”. In a net exercise of an option, the Company does not require a payment of the exercise price of the option from the optionee but reduces the number of shares of common stock issued upon the exercise of the option by the smallest number of whole shares that has an aggregate fair market value equal to or in excess of the aggregate exercise price for the option shares covered by the option exercised. Each option is exercisable to one share of the Company’s common stock. Most options expire within six years from the date of the grant and generally vest on the first anniversary date of their issuance. Pursuant to the Equity Incentive Plan the Company’s board of directors approved on November 12, 2018, an aggregate of 5,760,000 options have been issued to directors and investor relations professionals.

The Company utilized the Black-Scholes option-pricing model to estimate fair value, utilizing the following assumptions for the respective periods (all in weighted averages):

	Six Months Ended June 30,
	2023			2022
Risk-free interest rate		3.5	%		1.5	%
Expected term of options, in years		4.0			3.9
Expected annual volatility		191.1	%		185.8	%
Expected dividend yield		0	%		0	%
Determined weighted average grant date fair value per option	$	0.19		$	0.27

The expected term of the options represents an estimate of the length of time until the expected date of exercising the options. Options granted have a maximum life of 7 years. With respect to determining expected exercise behavior, the Company has grouped its option grants into certain groups to track exercise behavior and establish historical rates. The Company estimated volatility by considering historical stock volatility over the expected term of the option. The risk-free interest rates are based on the U.S. Treasury yields for a period consistent with the expected term. The dividend yield of 0% is based on the Company’s history and expectation of dividend payout. The Company has not paid and does not anticipate paying dividends in the near future.

A summary of the Company’s option plans for the six months ended June 30, 2023, is presented below (unaudited):

SCHEDULE OF STOCK OPTION ACTIVITIES

	Number		Weighted
	of		Average
	Options		Exercise
	(in shares)		Price
Outstanding, December 31, 2022		5,400,000	$	0.14
Granted		360,000		0.20
Outstanding, June 30, 2023		5,760,000	$	0.14
Exercisable, June 30, 2023		5,400,000	$	0.14

Stock-based compensation expense related to stock options was approximately $32,000 and $15,000 in the six months and three months ended June 30, 2023, respectively. Stock-based compensation expense related to stock options was approximately $123,000 and $74,000 for the six months and three months ended June 30, 2022, respectively.

The total compensation cost related to non-vested awards not yet recognized was approximately $50,000 as of June 30, 2023. As of June 30, 2023, 360,000 options were unvested. These options vest one year from their grant date which is March 2024.

(d) Warrants

The Company has issued warrants at exercise prices equal to or greater than the market value of the Company’s common stock at the date of issuance. A summary of warrant activity follows (unaudited):

SUMMARY OF WARRANTS ACTIVITY

	Number of		Weighted
	shares		Average
	underlying		Exercise
	warrants		Price
Outstanding, December 31, 2022		3,000,000	$	0.12
Granted		-		-
Exercised		-		-
Forfeited or expired		-		-
Outstanding, June 30, 2023		3,000,000	$	0.12

The warrant agreements were amended on May 12, 2023 to extend the expiration date to June 28, 2025. The warrants outstanding at June 30, 2023 have a weighted average remaining contractual life of approximately two years. The Company recognized $243,000 in stock-based compensation expense related to the increase in fair value of warrants pursuant to the modification of the warrant term during the six and three months ended June 30, 2023.

NOTE 6—INCOME TAXES

The Company’s income tax provision differs from the expense that would result from applying statutory rates to income (loss) before taxes. A reconciliation of the provision (benefit) for income taxes with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows (unaudited):

SCHEDULE OF INCOME BEFORE INCOME TAX

	2023			2022
	Six Months Ended June 30,
	2023			2022
Computed tax at the federal statutory rate of 21%	$	(609,122	)	$	(81,073	)
State income taxes, net of federal income tax benefit		(126,030	)		(16,774	)
Change in federal valuation allowance		764,756			149,930
Foreign rate differential		(29,604	)		(52,083	)
Total provision for income tax	$	-		$	-

		2023			2022
		Three Months Ended June 30,
		2023			2022
Computed tax at the federal statutory rate of 21%	$	(56,452	)	$	(76,345	)
State income taxes, net of federal income tax benefit		(11,680	)		(15,796	)
Change in federal valuation allowance		87,972			154,045
Foreign rate differential		(19,840	)		(61,904	)
Total provision for income tax	$	-		$	-

NOTE 7—COMMITMENTS AND CONTINGENCIES

The Company was the claimant in an arbitration proceeding against their 50% partner in NetCo. The Company initiated the arbitration proceeding in an effort to maximize the total potential value to be derived from fully utilizing the NetCo intellectual property across publishing, entertainment, digital media, merchandising and other ancillary markets. Arbitration hearings were held at the end of July 2022. Arbitration proceedings for the joint owners of NetCo concluded during 2022 and the arbitrator rendered a decision in July 2023. The Arbitrator ruled in the Company’s favor on two key issues of the arbitration.

The Arbitrator ruled in NovelStem’s favor on the issue of contract interpretation of the Netco Partners JV Agreement. The Arbitrator also found that the Company’s joint venture partner failed to use “reasonable, good faith efforts” to license and exploit the Net Force concept, in breach of its contractual obligations under the Netco Partners’ Joint Venture Agreement. The Arbitrator confirmed NovelStem’s contractual right to use Tom Clancy’s name as a possessory credit in the Net Force title (Tom Clancy’s Net Force).

As a result of this ruling, the costs related to the litigation funding agreement disclosed in Note 4 were recognized. Total costs related to the litigation and the related litigation funding agreement of $2,332,663, including a reversal of the prior period contra expenses, were recorded in June 2023 and were separately stated in the condensed statement of operations (unaudited).

NOTE 8—SUBSEQUENT EVENTS

As disclosed in Note 4 and Note 7, in July 2023 the Company’s arbitration proceedings were settled with a favorable outcome. Additional costs of $466,533 related to the litigation funding agreement were incurred on August 11, 2023.

NOVELSTEM INTERNATIONAL CORP.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Statements in the following discussion and throughout this Form 10-Q that are not historical in nature are “forward-looking statements.” You can identify forward-looking statements by the use of words such as “expect,” “anticipate,” “estimate,” “may,” “will,” “should,” “intend,” “believe,” and similar expressions. Although we believe the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risk and we can give no assurances that our expectations will prove to be correct. Actual results could differ from those described in this Form 10-Q because of numerous factors, many of which are beyond our control. We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect actual outcomes.

Overview

We are a development stage company and reported net losses of approximately $3,144,000 and $387,000 for the six months ended June 30, 2023 and 2022 and approximately $2,875,000 and $169,000 for the three months ended June 30, 2023 and 2022, respectively. We had current assets of approximately $60,000 and current liabilities of $1,072,000 as of June 30, 2023. As of December 31, 2022, our current assets and current liabilities were approximately $59,000 and $65,000, respectively.

We have prepared our financial statements for the six and three months ended June 30, 2023 assuming that we will continue as a going concern. Our continuation as a going concern is dependent upon NewStem’s ability to successfully develop and commercialize its products, improving our profitability and the continuing financial support from our shareholders as well as our ability to utilize the NetCo intellectual property. Our sources of capital in the past have included the sale of equity securities, which include common stock sold in private transactions, large alternative minimum tax refunds, litigation funding and related party debt. We believe that our current financing resources are sufficient for the operations of the Company until April 2024.

NewStem is a development stage Israeli biotech limited liability company focused on pioneering intellectual property related to haploid human embryonic stem cells for the development of personalized diagnostics and therapeutics for genetic and epigenetic diseases. NewStem has incurred losses related to in process research and development since inception and the Company records our percentage allocation of these net losses as incurred. We have included the condensed financial statements of NewStem as an exhibit to this Form 10-Q.

RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes thereto and other financial information appearing elsewhere in this Form 10-Q. In the discussion below, general and administrative expenses are referred to as “G&A expenses”.

	Six Months Ended June 30,									Three Months Ended June 30,
	2023			2022			Change			2023			2022			Change
Operating expenses:
G&A expenses	$	551,153		$	368,531		$	182,622		$	386,361		$	229,575		$	156,786
Litigation expenses (contra expenses)		2,332,663			(310,000	)		2,642,663			2,332,663			-			2,332,663
Total operating expenses		2,883,816			58,531			2,825,285			2,719,024			229,575			2,489,449
Loss from operations		(2,883,816	)		(58,531	)		2,825,285			(2,719,024	)		(229,575	)		2,489,449
Other expenses:
Loss on derivative instrument		54,795			-			54,795			54,795			-			54,795
Interest expense		27,823			2,012			25,811			20,510			407			20,103
Total other expenses		82,618			2,012			80,606			75,305			407			74,898
Net loss before equity in net
loss of equity method investees		(2,966,434	)		(60,543	)		(2,905,891	)		(2,794,329	)		(229,982	)		(2,564,347	)
Equity in net loss of equity method investees		(177,147	)		(326,256	)		149,101			(80,431	)		(60,647	)		(141,078	)
Net loss	$	(3,143,581	)	$	(386,799	)	$	(2,756,782	)	$	(2,874,760	)	$	(169,335	)	$	(2,705,425	)

We are a holding company whose primary assets are our ownership of equity interests in NewStem and NetCo. We conduct no other business and as a result, we have no revenue or cost of revenue.

The Company incurs G&A expenses primarily related to professional fees and insurance. We incurred G&A expenses of approximately $551,000 and $369,000 for the six months ended June 30, 2023 and 2022, respectively. Specifically, the increase of approximately $183,000 is comprised of a reduction of nonrecurring professional fees related to the filing of our Form 10 in 2022 of approximately $60,000 combined with an increase in stock compensation expense related to a modification of our outstanding warrants as described below.

We incurred G&A expenses of approximately $386,000 and $229,000 for the three months ended June 30, 2023 and 2022, respectively. The increase in G&A expenses relates primarily an increase in stock compensation expense offset by a decrease in professional fees incurred in the previous period related to the filing of our Form 10 which are non-recurring. Specifically, professional fees decreased by approximately $86,000 in the three months ended June 30, 2023 as compared to the three months ended June 30, 2022. Stock compensation expense related to a modification of our outstanding warrants increased as described below, which when combined with the decrease in professional fees, comprises our increase in G&A expenses of approximately $157,000 for the three months ended June 30, 2023 compared to the three months ended June 30, 2022.

Total stock compensation expense, included in G&A expenses, increased by approximately $152,000 in the six months ended June 30, 2023 as compared to the six months ended June 30, 2022 due to a smaller number of options awarded in the current period as compared to the prior period offset by the recognition of $243,000 in stock compensation expense related to the increased value of our outstanding warrants due to the amendment of the agreements to extend the due date by two years.

Total stock compensation expense, included in G&A expenses, increased by approximately $186,000 in the three months ended June 30, 2023 as compared to the three months ended June 30, 2022 due to a smaller number of options awarded in the current period as compared to the prior period offset by the recognition of $243,000 in stock compensation expense related to the increased value of our outstanding warrants due to the amendment of the agreements to extend the due date by two years.

We incurred costs related to litigation and the litigation funding agreement involving our arbitration with our NetCo joint venture partner of approximately $2,333,000 for the six and three months ended June 30, 2023. We recognized contra expenses of $310,000 during the three months ended June 30, 2022 in relation to the same litigation and related litigation funding agreement. No related costs were incurred in the three months ended June 30, 2022. Specifically, the increase of approximately $2,643,000 is comprised of legal fees related to our NetCo arbitration including litigation funding fees due to Omni pursuant to the litigation funding agreement combined with the reversal of the contra expenses recognized in the previous period. These expenses and contra expenses were funded by a litigation funding agreement. This agreement was signed during the first quarter of 2022 with Omni Bridgeway to fund our arbitration against our 50% joint venture partner, C.P. Group. This is a nonrecourse agreement, and the Company had no obligation to repay any funds received under the agreement unless the NetCo arbitration resulted in a favorable outcome. These amounts are included in the note payable to Omni which was recorded in June 2023 as a result of the favorable arbitration ruling.

The Company has recorded a loss on derivative instrument of approximately $55,000 for the six and three months ended June 30, 2023 related to a guarantee included in the note payable shareholder entered into in May 2023. No such instrument was in effect in the six and three months ended June 30, 2022.

Interest expense increased by approximately $26,000 in the six months ended June 30, 2023 as compared to the six months ended June 30, 2022. The increases in interest expense are related to increased debt incurred for operations.

The Company has recorded no income tax expense as we have incurred operating losses and all deferred tax assets are fully offset by an income tax valuation allowance.

We reported net losses from equity method investees in all periods presented. The net losses reported for the six months ended June 30, 2023 included income of $7,875 from NetCo which was offset by net loss of $185,022 from NewStem. The net losses reported for the six months ended June 30, 2022 were fully comprised of net losses from NewStem.

The net losses from equity method investees reported for the three months ended June 30, 2023 and 2022 were fully comprised of net losses from NewStem.

Liquidity and Capital Resources

We have not paid dividends on our common stock since our name change and shift in business to biotech in September 2018. Our present policy is to apply cash to investments in product development at NewStem, acquisitions or expansion; consequently, we do not expect to pay dividends on common stock in the foreseeable future.

We expect to continue to incur greater expenses in the near future as we expand our business or enter into strategic partnerships. We expect our G&A expenses to remain consistent in the near term as we have expanded our finance and administrative staff and incurred additional costs related to being a reporting act company, including directors’ and officers’ insurance and increased professional fees, which should all now be normalized for our current operations.

In May 2022, the Company entered into an agreement with Jan Loeb, our Executive Chairman and Jerry Wolasky, a member of the Board, which was amended in July 2022, to borrow up to an aggregate of $600,000 for working capital needs. This agreement provides for funding through January 31, 2024, provides for interest at a rate of 8% per annum, increased to 10% per annum for advances subsequent to November 11, 2022, and matures the earlier of January 31, 2024 or twenty months from the date of the first funded amount unless the lenders agree to extend the due date at that time. As of the date of this Form 10-Q, the Company has drawn $355,000 pursuant to the aforementioned agreement.

On May 5, 2023 the Company entered into a financing agreement with a shareholder to borrow $300,000 consisting of advances of $150,000 in May 2023 and $150,000 in October 2023. This agreement bears no interest and matures May 5, 2025. The agreement includes a guarantee which has been identified as an embedded derivative with a fair value of a liability of $204,795 at June 30, 2023.

In July 2023 the Company received a favorable ruling on our arbitration related to NetCo, as such, the contingent litigation funding note payable became probable and reasonably estimable. A liability of approximately $2,333,000 was recorded for litigation costs funded by the agreement along with fees and investment return to Omni related to the litigation funding agreement (note payable). The ruling did not provide any claim recovery to the Company. This note is payable in four quarterly installments beginning April 2024. Management plans to work to maximize the potential of the NetCo assets based on the favorable arbitration ruling in order to service this debt and future operations.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

This section is not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Our Principal Executive Officer and Chief Financial Officer conducted an evaluation of our controls and procedures. We have identified material weaknesses in our internal control and procedures and internal control over financial reporting. If not remediated, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which could have a material adverse effect on our financial condition and the trading price of our common stock.

Maintaining effective internal control over financial reporting and effective disclosure controls and procedures are necessary for us to produce reliable financial statements. We have re-evaluated our internal control over financial reporting and our disclosure controls and procedures and concluded that they were not effective as of June 30, 2023 and we concluded there was a material weakness in the design of our internal control over financial reporting.

A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

The material weaknesses identified included insufficient resources to employ proper segregation of duties over the processing of transactions and financial reporting.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II

ITEM 1. LEGAL PROCEEDINGS

NetCo owns all rights in all media to the NetForce intellectual property including film, television, and video games. Consistent with our contractual and statutory rights, NovelStem is intent on commercially exploiting the full array of media rights relating to Net Force. We initiated an arbitration proceeding against our 50% partner in Netco, C.P. Group, in an effort to maximize the total potential value to be derived from fully utilizing the Netco intellectual property across video games, streaming, entertainment, digital media, merchandising and other ancillary markets. Arbitration proceedings for the joint owners of NetCo began in July 2022 and a ruling was issued in July 2023. To fund efforts to maximize the value of Netco, NovelStem has secured non-recourse litigation funding.

Arbitration proceedings for the joint owners of NetCo concluded during 2022 with final briefs being filed in January 2023. In July 2023 the Arbitrator ruled in NovelStem’s favor on the issue of contract interpretation of the Netco Partners JV Agreement. The Arbitrator also found that the Company’s joint venture partner failed to use “reasonable, good faith efforts” to license and exploit the Net Force concept, in breach of its contractual obligations under the Netco Partners’ Joint Venture Agreement. The Arbitrator confirmed NovelStem’s contractual right to use Tom Clancy’s name as a possessory credit in the Net Force title (Tom Clancy’s Net Force).

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

	(a)	Not applicable.

	(b)	Not applicable.

	(c)	Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

#31.1	Certification of Principal Executive Officer and Executive Chairman pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
#31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
#32.1	Certification of Principal Executive Officer and Executive Chairman pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
#32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
#33.1	Condensed Financial Statements of NewStem Ltd. as of and for the nine months ended June 30, 2023

#101.1 The following financial statements from NovelStem International Corp.’s Form 10-Q for the quarter ended June 30, 2023, filed on August 14, 2023, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Balance Sheets, (ii) Condensed Statements of Operations, (iii) Condensed Statements of Changes in Shareholders’ Equity, (iv) Condensed Statements of Cash Flows and (v) Notes to Condensed Financial Statements, tagged as blocks of text.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

#	This exhibit is filed or furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

	NOVELSTEM INTERNATIONAL CORP.

Date: August 14, 2023	By:	/s/ Jan Loeb
	Name:	Jan Loeb
	Title:	Executive Chairman

EX-31.1 2 ex31-1.htm

Exhibit 31.1

I, Jan H. Loeb, the Principal Executive Officer and Executive Chairman of NovelStem International Corp. certify that:

	1.	I have reviewed this report on Form 10-Q of NovelStem International Corp.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and l have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 14, 2023

By:	/s/ JAN H. LOEB
	Jan H Loeb
	Principal Executive Officer and Executive Chairman

EX-31.2 3 ex31-2.htm

Exhibit 31.2

I, Christine T. Jenkins, the Chief Financial Officer of NovelStem International Corp. certify that:

	1.	I have reviewed this report on Form 10-Q of NovelStem International Corp.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and l have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 14, 2023

	By:	/s/ CHRISTINE T. JENKINS
		Christine T. Jenkins
		Chief Financial Officer

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of NovelStem International Corp. (the “Company”) for the quarterly period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jan H. Loeb, Principal Executive Officer and Executive Chairman of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Jan H. Loeb
Jan H. Loeb
Principal Executive Officer and Executive Chairman
August 14, 2023

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of NovelStem International Corp. (the “Company”) for the quarterly period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christine T. Jenkins, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Christine T. Jenkins
Christine T. Jenkins
Chief Financial Officer
August 14, 2023

EX-33.1 6 ex33-1.htm

Exhibit 33.1

NewStem Ltd.

Condensed Interim Financial Statements

As of June 30, 2023

(Unaudited)

NewStem Ltd.

Condensed Interim Financial Statements as of June 30, 2023

Contents

	Page

Condensed Interim Balance Sheets	3

Condensed Interim Statements of Operations	4

Condensed Interim Statements of Changes in Shareholders’ Equity	5

Condensed Interim Statements of Cash Flows	6

Notes to the Condensed Interim Financial Statements	7

NewStem Ltd.

Condensed Interim Balance Sheets as of

(Unaudited)

	June 30			December 31
	2023			2022
	US$ thousands			US$ thousands
Assets

Current assets
Cash and cash equivalents		407			878
Other current assets		37			33
Total current assets		444			911

Non-current assets
Property and equipment, net		15			23

Total assets		459			934

Liabilities and shareholders’ equity

Current liabilities
Accounts payable		76			97

Non-current liabilities
Convertible financial instrument		126			121
Total liabilities		202			218

Shareholders’ equity
Ordinary shares		*			*
Additional paid-in capital		8,832			8,686
Accumulated deficit		(8,575	)		(7,970	)
Total shareholders’ equity		257			716

Total liabilities and shareholders’ equity		459			934

/s/ Ayelet Dilion Mashiah
Ayelet Dilion Mashiah
CEO

Date of approval of the financial statements: August 9, 2023

* Represents an amount lower than $1 thousand.

The accompanying notes are an integral part of the condensed interim financial statements.

NewStem Ltd.

Condensed Interim Statements of Operations for the

(Unaudited)

			Six-month		Six-month
			period ended		period ended
			June 30,		June 30,
			2023		2022
	Note		US$ thousands		US$ thousands
Revenues		5B		95		-

Cost of revenues		5B		11		-

Gross profit				84		-

Operating expenses:

Research and development expenses				590		1,571
Less – grants and participations received				-		(100	)
Research and development expenses, net				590		1,471

General and administrative expenses, net				91		189

Operating loss				597		1,660

Financial expenses (income), net				8		(1	)

Loss for the period				605		1,659

The accompanying notes are an integral part of the condensed interim financial statements.

NewStem Ltd.

Condensed Interim Statements of Changes in Shareholders’ Equity

(Unaudited)

					Additional
					paid-in		Accumulated
	Ordinary shares				capital		deficit			Total
	Number of shares		US$ thousands		US$ thousands		US$ thousands			US$ thousands
For the six - month period ended June 30, 2023

Balance as of January 1, 2023		158,696		*		8,686		(7,970	)		716


Share based compensation		-		-		146		-			146
Loss for the period		-		-		-		(605	)		(605	)

Balance as of June 30, 2023		158,696		*		8,832		(8,575	)		257

For the six - month period ended
June 30, 2022		158,696		*		6,734		(5,629	)		1,105

Balance as of January 1, 2022
Issuance of ordinary shares, net		2,647		*		800		-			800
Share based compensation		-		-		316		-			316
Loss for the period		-		-		-		(1,659	)		(1,659	)

Balance as of June 30, 2022		161,343		*		7,850		(7,288	)		562

* Represents an amount less than $1 thousand.

The accompanying notes are an integral part of the condensed interim financial statements.

NewStem Ltd.

Condensed Interim Statements of Cash Flows for the

(Unaudited)

	Six-month			Six-month
	period ended			period ended
	June 30,			June 30,
	2023			2022
	US$ thousands			US$ thousands
Cash flows from operating activities

Loss for the period		(605	)		(1,659	)

Adjustments required to reconcile loss to net cash used in operating activities:

Depreciation		8			10
Revaluation of convertible financial instrument		5			(13	)
Share based compensation		146			1,087
(Increase) decrease in other current assets		(4	)		9
Decrease in accounts payable		(21	)		(33	)

Net cash used in operating activities		(471	)		(599	)

Cash flows from investing activities

Net cash used in investing activities		-			-

Cash flows from financing activities

Proceeds from issuance of ordinary shares, net		-			800

Net cash provided by financing activities		-			800


Net (decrease) increase in cash and cash equivalents		(471	)		201

Cash and cash equivalents at the beginning of the period		878			601

Cash and cash equivalents at the end of the period		407			802

The accompanying notes are an integral part of the condensed interim financial statements.

NewStem Ltd.

Notes to the Condensed Interim Financial Statements as of June 30, 2023

(Unaudited)

Note 1 - General

NewStem Ltd. (“the Company”) was incorporated in September 2016 under the laws of the State of Israel and commenced its business operations in July 2018.

The Company is a development stage company utilizing its pioneering intellectual property related to haploid human embryonic stem cells for the development of personalized diagnostics and therapeutics for genetic and epigenetic diseases.

Since inception, the Company has accumulated losses of US$8,575 thousand. As of June 30, 2023, the Company’s cash and cash equivalents balance is US$407 thousand, and the net cash used in operating activities during the six-month period ended June 30, 2023, is US$471 thousand.

The Company will need to obtain additional funds to continue its operations over the next 12 months. Management’s plans with regard to these matters include continued development, marketing and licensing of its products, as well as seeking additional financing arrangements. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from sales, licensing or financing on terms acceptable to the Company. See also Note 5A regarding the Convertible Loan Agreement which was not executed. The Company’s management has adopted a cost reduction plan in order to adjust future operation expenses to its cash balance and is considering further reductions.

The Company may incur difficulties to continue to operate its business and there is a substantial doubt about its ability to continue as a going concern during the look-forward period. The condensed interim financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company were unable to continue as a going concern.

Definitions

In these financial statements –

	1.	The Company – NewStem Ltd.
	2.	Related Party – Within its meaning in ASC 850, “Related Party Transactions”.

Note 2 - Basis of Presentation

The accompanying condensed interim balance sheet as of June 30, 2023, and the condensed interim statements of operations, changes in shareholders’ equity and cash flows for the six-month period ended June 30, 2023, are unaudited. These unaudited condensed interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America.

The unaudited condensed interim financial statements contain all adjustments which, in the opinion of management, are necessary to present fairly, the financial information included therein. It is suggested that these condensed interim financial statements be read in conjunction with the audited financial statements and accompanying notes included in the Company’s report for the year ended December 31, 2022. Results for the interim periods presented are not necessarily indicative of the results to be expected for the full year.

The accounting principles used in the preparation of the interim statements are consistent with those used in the preparation of the financial statements of the Company as of December 31, 2022, except the application for the first time of ASC 606 Revenue from Contracts with Customers, as stated in note 5B.

NewStem Ltd.

Notes to the Condensed Interim Financial Statements as of June 30, 2023

(Unaudited)

Note 3 - Related Parties

The Company engaged with its shareholders to receive consulting services and lab renting.

In addition, the Company is required to pay a shareholder sublicense fees at a rate of up to 12% of sublicense.

Transactions

	Six-month		Six-month
	period ended		period ended
	June 30,		June 30,
	2023		2022
	US$ thousands		US$ thousands
Cost of revenues		11		-

Research and development expenses		129		178

Balances

	June 30,		June 30,
	2023		2022
	US$ thousands		US$ thousands
Other current assets		7		-

Accounts payable		11		-

Note 4 - Convertible Financial Instrument

In November 2021, the Company signed a Simple Agreement for Future Equity (“SAFE”) with an investor in the amount of 100 thousand Great British Pound (“GBP”) (approximately US$134 thousands).

The convertible financial instrument is presented at fair value. The convertible financial instrument is considered a Level 3 fair value measurement.

The changes in the liability measured at fair value for which the Company has used Level 3 inputs to determine fair value are as follows:

	2023		2022
	US$ thousands		US$ thousands
Balance as of January 1,		121		134
Change in fair value		5		(13	)

Balance as of June 30,		126		121

NewStem Ltd.

Notes to the Condensed Interim Financial Statements as of June 30, 2023

(Unaudited)

Note 5 - Events during the period

Convertible Loan Agreement

On March 20, 2023, the Company signed a Convertible Loan Agreement (“the Loan” or “the Agreement”) in the amount of US$200 thousands which bear simple interest at the rate of 12.5% per annum, paid in kind. At the end of a period of 24 months after the date on which the loan funds are provided or in M&A Event, the Loan together with the accrued interest (“Outstanding Amount”) shall convert into shares of the Company’s then most senior class of shares at the price per share paid by the investors in the last financing.

If the Company obtains financing at an earlier date, then the Outstanding Amount shall convert into shares of the Company’s most senior class as shall be issued in such financing transaction, at a price per share equal to 75% of the lowest price per share paid by the investors participating in the financing.

In an event of liquidation only (as defined in the Agreement), the interest rate shall increase to 20% per annum.

As of the date of the approval of the condensed interim financial statements, the lender didn’t transfer the Loan and as such the Agreement was not executed.

Sub-License Agreement

On December 23, 2022, The Company signed a Sub-License Agreement (the “Agreement”), which entered into effect in January 2023, for a sub-license of the Company’s intellectual property related to Fragile X Syndrome (“IP”).

In consideration for the grant of each period of the sub-license, the Company will be entitled to license fees of a lump sum of US$95 thousands for years 1-5 (“First License Period”), US$50 thousand per year for years 6-7, US$100 thousand per year for year 8 and onwards. The Company is also entitled for reimbursement of patent costs that were incurred in the past relating the intellectual property, of approximately $24 thousand and will entitled for reimbursement of future patent costs. These reimbursements will be accounted for as reduction of General and administrative expenses.

In addition, the Company will be entitled to royalties upon future sales of products that are based on the Company’s licensed intellectual property at a rate of 3.5% of the net sales or 50% of sales-based sub-license income, sublicense fees at a rate of up to 13.2% - 22.0% of sublicense consideration, subject to certain terms, as outlined in the Agreement. Moreover, the Company is entitled to certain future milestones payments, partly based on sales and partly based on reaching Phase III clinical trials. The Company also received a right to receive a fee equal to 0.5% of the customer’s exit consideration (“Exit Fee”), which will be received upon an exit event of the customer, as defined in the Agreement. Based on the estimated date of the customer’s exit event and the discount rate used to calculate the current value of the Exit Fee, the fair value of the Exit Fee as of the inception date of the Agreement was considered to be immaterial. Subsequent changes in the fair value of the Exit Fee will be recorded as financial income. As of June 30, 2023, the fair value of the Exit Fee was considered to be immaterial.

In addition, according to this Agreement, it was acknowledged that the Company received US$200 thousand to support certain research activities (performed and accounted for during 2022), and will acquire certain services from the customer for US$100 thousand to evaluate the toxicity of potential drugs candidates.

The Company views granting of licenses and sublicenses as outputs of its ordinary business activities, and recipients of such licenses as customers. Thus, the Company considered this Agreement to be in the scope of ASC 606 Revenue from Contracts with Customers (“ASC 606”). The Company determined that the customer has received rights of use of the IP, which are functional in nature, since the Company will not perform any activities to change functionality of the IP during the terms of the sub-license. As prescribed by ASC 606, revenue from right to use IP is recognized at a point in time, when the customer receives access to the IP. The Company did not identify a promise to provide future services in the Agreement, and hence the rights to use the IP are the only performance obligations in the Agreement.

Therefore, the Company recognized revenues of $95 thousand in the six-month period ending June 30, 2023, for the First License Period. Sales-based royalties and milestone payments dependent of future sales will be recognized upon the occurrence of applicable future sales, under the royalty exception. Other milestone payments are currently fully constrained under the variable consideration guidance.

EX-101.SCH 7 nstm-20230630.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Shareholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - EQUITY METHOD INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - EQUITY METHOD INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - EQUITY (DEFICIT) (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - NATURE OF OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SCHEDULE OF WARRANTS AND STOCK OPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SCHEDULE OF INVESTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - EQUITY METHOD INVESTMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SUMMARY OF WARRANTS ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - EQUITY (DEFICIT) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SCHEDULE OF INCOME BEFORE INCOME TAX (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SCHEDULE OF INCOME BEFORE INCOME TAX (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 nstm-20230630_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 nstm-20230630_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 nstm-20230630_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Treasury Stock, Common [Member] Investment, Name [Axis] New Stem Ltd [Member] Net Co Partners [Member] Scenario [Axis] Forecast [Member] Antidilutive Securities [Axis] Warrant [Member] Equity Option [Member] Statistical Measurement [Axis] Maximum [Member] Ownership [Axis] Affiliation [Axis] Investment, Affiliated Issuer, Controlled, Not Majority-Owned [Member] Investment, Issuer Affiliation [Axis] Title of Individual [Axis] New Stem [Member] Legal Entity [Axis] Related Party, Type [Axis] Related Party [Member] Director and Executive Chairman [Member] Shareholder [Member] Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member] Debt Instrument [Axis] Promissory Note [Member] Directot and Investor [Member] Award Type [Axis] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash Accounts receivable, administrative fees Prepaid expenses Total current assets Investment in Netco Partners Investment in NewStem Ltd Total assets LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable Current portion of long-term notes payable Accrued expenses Total current liabilities Long-term liabilities: Long-term notes payable, including accrued interest, net Derivative liability, guarantee Total long-term liabilities Total liabilities Commitments and contingencies (see Note 7) Shareholders’ (deficit) equity: Common stock, $.01 par value, 100,000,000 shares authorized, 50,316,672 shares issued, and 46,881,475 shares outstanding as of June 30, 2023 and December 31, 2022 Additional paid-in capital Accumulated deficit Treasury stock, at cost, 3,435,197 shares as of June 30, 2023 and December 31, 2022 Total shareholders’ (deficit) equity Total liabilities and shareholders’ equity (deficit) Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, shares Income Statement [Abstract] Operating expenses: General and administrative expenses Litigation expenses (contra expenses) (Note 7) Total operating expenses Loss from operations Other expenses: Loss on derivative instrument Interest expense Total other expenses Loss before income taxes Provision for income tax Loss before equity in net income of equity method investees Equity in net loss of equity method investees Net loss Basic and diluted net loss per share: Net loss per share - basic Net loss per share - diluted Weighted average number of shares outstanding - basic Weighted average number of shares outstanding - diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Net loss Stock option compensation Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Equity in loss of equity method investees Distribution from NetCo Partners Accretion of discount on note payable Legal fees and litigation funding fees funded by litigation funding agreement Accrued interest added to long-term note payable Stock-based compensation Change in operating assets and liabilities: Accounts receivable, administrative fees Prepaid expenses Accounts payable Accrued expenses Net cash (used in) provided by operating activities Cash flows from financing activities: Repayment of short term note payable Proceeds from long term notes payable Net cash from financing activities Net change in cash Cash at the beginning of the period Cash at the end of the period Supplemental cash flow information: Cash paid during the period for: Interest Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Equity Method Investments and Joint Ventures [Abstract] EQUITY METHOD INVESTMENTS Debt Disclosure [Abstract] NOTES PAYABLE Equity [Abstract] EQUITY (DEFICIT) Income Tax Disclosure [Abstract] INCOME TAXES Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Equity Investments EX-101.PRE 11 nstm-20230630_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2023	Aug. 14, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-14322
Entity Registrant Name	NOVELSTEM INTERNATIONAL CORP.
Entity Central Index Key	0000912544
Entity Tax Identification Number	65-0385686
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	2255 Glades Road
Entity Address, Address Line Two	Suite 221A
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	410
Local Phone Number	598-9024
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		46,881,475

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 34,325	$ 6,346
Accounts receivable, administrative fees		12,000
Prepaid expenses	26,067	40,561
Total current assets	60,392	58,907
Investment in Netco Partners	137,011	137,011
Investment in NewStem Ltd	1,905,264	2,090,286
Total assets	2,102,667	2,286,204
Current liabilities:
Accounts payable	17,098	21,203
Current portion of long-term notes payable	962,464
Accrued expenses	92,650	43,673
Total current liabilities	1,072,212	64,876
Long-term liabilities:
Long-term notes payable, including accrued interest, net	1,761,004	288,450
Derivative liability, guarantee	204,795
Total long-term liabilities	1,965,799	288,450
Total liabilities	3,038,011	353,326
Commitments and contingencies (see Note 7)
Shareholders’ (deficit) equity:
Common stock, $.01 par value, 100,000,000 shares authorized, 50,316,672 shares issued, and 46,881,475 shares outstanding as of June 30, 2023 and December 31, 2022	468,815	468,815
Additional paid-in capital	290,879,686	290,604,327
Accumulated deficit	(292,084,091)	(288,940,510)
Treasury stock, at cost, 3,435,197 shares as of June 30, 2023 and December 31, 2022	(199,754)	(199,754)
Total shareholders’ (deficit) equity	(935,344)	1,932,878
Total liabilities and shareholders’ equity (deficit)	$ 2,102,667	$ 2,286,204

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	50,316,672	50,316,672
Common stock, shares outstanding	46,881,475	46,881,475
Treasury stock, shares	3,435,197	3,435,197

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
General and administrative expenses	$ 386,361	$ 229,575	$ 551,153	$ 368,531
Litigation expenses (contra expenses) (Note 7)	2,332,663		2,332,663	(310,000)
Total operating expenses	2,719,024	229,575	2,883,816	58,531
Loss from operations	(2,719,024)	(229,575)	(2,883,816)	(58,531)
Other expenses:
Loss on derivative instrument	54,795		54,795
Interest expense	20,510	407	27,823	2,012
Total other expenses	75,305	407	82,618	2,012
Loss before income taxes	(2,794,329)	(229,982)	(2,966,434)	(60,543)
Provision for income tax
Loss before equity in net income of equity method investees	(2,794,329)	(229,982)	(2,966,434)	(60,543)
Equity in net loss of equity method investees	(80,431)	60,647	(177,147)	(326,256)
Net loss	$ (2,874,760)	$ (169,335)	$ (3,143,581)	$ (386,799)
Basic and diluted net loss per share:
Net loss per share - basic	$ (0.06)		$ (0.07)	$ (0.01)
Net loss per share - diluted	$ (0.06)		$ (0.07)	$ (0.01)
Weighted average number of shares outstanding - basic	46,881,475	46,881,475	46,881,475	46,881,475
Weighted average number of shares outstanding - diluted	46,881,475	46,881,475	46,881,475	46,881,475

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Shareholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 468,815	$ 290,321,665	$ (288,174,780)	$ (199,754)	$ 2,415,946
Beginning balance, shares at Dec. 31, 2021	46,881,475			3,435,197
Net loss			(217,464)		(217,464)
Stock option compensation		49,011			49,011
Ending balance, value at Mar. 31, 2022	$ 468,815	290,370,676	(288,392,244)	$ (199,754)	2,247,493
Ending balance, shares at Mar. 31, 2022	46,881,475			3,435,197
Beginning balance, value at Dec. 31, 2021	$ 468,815	290,321,665	(288,174,780)	$ (199,754)	2,415,946
Beginning balance, shares at Dec. 31, 2021	46,881,475			3,435,197
Net loss					(386,799)
Ending balance, value at Jun. 30, 2022	$ 468,815	290,445,009	(288,561,579)	$ (199,754)	2,152,491
Ending balance, shares at Jun. 30, 2022	46,881,475			3,435,197
Beginning balance, value at Mar. 31, 2022	$ 468,815	290,370,676	(288,392,244)	$ (199,754)	2,247,493
Beginning balance, shares at Mar. 31, 2022	46,881,475			3,435,197
Net loss			(169,335)		(169,335)
Stock option compensation		74,333			74,333
Ending balance, value at Jun. 30, 2022	$ 468,815	290,445,009	(288,561,579)	$ (199,754)	2,152,491
Ending balance, shares at Jun. 30, 2022	46,881,475			3,435,197
Beginning balance, value at Dec. 31, 2022	$ 468,815	290,604,327	(288,940,510)	$ (199,754)	1,932,878
Beginning balance, shares at Dec. 31, 2022	46,881,475			3,435,197
Net loss			(268,821)		(268,821)
Stock option compensation		15,077			15,077
Ending balance, value at Mar. 31, 2023	$ 468,815	290,619,404	(289,209,331)	$ (199,754)	1,679,134
Ending balance, shares at Mar. 31, 2023	46,881,475			3,435,197
Beginning balance, value at Dec. 31, 2022	$ 468,815	290,604,327	(288,940,510)	$ (199,754)	1,932,878
Beginning balance, shares at Dec. 31, 2022	46,881,475			3,435,197
Net loss					(3,143,581)
Ending balance, value at Jun. 30, 2023	$ 468,815	290,879,686	(292,084,091)	$ (199,754)	(935,344)
Ending balance, shares at Jun. 30, 2023	46,881,475			3,435,197
Beginning balance, value at Mar. 31, 2023	$ 468,815	290,619,404	(289,209,331)	$ (199,754)	1,679,134
Beginning balance, shares at Mar. 31, 2023	46,881,475			3,435,197
Net loss			(2,874,760)		(2,874,760)
Stock option compensation		260,282			260,282
Ending balance, value at Jun. 30, 2023	$ 468,815	$ 290,879,686	$ (292,084,091)	$ (199,754)	$ (935,344)
Ending balance, shares at Jun. 30, 2023	46,881,475			3,435,197

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (3,143,581)	$ (386,799)
Equity in loss of equity method investees	177,147	326,256
Distribution from NetCo Partners	7,875
Accretion of discount on note payable	11,507
Loss on derivative instrument	54,795
Legal fees and litigation funding fees funded by litigation funding agreement	2,332,663
Accrued interest added to long-term note payable	15,848
Stock-based compensation	275,359	123,344
Change in operating assets and liabilities:
Accounts receivable, administrative fees	12,000
Prepaid expenses	14,494	(1,173)
Accounts payable	(4,105)	(40,397)
Accrued expenses	48,977	49,248
Net cash (used in) provided by operating activities	(197,021)	70,479
Cash flows from financing activities:
Repayment of short term note payable		(100,000)
Proceeds from long term notes payable	225,000	100,000
Net cash from financing activities	225,000
Net change in cash	27,979	70,479
Cash at the beginning of the period	6,346	8,666
Cash at the end of the period	34,325	79,145
Cash paid during the period for:
Interest	$ 468	$ 7,764

XML 18 R7.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS

6 Months Ended

Jun. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

NOTE 1—NATURE OF OPERATIONS

Description of Business

Going Concern, Liquidity and Management’s Plans

XML 19 R8.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Equity Investments

The Company reviews equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable.

Basic and Diluted Net Loss Per Share

The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited):

	2023			2022			2023			2022
	Six Months Ended June 30,						Three Months Ended June 30,
	2023			2022			2023			2022
Net loss available to common shareholders	$	(3,143,581	)	$	(386,799	)	$	(2,874,760	)	$	(169,335	)

Weighted average shares outstanding:
-Basic		46,881,475			46,881,475			46,881,475			46,881,475
Add: Warrants		-			-			-			-
Add: Stock options		-			-			-			-
-Diluted		46,881,475			46,881,475			46,881,475			46,881,475

Basic and diluted net loss per share	$	(0.07	)	$	(0.01	)	$	(0.06	)	$	(-	)

Warrants and stock options excluded from the above calculations are as follows:

SCHEDULE OF WARRANTS AND STOCK OPTIONS

	2023		2022		2023		2022
	Six Months Ended June 30,				Three Months Ended March 31,
	2023		2022		2023		2022
Warrants		3,000,000		3,000,000		3,000,000		3,000,000
Stock options		5,760,000		5,400,000		5,760,000		5,400,000

XML 20 R9.htm IDEA: XBRL DOCUMENT

EQUITY METHOD INVESTMENTS

6 Months Ended

Jun. 30, 2023

Equity Method Investments and Joint Ventures [Abstract]

EQUITY METHOD INVESTMENTS

NOTE 3—EQUITY METHOD INVESTMENTS

Investment in NewStem

The following table represents the Company’s investment in NewStem:

SCHEDULE OF INVESTMENTS

	Six Months Ended June 30, 2023			Year Ended December 31, 2022
	(Unaudited)
Investment in NewStem, beginning	$	2,090,286		$	2,435,155
Allocation of net loss from NewStem, Ltd.		(185,022	)		(732,393	)
Gain on dilution of equity method investment		-			387,524
Investment in NewStem, ending	$	1,905,264		$	2,090,286

The results of operations of the Company’s investment in NewStem is summarized below (unaudited):

	2023			2022			2023			2022
	Six Months Ended June 30,						Three Months Ended June 30,
	2023			2022			2023			2022
Condensed income statement information:
Net revenues	$	95,000		$	-		$	95,000		$	-
Gross margin	$	84,000		$	-		$	84,000		$	-
Net loss	$	(605,000	)	$	(1,659,000	)	$	(342,000	)	$	(431,000	)
Company’s allocation of net loss from NewStem, Ltd.	$	(185,022	)	$	(326,256	)	$	(80,431	)	$	(60,647	)

The financial position of the Company’s investment in NewStem is summarized below:

	June 30,		December 31,
	As of
	June 30,		December 31,
	2023		2022
	(Unaudited)
Condensed balance sheet information:
Current assets	$	444,000	$	911,000
Non-current assets	$	15,000	$	23,000
Current liabilities	$	76,000	$	97,000
Non-current liabilities	$	126,000	$	121,000

Investment in NetCo

The following table represents the Company’s investment in NetCo:

SCHEDULE OF INVESTMENTS

	Six Months Ended June 30, 2023			Year Ended December 31, 2022
		(Unaudited)
Investment in NetCo, beginning	$	137,011		$	137,011
Allocation of net income from NetCo		7,875			12,591
Distribution from NetCo		(7,875	)		(12,591	)
Investment in NetCo, ending	$	137,011		$	137,011

The results of operations of the Company’s investment in NetCo is summarized below (unaudited):

	2023		2022		2023		2022
	Six Months Ended June 30,				Three Months Ended June 30,
	2023		2022		2023		2022
Condensed income statement information:
Net sales	$	15,750	$	-	$	-	$	-
Gross margin	$	15,750	$	-	$	-	$	-
Net income	$	15,750	$	-	$	-	$	-
Net income (loss)	$	15,750	$	-	$	-	$	-
Company’s allocation of net income from NetCo	$	7,875	$	-	$	-	$	-

The financial position of the Company’s investment in NetCo is summarized below:

	June 30,		December 31,
	As of
	June 30,		December 31,
	2023		2022
	(Unaudited)
Condensed balance sheet information:
Current assets	$	4,197	$	13,475
Non-current assets	$	272,799	$	272,799
Current liabilities	$	2,974	$	12,252
Non-current liabilities	$	-	$	-

XML 21 R10.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

6 Months Ended

Jun. 30, 2023

Debt Disclosure [Abstract]

NOTES PAYABLE

NOTE 4—NOTES PAYABLE

Notes payable are summarized as follows:

SCHEDULE OF NOTES PAYABLE

	As of
	June 30,			December 31,
	2023			2022
	(Unaudited)
Notes payable related parties:
Notes payable director and Executive Chairman	$	355,000		$	280,000
Accrued interest added to note balance		24,298			8,450
Total notes payable director and Executive Chairman		379,298			288,450
Note payable shareholder, principal amount		150,000			-
Less unamortized discount		(138,493	)		-
Total note payable shareholder		11,507			-
Note payable, litigation funding agreement:
Note payable Omni Bridgeway (Fund 4) Invt. 3 L.P.		2,332,663			-
Total notes payable		2,723,468			288,450
Less current portion		(962,464	)		-
Long-term notes payable	$	1,761,004		$	288,450

Notes Payable Related Parties

Note Payable, Litigation Funding Agreement

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

EQUITY (DEFICIT)

6 Months Ended

Jun. 30, 2023

Equity [Abstract]

EQUITY (DEFICIT)

NOTE 5—EQUITY (DEFICIT)

(a) General

(b) Summary Employee Option Information

The Company utilized the Black-Scholes option-pricing model to estimate fair value, utilizing the following assumptions for the respective periods (all in weighted averages):

	Six Months Ended June 30,
	2023			2022
Risk-free interest rate		3.5	%		1.5	%
Expected term of options, in years		4.0			3.9
Expected annual volatility		191.1	%		185.8	%
Expected dividend yield		0	%		0	%
Determined weighted average grant date fair value per option	$	0.19		$	0.27

A summary of the Company’s option plans for the six months ended June 30, 2023, is presented below (unaudited):

SCHEDULE OF STOCK OPTION ACTIVITIES

	Number		Weighted
	of		Average
	Options		Exercise
	(in shares)		Price
Outstanding, December 31, 2022		5,400,000	$	0.14
Granted		360,000		0.20
Outstanding, June 30, 2023		5,760,000	$	0.14
Exercisable, June 30, 2023		5,400,000	$	0.14

(d) Warrants

SUMMARY OF WARRANTS ACTIVITY

	Number of		Weighted
	shares		Average
	underlying		Exercise
	warrants		Price
Outstanding, December 31, 2022		3,000,000	$	0.12
Granted		-		-
Exercised		-		-
Forfeited or expired		-		-
Outstanding, June 30, 2023		3,000,000	$	0.12

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

INCOME TAXES

6 Months Ended

Jun. 30, 2023

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 6—INCOME TAXES

SCHEDULE OF INCOME BEFORE INCOME TAX

	2023			2022
	Six Months Ended June 30,
	2023			2022
Computed tax at the federal statutory rate of 21%	$	(609,122	)	$	(81,073	)
State income taxes, net of federal income tax benefit		(126,030	)		(16,774	)
Change in federal valuation allowance		764,756			149,930
Foreign rate differential		(29,604	)		(52,083	)
Total provision for income tax	$	-		$	-

		2023			2022
		Three Months Ended June 30,
		2023			2022
Computed tax at the federal statutory rate of 21%	$	(56,452	)	$	(76,345	)
State income taxes, net of federal income tax benefit		(11,680	)		(15,796	)
Change in federal valuation allowance		87,972			154,045
Foreign rate differential		(19,840	)		(61,904	)
Total provision for income tax	$	-		$	-

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 7—COMMITMENTS AND CONTINGENCIES

XML 25 R14.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2023

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 8—SUBSEQUENT EVENTS

XML 26 R15.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Equity Investments

Equity Investments

The Company reviews equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable.

Basic and Diluted Net Loss Per Share

Basic and Diluted Net Loss Per Share

The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited):

	2023			2022			2023			2022
	Six Months Ended June 30,						Three Months Ended June 30,
	2023			2022			2023			2022
Net loss available to common shareholders	$	(3,143,581	)	$	(386,799	)	$	(2,874,760	)	$	(169,335	)

Weighted average shares outstanding:
-Basic		46,881,475			46,881,475			46,881,475			46,881,475
Add: Warrants		-			-			-			-
Add: Stock options		-			-			-			-
-Diluted		46,881,475			46,881,475			46,881,475			46,881,475

Basic and diluted net loss per share	$	(0.07	)	$	(0.01	)	$	(0.06	)	$	(-	)

Warrants and stock options excluded from the above calculations are as follows:

SCHEDULE OF WARRANTS AND STOCK OPTIONS

	2023		2022		2023		2022
	Six Months Ended June 30,				Three Months Ended March 31,
	2023		2022		2023		2022
Warrants		3,000,000		3,000,000		3,000,000		3,000,000
Stock options		5,760,000		5,400,000		5,760,000		5,400,000

XML 27 R16.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE

The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited):

	2023			2022			2023			2022
	Six Months Ended June 30,						Three Months Ended June 30,
	2023			2022			2023			2022
Net loss available to common shareholders	$	(3,143,581	)	$	(386,799	)	$	(2,874,760	)	$	(169,335	)

Weighted average shares outstanding:
-Basic		46,881,475			46,881,475			46,881,475			46,881,475
Add: Warrants		-			-			-			-
Add: Stock options		-			-			-			-
-Diluted		46,881,475			46,881,475			46,881,475			46,881,475

Basic and diluted net loss per share	$	(0.07	)	$	(0.01	)	$	(0.06	)	$	(-	)

SCHEDULE OF WARRANTS AND STOCK OPTIONS

Warrants and stock options excluded from the above calculations are as follows:

SCHEDULE OF WARRANTS AND STOCK OPTIONS

	2023		2022		2023		2022
	Six Months Ended June 30,				Three Months Ended March 31,
	2023		2022		2023		2022
Warrants		3,000,000		3,000,000		3,000,000		3,000,000
Stock options		5,760,000		5,400,000		5,760,000		5,400,000

XML 28 R17.htm IDEA: XBRL DOCUMENT

EQUITY METHOD INVESTMENTS (Tables)

6 Months Ended

Jun. 30, 2023

New Stem Ltd [Member]

SCHEDULE OF INVESTMENTS

The following table represents the Company’s investment in NewStem:

SCHEDULE OF INVESTMENTS

	Six Months Ended June 30, 2023			Year Ended December 31, 2022
	(Unaudited)
Investment in NewStem, beginning	$	2,090,286		$	2,435,155
Allocation of net loss from NewStem, Ltd.		(185,022	)		(732,393	)
Gain on dilution of equity method investment		-			387,524
Investment in NewStem, ending	$	1,905,264		$	2,090,286

SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT

The results of operations of the Company’s investment in NewStem is summarized below (unaudited):

	2023			2022			2023			2022
	Six Months Ended June 30,						Three Months Ended June 30,
	2023			2022			2023			2022
Condensed income statement information:
Net revenues	$	95,000		$	-		$	95,000		$	-
Gross margin	$	84,000		$	-		$	84,000		$	-
Net loss	$	(605,000	)	$	(1,659,000	)	$	(342,000	)	$	(431,000	)
Company’s allocation of net loss from NewStem, Ltd.	$	(185,022	)	$	(326,256	)	$	(80,431	)	$	(60,647	)

The financial position of the Company’s investment in NewStem is summarized below:

	June 30,		December 31,
	As of
	June 30,		December 31,
	2023		2022
	(Unaudited)
Condensed balance sheet information:
Current assets	$	444,000	$	911,000
Non-current assets	$	15,000	$	23,000
Current liabilities	$	76,000	$	97,000
Non-current liabilities	$	126,000	$	121,000

Net Co Partners [Member]

SCHEDULE OF INVESTMENTS

The following table represents the Company’s investment in NetCo:

SCHEDULE OF INVESTMENTS

	Six Months Ended June 30, 2023			Year Ended December 31, 2022
		(Unaudited)
Investment in NetCo, beginning	$	137,011		$	137,011
Allocation of net income from NetCo		7,875			12,591
Distribution from NetCo		(7,875	)		(12,591	)
Investment in NetCo, ending	$	137,011		$	137,011

SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT

The results of operations of the Company’s investment in NetCo is summarized below (unaudited):

	2023		2022		2023		2022
	Six Months Ended June 30,				Three Months Ended June 30,
	2023		2022		2023		2022
Condensed income statement information:
Net sales	$	15,750	$	-	$	-	$	-
Gross margin	$	15,750	$	-	$	-	$	-
Net income	$	15,750	$	-	$	-	$	-
Net income (loss)	$	15,750	$	-	$	-	$	-
Company’s allocation of net income from NetCo	$	7,875	$	-	$	-	$	-

The financial position of the Company’s investment in NetCo is summarized below:

	June 30,		December 31,
	As of
	June 30,		December 31,
	2023		2022
	(Unaudited)
Condensed balance sheet information:
Current assets	$	4,197	$	13,475
Non-current assets	$	272,799	$	272,799
Current liabilities	$	2,974	$	12,252
Non-current liabilities	$	-	$	-

XML 29 R18.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Tables)

6 Months Ended

Jun. 30, 2023

Debt Disclosure [Abstract]

SCHEDULE OF NOTES PAYABLE

Notes payable are summarized as follows:

SCHEDULE OF NOTES PAYABLE

	As of
	June 30,			December 31,
	2023			2022
	(Unaudited)
Notes payable related parties:
Notes payable director and Executive Chairman	$	355,000		$	280,000
Accrued interest added to note balance		24,298			8,450
Total notes payable director and Executive Chairman		379,298			288,450
Note payable shareholder, principal amount		150,000			-
Less unamortized discount		(138,493	)		-
Total note payable shareholder		11,507			-
Note payable, litigation funding agreement:
Note payable Omni Bridgeway (Fund 4) Invt. 3 L.P.		2,332,663			-
Total notes payable		2,723,468			288,450
Less current portion		(962,464	)		-
Long-term notes payable	$	1,761,004		$	288,450

XML 30 R19.htm IDEA: XBRL DOCUMENT

EQUITY (DEFICIT) (Tables)

6 Months Ended

Jun. 30, 2023

Equity [Abstract]

SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS

The Company utilized the Black-Scholes option-pricing model to estimate fair value, utilizing the following assumptions for the respective periods (all in weighted averages):

	Six Months Ended June 30,
	2023			2022
Risk-free interest rate		3.5	%		1.5	%
Expected term of options, in years		4.0			3.9
Expected annual volatility		191.1	%		185.8	%
Expected dividend yield		0	%		0	%
Determined weighted average grant date fair value per option	$	0.19		$	0.27

SCHEDULE OF STOCK OPTION ACTIVITIES

A summary of the Company’s option plans for the six months ended June 30, 2023, is presented below (unaudited):

SCHEDULE OF STOCK OPTION ACTIVITIES

	Number		Weighted
	of		Average
	Options		Exercise
	(in shares)		Price
Outstanding, December 31, 2022		5,400,000	$	0.14
Granted		360,000		0.20
Outstanding, June 30, 2023		5,760,000	$	0.14
Exercisable, June 30, 2023		5,400,000	$	0.14

SUMMARY OF WARRANTS ACTIVITY

	Number of		Weighted
	shares		Average
	underlying		Exercise
	warrants		Price
Outstanding, December 31, 2022		3,000,000	$	0.12
Granted		-		-
Exercised		-		-
Forfeited or expired		-		-
Outstanding, June 30, 2023		3,000,000	$	0.12

XML 31 R20.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

6 Months Ended

Jun. 30, 2023

Income Tax Disclosure [Abstract]

SCHEDULE OF INCOME BEFORE INCOME TAX

	2023			2022
	Six Months Ended June 30,
	2023			2022
Computed tax at the federal statutory rate of 21%	$	(609,122	)	$	(81,073	)
State income taxes, net of federal income tax benefit		(126,030	)		(16,774	)
Change in federal valuation allowance		764,756			149,930
Foreign rate differential		(29,604	)		(52,083	)
Total provision for income tax	$	-		$	-

		2023			2022
		Three Months Ended June 30,
		2023			2022
Computed tax at the federal statutory rate of 21%	$	(56,452	)	$	(76,345	)
State income taxes, net of federal income tax benefit		(11,680	)		(15,796	)
Change in federal valuation allowance		87,972			154,045
Foreign rate differential		(19,840	)		(61,904	)
Total provision for income tax	$	-		$	-

XML 32 R21.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
NATURE OF OPERATIONS (Details Narrative) - USD ($)	Jul. 31, 2022	Jun. 30, 2023	Oct. 31, 2023	May 31, 2023	Dec. 31, 2022	Sep. 30, 2018
Accumulated deficit		$ 292,084,091			$ 288,940,510	$ 5,400,000
Working capital	$ 600,000	$ 600,000
Borrowings				$ 300,000
Advance from borrowings				$ 150,000
Forecast [Member]
Advance from borrowings			$ 150,000
New Stem Ltd [Member]
Equity interest percentage		30.58%
Net Co Partners [Member]
Equity interest percentage		50.00%

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Accounting Policies [Abstract]
Net loss available to common shareholders	$ (2,874,760)	$ (268,821)	$ (169,335)	$ (217,464)	$ (3,143,581)	$ (386,799)
Weighted average shares outstanding:
-Basic	46,881,475		46,881,475		46,881,475	46,881,475
Add: Warrants
Add: Stock options
-Diluted	46,881,475		46,881,475		46,881,475	46,881,475
Basic net loss per share	$ (0.06)				$ (0.07)	$ (0.01)
Diluted net loss per share	$ (0.06)				$ (0.07)	$ (0.01)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 34 R23.htm IDEA: XBRL DOCUMENT

SCHEDULE OF WARRANTS AND STOCK OPTIONS (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock options	3,000,000	3,000,000	3,000,000	3,000,000
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock options	5,760,000	5,400,000	5,760,000	5,400,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	6 Months Ended
	Jun. 30, 2023
Equity method investment description	investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the investee company
Net Co Partners [Member]
Equity interest percentage	50.00%

XML 36 R25.htm IDEA: XBRL DOCUMENT

SCHEDULE OF INVESTMENTS (Details) - USD ($)	6 Months Ended	12 Months Ended
SCHEDULE OF INVESTMENTS (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
New Stem Ltd [Member]
Investment in NetCo, beginning	$ 2,090,286	$ 2,435,155
Allocation of net income from NetCo	(185,022)	(732,393)
Gain on dilution of equity method investment		387,524
Investment in NetCo, ending	1,905,264	2,090,286
Net Co Partners [Member]
Investment in NetCo, beginning	137,011	137,011
Allocation of net income from NetCo	7,875	12,591
Investment in NetCo, ending	137,011	137,011
Distribution from NetCo	$ (7,875)	$ (12,591)

- Definition

Fair value of investment in security owned.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480493/946-210-55-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-2

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(11))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(2)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(2)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6

+ Details

XML 37 R26.htm IDEA: XBRL DOCUMENT

SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Net income (loss)	$ (2,874,760)	$ (268,821)	$ (169,335)	$ (217,464)	$ (3,143,581)	$ (386,799)
Company’s allocation of net income from NetCo	(80,431)		60,647		(177,147)	(326,256)
Current assets	60,392				60,392		$ 58,907
Current liabilities	1,072,212				1,072,212		64,876
Non-current liabilities	1,965,799				1,965,799		288,450
New Stem Ltd [Member]
Net sales	95,000				95,000
Gross margin	84,000				84,000
Net income (loss)	(342,000)		(431,000)		(605,000)	(1,659,000)
Company’s allocation of net income from NetCo	(80,431)		(60,647)		(185,022)	(326,256)
Current assets	444,000				444,000		911,000
Non-current assets	15,000				15,000		23,000
Current liabilities	76,000				76,000		97,000
Non-current liabilities	126,000				126,000		121,000
Net Co Partners [Member]
Net sales					15,750
Gross margin					15,750
Net income (loss)					15,750
Company’s allocation of net income from NetCo					7,875
Current assets	4,197				4,197		13,475
Non-current assets	272,799				272,799		272,799
Current liabilities	2,974				2,974		12,252
Non-current liabilities

XML 38 R27.htm IDEA: XBRL DOCUMENT

EQUITY METHOD INVESTMENTS (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
EQUITY METHOD INVESTMENTS (Details Narrative) - USD ($)	Apr. 30, 2022	Dec. 31, 2020	Dec. 31, 2018	Jun. 30, 2023	Dec. 31, 2022
New Stem [Member]
Schedule of Equity Method Investments [Line Items]
Additional funding	$ 1,450,000
New Stem Ltd [Member]
Schedule of Equity Method Investments [Line Items]
Ownership investment percentage			20.00%	30.58%	30.58%
New Stem Ltd [Member]
Schedule of Equity Method Investments [Line Items]
Sale of stock			50,000
Percentage of outstanding shares			33.00%
Shares acquisitions shares		12,500	25,000
Shares acquisitions		$ 1,000,000	$ 2,000,000
Equity interest percentage				30.58%
New Stem Ltd [Member] \| Investment, Affiliated Issuer, Controlled, Not Majority-Owned [Member]
Schedule of Equity Method Investments [Line Items]
Carrying value of investment					$ 2,090,286
New Stem Ltd [Member] \| Investment, Affiliated Issuer, Controlled, Not Majority-Owned [Member]
Schedule of Equity Method Investments [Line Items]
Carrying value of investment				$ 1,905,264
Net Co Partners [Member]
Schedule of Equity Method Investments [Line Items]
Equity interest percentage				50.00%
Maximum [Member] \| New Stem Ltd [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investments			$ 4,000,000

XML 39 R28.htm IDEA: XBRL DOCUMENT

SCHEDULE OF NOTES PAYABLE (Details) - USD ($)	Jun. 30, 2023	May 05, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Total notes payable	$ 2,723,468		$ 288,450
Less current portion	(962,464)
Long-term notes payable	1,761,004		288,450
Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member]
Defined Benefit Plan Disclosure [Line Items]
Total notes payable	2,332,663
Director and Executive Chairman [Member]
Defined Benefit Plan Disclosure [Line Items]
Total notes payable	379,298		288,450
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued interest added to note balance	24,298		8,450
Note payable shareholder, principal amount	150,000
Less unamortized discount	(138,493)
Related Party [Member] \| Director and Executive Chairman [Member]
Defined Benefit Plan Disclosure [Line Items]
Total notes payable	355,000		280,000
Related Party [Member] \| Shareholder [Member]
Defined Benefit Plan Disclosure [Line Items]
Total notes payable	$ 11,507
Long-term notes payable		$ 300,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($)						1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Aug. 11, 2023	May 05, 2023	Nov. 11, 2022	Feb. 11, 2022	Apr. 12, 2021	Jul. 31, 2022	May 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Oct. 05, 2023	Feb. 16, 2022
Short-Term Debt [Line Items]
Interest rate							8.00%
Maturity date							Jan. 31, 2024
Interest expense								$ 20,510	$ 407	$ 27,823	$ 2,012
[custom:WorkingCapital]						$ 600,000				600,000
Short-Term Debt, Interest Rate Increase			10.00%
Advances to Affiliate								355,000		355,000		$ 280,000
Long term note payable								1,761,004		1,761,004		288,450
Accretion of note discount										11,507
Contra expenses - legal fees and administrative costs											310,000
Liability								$ 3,038,011		$ 3,038,011		353,326
Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member]
Short-Term Debt [Line Items]
Interest rate								5.00%		5.00%
Litigation settlement, expense				$ 1,000,000
Investment return due										$ 1,399,598
Forecast [Member] \| Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member]
Short-Term Debt [Line Items]
Investment return due	$ 466,533
Related Party [Member] \| Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member]
Short-Term Debt [Line Items]
Due to related parties								$ 933,065		933,065
Working capital and related fees								310,000		310,000
Liability								2,333,663		2,333,663
Related Party [Member] \| Shareholder [Member]
Short-Term Debt [Line Items]
Interest rate		0.00%
Maturity date		May 05, 2025
Long term note payable		$ 300,000
Advance of long term note payable		$ 150,000
Derivative fair value liability								204,795		204,795
Accretion of note discount								$ 11,507		11,507
Related Party [Member] \| Shareholder [Member] \| Forecast [Member]
Short-Term Debt [Line Items]
Advance of long term note payable													$ 150,000
Promissory Note [Member]
Short-Term Debt [Line Items]
Related party amount					$ 100,000
Interest rate					8.00%
Maturity date					Apr. 12, 2022
Interest expense										$ 15,847	$ 1,198	$ 8,768
Interest expense paid														$ 6,752

XML 41 R30.htm IDEA: XBRL DOCUMENT

SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Equity [Abstract]
Risk-free interest rate	3.50%	1.50%
Expected term, in years	4 years	3 years 10 months 24 days
Expected annual volatility	191.10%	185.80%
Expected dividend yield	0.00%	0.00%
Determined weighted average grant date fair value per option	$ 0.19	$ 0.27

XML 42 R31.htm IDEA: XBRL DOCUMENT

SCHEDULE OF STOCK OPTION ACTIVITIES (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Granted	$ 0.19	$ 0.27
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding beginning	5,400,000
Weighted Average Exercise Price Outstanding beginning	$ 0.14
Number of Options, Granted	360,000
Weighted Average Exercise Price, Granted	$ 0.20
Number of Options Outstanding ending	5,760,000
Weighted Average Exercise Price Outstanding ending	$ 0.14
Number of Options Exercisable	5,400,000
Weighted Average Exercise Price, Exercisable	$ 0.14

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

XML 43 R32.htm IDEA: XBRL DOCUMENT

SUMMARY OF WARRANTS ACTIVITY (Details) - Warrant [Member]	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares underlying warrants, Beginning balance	3,000,000
Weighted average exercise price, Beginning balance \| $ / shares	$ 0.12
Number of shares underlying warrants, Granted
Weighted average exercise price, Granted \| $ / shares
Number of shares underlying warrants, Exercised
Number of shares underlying warrants, Forfeited or expired
Number of shares underlying warrants, Ending balance	3,000,000
Weighted average exercise price, Ending balance \| $ / shares	$ 0.12

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

XML 44 R33.htm IDEA: XBRL DOCUMENT

EQUITY (DEFICIT) (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
EQUITY (DEFICIT) (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Nov. 12, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares outstanding	46,881,475		46,881,475		46,881,475
Common stock, par value	$ 0.01		$ 0.01		$ 0.01
Expected term of options, in years			4 years	3 years 10 months 24 days
Dividend yield			0.00%	0.00%
Stock based compensation expense			$ 275,359	$ 123,344
Compensation cost	$ 50,000		$ 50,000
Options unvested	360,000		360,000
Equity Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options, shares	5,760,000		5,760,000		5,400,000
Stock based compensation expense	$ 15,000	$ 74,000	$ 32,000	$ 123,000
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected term of options, in years			7 years
Directot and Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options, shares						5,760,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued	46,881,475		46,881,475		46,881,475
Common stock, shares outstanding		46,881,475		46,881,475	46,881,475
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock based compensation expense			$ 243,000
Warrants outstanding weighted average remaining contractual life			2 years

XML 45 R34.htm IDEA: XBRL DOCUMENT

SCHEDULE OF INCOME BEFORE INCOME TAX (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Computed tax at the federal statutory rate of 21%	$ (56,452)	$ (76,345)	$ (609,122)	$ (81,073)
State income taxes, net of federal income tax benefit	(11,680)	(15,796)	(126,030)	(16,774)
Change in federal valuation allowance	87,972	154,045	764,756	149,930
Foreign rate differential	(19,840)	(61,904)	(29,604)	(52,083)
Total provision for income tax

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 46 R35.htm IDEA: XBRL DOCUMENT

SCHEDULE OF INCOME BEFORE INCOME TAX (Details) (Parenthetical)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Computed tax at the federal statutory rate	21.00%	21.00%	21.00%	21.00%

XML 47 R36.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Litigation expenses	$ 2,332,663		$ 2,332,663	$ (310,000)
Net Co Partners [Member]
Equity interest percentage	50.00%		50.00%

XML 48 R37.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member] - USD ($)		6 Months Ended
	Aug. 11, 2023	Jun. 30, 2023
Investment return due		$ 1,399,598
Forecast [Member]
Investment return due	$ 466,533

XML 49 form10-q_htm.xml IDEA: XBRL DOCUMENT 0000912544 2023-01-01 2023-06-30 0000912544 2023-08-14 0000912544 2023-06-30 0000912544 2022-12-31 0000912544 2022-01-01 2022-06-30 0000912544 2023-04-01 2023-06-30 0000912544 2022-04-01 2022-06-30 0000912544 us-gaap:CommonStockMember 2022-12-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000912544 us-gaap:RetainedEarningsMember 2022-12-31 0000912544 us-gaap:TreasuryStockCommonMember 2022-12-31 0000912544 us-gaap:CommonStockMember 2023-03-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000912544 us-gaap:RetainedEarningsMember 2023-03-31 0000912544 us-gaap:TreasuryStockCommonMember 2023-03-31 0000912544 2023-03-31 0000912544 us-gaap:CommonStockMember 2021-12-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000912544 us-gaap:RetainedEarningsMember 2021-12-31 0000912544 us-gaap:TreasuryStockCommonMember 2021-12-31 0000912544 2021-12-31 0000912544 us-gaap:CommonStockMember 2022-03-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000912544 us-gaap:RetainedEarningsMember 2022-03-31 0000912544 us-gaap:TreasuryStockCommonMember 2022-03-31 0000912544 2022-03-31 0000912544 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000912544 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000912544 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000912544 2023-01-01 2023-03-31 0000912544 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000912544 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000912544 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000912544 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000912544 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000912544 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000912544 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0000912544 2022-01-01 2022-03-31 0000912544 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000912544 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000912544 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000912544 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0000912544 us-gaap:CommonStockMember 2023-06-30 0000912544 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000912544 us-gaap:RetainedEarningsMember 2023-06-30 0000912544 us-gaap:TreasuryStockCommonMember 2023-06-30 0000912544 us-gaap:CommonStockMember 2022-06-30 0000912544 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000912544 us-gaap:RetainedEarningsMember 2022-06-30 0000912544 us-gaap:TreasuryStockCommonMember 2022-06-30 0000912544 2022-06-30 0000912544 NSTM:NewStemLtdMember 2023-06-30 0000912544 NSTM:NetCoPartnersMember 2023-06-30 0000912544 2018-09-30 0000912544 2023-05-31 0000912544 srt:ScenarioForecastMember 2023-10-31 0000912544 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000912544 us-gaap:WarrantMember 2022-01-01 2022-06-30 0000912544 us-gaap:WarrantMember 2023-04-01 2023-06-30 0000912544 us-gaap:WarrantMember 2022-04-01 2022-06-30 0000912544 us-gaap:StockOptionMember 2023-01-01 2023-06-30 0000912544 us-gaap:StockOptionMember 2022-01-01 2022-06-30 0000912544 us-gaap:StockOptionMember 2023-04-01 2023-06-30 0000912544 us-gaap:StockOptionMember 2022-04-01 2022-06-30 0000912544 srt:MaximumMember NSTM:NewStemLtdMember 2018-12-31 0000912544 NSTM:NewStemLtdMember 2018-01-01 2018-12-31 0000912544 NSTM:NewStemLtdMember 2018-12-31 0000912544 NSTM:NewStemLtdMember 2020-01-01 2020-12-31 0000912544 NSTM:NewStemLtdMember 2023-06-30 0000912544 NSTM:NewStemLtdMember 2022-12-31 0000912544 NSTM:NewStemLtdMember us-gaap:OtherControlledCompaniesMember 2023-06-30 0000912544 NSTM:NewStemLtdMember us-gaap:OtherControlledCompaniesMember 2022-12-31 0000912544 NSTM:NewStemMember 2022-04-01 2022-04-30 0000912544 NSTM:NewStemLtdMember 2023-01-01 2023-06-30 0000912544 NSTM:NetCoPartnersMember 2023-01-01 2023-06-30 0000912544 NSTM:NewStemLtdMember 2022-12-31 0000912544 NSTM:NewStemLtdMember 2021-12-31 0000912544 NSTM:NewStemLtdMember 2022-01-01 2022-12-31 0000912544 NSTM:NewStemLtdMember 2023-06-30 0000912544 NSTM:NetCoPartnersMember 2022-12-31 0000912544 NSTM:NetCoPartnersMember 2021-12-31 0000912544 NSTM:NetCoPartnersMember 2022-01-01 2022-12-31 0000912544 NSTM:NetCoPartnersMember 2023-06-30 0000912544 NSTM:NewStemLtdMember 2022-01-01 2022-06-30 0000912544 NSTM:NewStemLtdMember 2023-04-01 2023-06-30 0000912544 NSTM:NewStemLtdMember 2022-04-01 2022-06-30 0000912544 NSTM:NetCoPartnersMember 2022-01-01 2022-06-30 0000912544 NSTM:NetCoPartnersMember 2023-04-01 2023-06-30 0000912544 NSTM:NetCoPartnersMember 2022-04-01 2022-06-30 0000912544 NSTM:DirectorAndExecutiveChairmanMember us-gaap:RelatedPartyMember 2023-06-30 0000912544 NSTM:DirectorAndExecutiveChairmanMember us-gaap:RelatedPartyMember 2022-12-31 0000912544 us-gaap:RelatedPartyMember 2023-06-30 0000912544 us-gaap:RelatedPartyMember 2022-12-31 0000912544 NSTM:DirectorAndExecutiveChairmanMember 2023-06-30 0000912544 NSTM:DirectorAndExecutiveChairmanMember 2022-12-31 0000912544 NSTM:ShareholderMember us-gaap:RelatedPartyMember 2023-06-30 0000912544 NSTM:ShareholderMember us-gaap:RelatedPartyMember 2022-12-31 0000912544 NSTM:OmniBridgewayFundMember 2023-06-30 0000912544 NSTM:OmniBridgewayFundMember 2022-12-31 0000912544 NSTM:PromissoryNoteMember 2021-04-12 2021-04-12 0000912544 NSTM:PromissoryNoteMember 2021-04-12 0000912544 NSTM:PromissoryNoteMember 2022-01-01 2022-06-30 0000912544 NSTM:PromissoryNoteMember 2022-02-16 0000912544 2022-07-01 2022-07-31 0000912544 2022-05-31 0000912544 2022-11-11 2022-11-11 0000912544 2022-05-01 2022-05-31 0000912544 NSTM:PromissoryNoteMember 2023-01-01 2023-06-30 0000912544 NSTM:PromissoryNoteMember 2022-01-01 2022-12-31 0000912544 NSTM:ShareholderMember us-gaap:RelatedPartyMember 2023-05-05 0000912544 srt:ScenarioForecastMember NSTM:ShareholderMember us-gaap:RelatedPartyMember 2023-10-05 0000912544 NSTM:ShareholderMember us-gaap:RelatedPartyMember 2023-05-05 2023-05-05 0000912544 NSTM:ShareholderMember us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0000912544 NSTM:ShareholderMember us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0000912544 NSTM:OmniBridgewayFundMember 2022-02-11 2022-02-11 0000912544 us-gaap:RelatedPartyMember NSTM:OmniBridgewayFundMember 2023-06-30 0000912544 NSTM:OmniBridgewayFundMember 2023-01-01 2023-06-30 0000912544 srt:ScenarioForecastMember NSTM:OmniBridgewayFundMember 2023-08-11 2023-08-11 0000912544 NSTM:DirectotAndInvestorMember 2018-11-12 0000912544 srt:MaximumMember 2023-01-01 2023-06-30 0000912544 us-gaap:StockOptionMember 2023-01-01 2023-06-30 0000912544 us-gaap:StockOptionMember 2023-04-01 2023-06-30 0000912544 us-gaap:StockOptionMember 2022-01-01 2022-06-30 0000912544 us-gaap:StockOptionMember 2022-04-01 2022-06-30 0000912544 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000912544 us-gaap:StockOptionMember 2022-12-31 0000912544 us-gaap:StockOptionMember 2023-06-30 0000912544 us-gaap:WarrantMember 2022-12-31 0000912544 us-gaap:WarrantMember 2023-06-30 iso4217:USD shares iso4217:USD shares pure iso4217:ILS iso4217:ILS shares iso4217:GBP 0000912544 false Q2 --12-31

10-Q true 2023-06-30 2023 false 001-14322 NOVELSTEM INTERNATIONAL CORP. FL 65-0385686 2255 Glades Road Suite 221A Boca Raton FL 33431 410 598-9024 No Yes Non-accelerated Filer true true false false 46881475

34325

6346

12000

26067

40561

60392

58907

137011 137011

1905264

2090286

2102667

2286204

17098

21203

962464

92650

43673

1072212

64876

1761004

288450

204795

1965799

288450

3038011

353326

0.01

100000000

50316672

46881475

468815

290879686

290604327

-292084091

-288940510

3435197

199754

-935344

1932878

2102667

2286204

551153

368531

386361

229575

-2332663 310000 -2332663

2883816

58531

2719024

229575

-2883816

-58531

-2719024

-229575

54795 54795

27823

2012

20510

407

-82618

-2012

-75305

-407

-2966434

-60543

-2794329

-229982

-2966434 -60543 -2794329 -229982

-177147

-326256

-80431

60647

-3143581

-386799

-2874760

-169335

-0.07

-0.01

-0.06

46881475

468815

290604327

-288940510

3435197

-199754

1932878

-268821

15077

46881475

468815

290619404

-289209331

3435197

-199754

1679134

-2874760

260282

46881475

468815

290879686

-292084091

3435197

-199754

-935344

46881475

468815

290321665

-288174780

3435197

-199754

2415946

-217464

49011

46881475

468815

290370676

-288392244

3435197

-199754

2247493

-169335

74333

46881475

468815

290445009

-288561579

3435197

-199754

2152491

-3143581

-386799

-177147

-326256

7875

11507

54795

2332663

15848

275359

123344

-12000

-14494

1173

-4105

-40397

48977

49248

-197021

70479

100000

225000

100000

225000

27979

70479

6346

8666

34325

79145

468

7764

NOTE 1—NATURE OF OPERATIONS Description of Business NovelStem International Corp. (“NovelStem” or the “Company”) is a holding company whose principal assets are a <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zqSsUCuuq33g" title="Equity interest percentage">30.58% equity interest in NewStem Ltd, an Israeli biotech company (“NewStem”), and a <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NetCoPartnersMember_zBvQu7bqOJke" title="Equity interest percentage">50% equity interest in NetCo Partners (“NetCo”). NovelStem was formerly known as Hollywood Media Corp. The Company was incorporated in the State of Florida on January 22, 1993 and changed its name to NovelStem International Corp. in September 2018 as a result of its business focus shift from a media business to biotech. NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is collaborating with life sciences companies for the development of drugs and reagents. NetCo is a legacy media business interest which owns “Net Force”, a book publishing franchise. Going Concern, Liquidity and Management’s Plans Management believes the accompanying condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern. Since inception, the Company has accumulated a deficit of approximately $292,000,000. The accumulated deficit of the Company subsequent to its business focus shift and name change in September 2018 is approximately $5,400,000 which is comprised primarily of allocated losses from equity method investments and general and administrative costs incurred by the Company. The Company will need to obtain additional funds to continue its operations. Management’s plans with regard to these matters include additional financing and fundraising until its equity investment in NewStem is profitable. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that NewStem will become profitable. The Company has in place a financing agreement with related parties to borrow up to $600,000 for working capital needs (see Note 4). Additionally, in May 2023, the Company entered into a financing agreement with a shareholder to borrow $300,000 consisting of advances of $150,000 in May 2023 and $150,000 in October 2023 (see Note 9). Following this financing, the Company believes that its cash resources are sufficient for the operations of the Company until April 2024. In view of the matters described above, the Company’s ability to meet financing requirements is dependent upon the ability to complete additional fundraising or obtain additional financing, and/or monetize its investment in NetCo, along with NewStem continuing as a going concern. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

0.3058

0.50

-292000000

-5400000

600000

300000

150000

NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The accompanying unaudited condensed financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed financial statements have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 31, 2023, from which the Company derived the balance sheet data at December 31, 2022. Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations for interim reporting. The Company believes that the disclosures contained herein are adequate to make the information presented not misleading. Equity Investments Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an investee depends on an evaluation of several factors, including, among others, representation on the investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the investee company. Under the equity method of accounting, an investee company’s accounts are not reflected within the Company’s balance sheets or statements of operations; however, the Company’s share of the earnings or losses of the investee company is reflected in the caption “Equity in net income (loss) of investee company” in the statements of operations. The Company’s carrying value in an equity method investee company is reflected in the caption “Investment in investee company’ in the Company’s balance sheets. The Company reviews equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable. The Company holds a minority investment in an entity, NewStem, which is accounted for pursuant to the equity method of accounting. Additionally, the Company is a <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NetCoPartnersMember_zZLs1myvDm46" title="Equity interest percentage">50% partner in NetCo (which is accounted for pursuant to the equity method of accounting). See Note 3. Basic and Diluted Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding during the period, excluding treasury stock. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding plus the dilutive potential of common shares which would result from the exercise of stock options and warrants. The dilutive effects of stock options and warrants are excluded from the computation of diluted net income (loss) per share if the effect of doing so would be antidilutive. <p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zf5Q5yylGoW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited): SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20230101__20230630_zo8KsuHDPrJ3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20220101__20220630_zKEpaOICmdI4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20230401__20230630_zAvbYd4opMjj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20220401__20220630_z0NFqL9DxSq2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zm6RTklI40Y7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Net loss available to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,143,581</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(386,799</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(2,874,760</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(169,335</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zng4QDsOyi92" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares outstanding:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_z242G4wQoct7" style="vertical-align: bottom; background-color: White"> <td>-Basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_zJicqhgfzQA9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Add: Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_znc0yghxjZrg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Add: Stock options</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_i01_zAnzGla8AEHb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>-Diluted</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basic and diluted net loss per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_900_eus-gaap--EarningsPerShareBasic_c20230101__20230630_zf0BGwu4NLTg" title="Basic net loss per share"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20230101__20230630_zWngsOtLKNN3" title="Diluted net loss per share">(0.07</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_900_eus-gaap--EarningsPerShareBasic_c20220101__20220630_zEsBMU89FKAk" title="Basic net loss per share"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20220630_zaYxZhXgdG86" title="Diluted net loss per share">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_903_eus-gaap--EarningsPerShareBasic_c20230401__20230630_zLXF896T8PHd" title="Basic net loss per share"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20230401__20230630_zu88zQrH6cng" title="Diluted net loss per share">(0.06</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_908_eus-gaap--EarningsPerShareBasic_dxL_c20220401__20220630_zXTvTAIGwF0l" title="Basic net loss per share::XDX::-"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_909_eus-gaap--EarningsPerShareDiluted_dxL_c20220401__20220630_zI6zGWxPImTa" title="Diluted net loss per share::XDX::-">(-</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zpmlE2sKEuNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Warrants and stock options excluded from the above calculations are as follows: SCHEDULE OF WARRANTS AND STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_493_20230101__20230630_zXLuPvmQgiql" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20220101__20220630_zg99dxhxV0Nc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20230401__20230630_z1EoFNei2pk9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20220401__20220630_zpceduLyJpNd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2gg4NxBt0Al" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_ziisrmj30AZ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,400,000</td><td style="text-align: left"> </td></tr> </table>

Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The accompanying unaudited condensed financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed financial statements have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 31, 2023, from which the Company derived the balance sheet data at December 31, 2022. Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations for interim reporting. The Company believes that the disclosures contained herein are adequate to make the information presented not misleading.

Equity Investments Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an investee depends on an evaluation of several factors, including, among others, representation on the investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the investee company. Under the equity method of accounting, an investee company’s accounts are not reflected within the Company’s balance sheets or statements of operations; however, the Company’s share of the earnings or losses of the investee company is reflected in the caption “Equity in net income (loss) of investee company” in the statements of operations. The Company’s carrying value in an equity method investee company is reflected in the caption “Investment in investee company’ in the Company’s balance sheets. The Company reviews equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable. The Company holds a minority investment in an entity, NewStem, which is accounted for pursuant to the equity method of accounting. Additionally, the Company is a <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NetCoPartnersMember_zZLs1myvDm46" title="Equity interest percentage">50% partner in NetCo (which is accounted for pursuant to the equity method of accounting). See Note 3.

investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the investee company

0.50

Basic and Diluted Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding during the period, excluding treasury stock. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding plus the dilutive potential of common shares which would result from the exercise of stock options and warrants. The dilutive effects of stock options and warrants are excluded from the computation of diluted net income (loss) per share if the effect of doing so would be antidilutive. <p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zf5Q5yylGoW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited): SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20230101__20230630_zo8KsuHDPrJ3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20220101__20220630_zKEpaOICmdI4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20230401__20230630_zAvbYd4opMjj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20220401__20220630_z0NFqL9DxSq2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zm6RTklI40Y7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Net loss available to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,143,581</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(386,799</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(2,874,760</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(169,335</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zng4QDsOyi92" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares outstanding:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_z242G4wQoct7" style="vertical-align: bottom; background-color: White"> <td>-Basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_zJicqhgfzQA9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Add: Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_znc0yghxjZrg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Add: Stock options</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_i01_zAnzGla8AEHb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>-Diluted</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basic and diluted net loss per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_900_eus-gaap--EarningsPerShareBasic_c20230101__20230630_zf0BGwu4NLTg" title="Basic net loss per share"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20230101__20230630_zWngsOtLKNN3" title="Diluted net loss per share">(0.07</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_900_eus-gaap--EarningsPerShareBasic_c20220101__20220630_zEsBMU89FKAk" title="Basic net loss per share"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20220630_zaYxZhXgdG86" title="Diluted net loss per share">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_903_eus-gaap--EarningsPerShareBasic_c20230401__20230630_zLXF896T8PHd" title="Basic net loss per share"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20230401__20230630_zu88zQrH6cng" title="Diluted net loss per share">(0.06</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_908_eus-gaap--EarningsPerShareBasic_dxL_c20220401__20220630_zXTvTAIGwF0l" title="Basic net loss per share::XDX::-"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_909_eus-gaap--EarningsPerShareDiluted_dxL_c20220401__20220630_zI6zGWxPImTa" title="Diluted net loss per share::XDX::-">(-</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zpmlE2sKEuNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Warrants and stock options excluded from the above calculations are as follows: SCHEDULE OF WARRANTS AND STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_493_20230101__20230630_zXLuPvmQgiql" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20220101__20220630_zg99dxhxV0Nc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20230401__20230630_z1EoFNei2pk9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20220401__20220630_zpceduLyJpNd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2gg4NxBt0Al" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_ziisrmj30AZ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,400,000</td><td style="text-align: left"> </td></tr> </table>

<p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zf5Q5yylGoW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited): SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20230101__20230630_zo8KsuHDPrJ3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20220101__20220630_zKEpaOICmdI4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20230401__20230630_zAvbYd4opMjj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20220401__20220630_z0NFqL9DxSq2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zm6RTklI40Y7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Net loss available to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,143,581</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(386,799</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(2,874,760</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(169,335</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zng4QDsOyi92" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares outstanding:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_z242G4wQoct7" style="vertical-align: bottom; background-color: White"> <td>-Basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_zJicqhgfzQA9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Add: Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_znc0yghxjZrg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Add: Stock options</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_i01_zAnzGla8AEHb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>-Diluted</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basic and diluted net loss per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_900_eus-gaap--EarningsPerShareBasic_c20230101__20230630_zf0BGwu4NLTg" title="Basic net loss per share"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20230101__20230630_zWngsOtLKNN3" title="Diluted net loss per share">(0.07</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_900_eus-gaap--EarningsPerShareBasic_c20220101__20220630_zEsBMU89FKAk" title="Basic net loss per share"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20220630_zaYxZhXgdG86" title="Diluted net loss per share">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_903_eus-gaap--EarningsPerShareBasic_c20230401__20230630_zLXF896T8PHd" title="Basic net loss per share"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20230401__20230630_zu88zQrH6cng" title="Diluted net loss per share">(0.06</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_908_eus-gaap--EarningsPerShareBasic_dxL_c20220401__20220630_zXTvTAIGwF0l" title="Basic net loss per share::XDX::-"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdFSUdIVEVEIEFWRVJBR0UgTlVNQkVSIE9GIFNIQVJFUyBPRiBESUxVVElWRSAoRGV0YWlscykA" id="xdx_909_eus-gaap--EarningsPerShareDiluted_dxL_c20220401__20220630_zI6zGWxPImTa" title="Diluted net loss per share::XDX::-">(-</td><td style="text-align: left">)</td></tr> </table>

-3143581

-386799

-2874760

-169335

46881475

-0.07

-0.01

-0.06

<p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zpmlE2sKEuNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Warrants and stock options excluded from the above calculations are as follows: SCHEDULE OF WARRANTS AND STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_493_20230101__20230630_zXLuPvmQgiql" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20220101__20220630_zg99dxhxV0Nc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20230401__20230630_z1EoFNei2pk9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20220401__20220630_zpceduLyJpNd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2gg4NxBt0Al" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_ziisrmj30AZ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,400,000</td><td style="text-align: left"> </td></tr> </table>

3000000

5760000

5400000

5760000

5400000

NOTE 3—EQUITY METHOD INVESTMENTS Investment in NewStem In 2018, the Company entered into a Share Purchase Agreement with NewStem and other related parties to provide aggregate funding of up to $<span id="xdx_900_eus-gaap--EquityMethodInvestments_iI_c20181231__srt--RangeAxis__srt--MaximumMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zg5IgFJMv5Kl" title="Equity method investments">4,000,000 to NewStem. This funding was to be provided through the sale of up to <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20180101__20181231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zaw4IwsvHw04" title="Sale of stock">50,000 common shares of NewStem to the Company representing <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20180101__20181231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zKLpCldIq9Tl" title="Percentage of outstanding shares">33% of New Stem’s outstanding shares. In 2018, the Company purchased <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20180101__20181231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zS0inijTmNBj" title="Shares acquisitions shares">25,000 shares of NewStem for $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20180101__20181231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zbosE3Fen4zc" title="Shares acquisitions">2,000,000 acquiring an ownership interest of 20%. The Company made additional investments in 2019 and 2020 purchasing <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zNFajymoUqBh" title="Shares acquisitions shares">12,500 shares each year for a $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zQmtO2UpWDY8" title="Shares acquisitions">1,000,000 investment each year. NewStem sold and issued shares to third party investors in 2021 and 2022 resulting in the Company recognizing a gain on dilution of equity method investment. These transactions resulted in the Company having an ownership interest of <span id="xdx_902_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20230630__srt--OwnershipAxis__custom--NewStemLtdMember_z6ezOfVRJpH5" title="Ownership investment percentage"><span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--NewStemLtdMember_zGrytpxsbeMj" title="Ownership investment percentage">30.58% as of June 30, 2023 and December 31, 2022. The Company accounts for its investment in NewStem under the equity method. At June 30, 2023 and December 31, 2022, the carrying value of the investment in NewStem exceeded the underlying net assets of NewStem by $<span id="xdx_907_eus-gaap--InvestmentOwnedAtFairValue_iI_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember__custom--AffiliationAxis__us-gaap--OtherControlledCompaniesMember_zOdJc0d0fcm1" title="Carrying value of investment">1,905,264 and $<span id="xdx_90F_eus-gaap--InvestmentOwnedAtFairValue_iI_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember__us-gaap--InvestmentIssuerAffiliationAxis__us-gaap--OtherControlledCompaniesMember_zVUu52bjMXU7" title="Carrying value of investment">2,090,286, respectively. The excess relates to identified intangible assets including license agreements, specialized work force (goodwill) and two separate projects of in process research and development (“IPR&D”) related to stem cell-based diagnostics and therapeutics for cancer chemotherapies. NewStem is in the development stage and has incurred losses since its inception and has yet to generate revenues sufficient to support operations. NewStem will need to obtain additional funds to continue its operations. NewStem management’s plans with regard to these matters include continued development, marketing, and licensing of its products, as well as seeking additional financing arrangements. Although NewStem’s management continues to pursue these plans, there is no assurance that the NewStem will be successful in obtaining sufficient cash from sales of products or financing on terms acceptable to NewStem’s management. NewStem obtained additional funding of approximately $1,450,000 in 2022 through the sale of shares of ordinary stock. <p id="xdx_89E_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_hdei--LegalEntityAxis__custom--NewStemLtdMember_zyC4DH0NSunf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table represents the Company’s investment in NewStem: SCHEDULE OF INVESTMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20230101__20230630__dei--LegalEntityAxis__custom--NewStemLtdMember_zwDVqp4h6eUi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30, 2023</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_499_20220101__20221231__dei--LegalEntityAxis__custom--NewStemLtdMember_z5SHtYFdsmPj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2022</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_403_eus-gaap--InvestmentOwnedAtFairValue_iS_z8Pq36wFMrIl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Investment in NewStem, beginning</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,090,286</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,435,155</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease_zgFi67ae0N2b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Allocation of net loss from NewStem, Ltd.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(185,022</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(732,393</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--GainOnDilutionOfEquityMethodInvestment_zDBvhKqhLivb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gain on dilution of equity method investment</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">387,524</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InvestmentOwnedAtFairValue_iE_zmPqHU2n1yBc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Investment in NewStem, ending</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,905,264</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,090,286</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_897_eus-gaap--EquityMethodInvestmentsTextBlock_hdei--LegalEntityAxis__custom--NewStemLtdMember_z1QJatki2ABi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The results of operations of the Company’s investment in NewStem is summarized below (unaudited): SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20230630__dei--LegalEntityAxis__custom--NewStemLtdMember_zZ42ND0OKKxc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220630__dei--LegalEntityAxis__custom--NewStemLtdMember_z3YSz7vrFCR5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20230401__20230630__dei--LegalEntityAxis__custom--NewStemLtdMember_zCRMRWDdzGwc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220401__20220630__dei--LegalEntityAxis__custom--NewStemLtdMember_zbzhd0qCFmXc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed income statement information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zEvfelDVVw6e" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 2.5pt">Net revenues</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">95,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">95,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GrossProfit_zkJwYeStpWp6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Gross margin</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">84,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">84,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zqHqim0Yndr9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(605,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,659,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(342,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(431,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromEquityMethodInvestments_zOW0Xdo47Tyk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Company’s allocation of net loss from NewStem, Ltd.</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(185,022</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(326,256</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(80,431</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(60,647</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The financial position of the Company’s investment in NewStem is summarized below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20230630__dei--LegalEntityAxis__custom--NewStemLtdMember_zfCmFCqrDe7b" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20221231__dei--LegalEntityAxis__custom--NewStemLtdMember_z3WLk8U1Sbqh" style="font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed balance sheet information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsCurrent_iI_zynGZcbBUcD2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">444,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">911,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_zAkvWyc8uSYk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Non-current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesCurrent_iI_zHY4tJmxCkb3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">97,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesNoncurrent_iI_zfLroQnlhkF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current liabilities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">126,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">121,000</td><td style="text-align: left"> </td></tr> </table> Investment in NetCo NovelStem owns a <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NetCoPartnersMember_zmfJl9BC5wwj" title="Equity interest percentage">50% interest in NetCo, a joint venture that owns the Net Force publishing franchise. The Company accounts for its investment in NetCo under the equity method and recognizes nominal royalties from this arrangement. The Company assesses its investment in NetCo for impairment on an annual basis. <p id="xdx_897_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_hdei--LegalEntityAxis__custom--NetCoPartnersMember_zWm5SsDfZgFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table represents the Company’s investment in NetCo: SCHEDULE OF INVESTMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20230101__20230630__dei--LegalEntityAxis__custom--NetCoPartnersMember_zAe8kqFiMMn7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30, 2023</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20220101__20221231__dei--LegalEntityAxis__custom--NetCoPartnersMember_zzvs4egSJi31" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2022</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_402_eus-gaap--InvestmentOwnedAtFairValue_iS_zIVZ3mHbrzk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Investment in NetCo, beginning</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">137,011</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">137,011</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease_zkFJxsULIzLf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Allocation of net income from NetCo</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,591</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossReductions_iN_di_z2TRBhprQTSk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Distribution from NetCo</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,875</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,591</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--InvestmentOwnedAtFairValue_iE_zVvNxqoZUIKh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Investment in NetCo, ending</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">137,011</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">137,011</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_894_eus-gaap--EquityMethodInvestmentsTextBlock_hdei--LegalEntityAxis__custom--NetCoPartnersMember_ziA5m9iZJBU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The results of operations of the Company’s investment in NetCo is summarized below (unaudited): SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20230101__20230630__dei--LegalEntityAxis__custom--NetCoPartnersMember_zLAxcaebKt87" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20220101__20220630__dei--LegalEntityAxis__custom--NetCoPartnersMember_zvHO8mLLCzl2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20230401__20230630__dei--LegalEntityAxis__custom--NetCoPartnersMember_zoHUpaXmnaT5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20220401__20220630__dei--LegalEntityAxis__custom--NetCoPartnersMember_z5YnRcTqL4Cc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed income statement information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_z4bSMDJdGVX7" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">Net sales</td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">15,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GrossProfit_zm329bzNQdZd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross margin</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,750</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_z0J6xunXvSy7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,750</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLoss_zv7WGAFDAB4g" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,750</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromEquityMethodInvestments_zwuPinx8YSrk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Company’s allocation of net income from NetCo</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,875</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> </table> The financial position of the Company’s investment in NetCo is summarized below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20230630__dei--LegalEntityAxis__custom--NetCoPartnersMember_zaCfBUshMK5j" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20221231__dei--LegalEntityAxis__custom--NetCoPartnersMember_zFZ5l3ZStVOb" style="font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed balance sheet information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsCurrent_iI_zcjC29eUH4Sk" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">4,197</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">13,475</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_znlxGjRLUKVh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">272,799</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">272,799</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesCurrent_iI_zIlQqKGNMxZ6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,974</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,252</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesNoncurrent_iI_zFmjD0eQkdR3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current liabilities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> </table>

4000000

50000

0.33

25000

2000000

0.20

12500

1000000

0.3058

1905264

2090286

1450000

<p id="xdx_89E_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_hdei--LegalEntityAxis__custom--NewStemLtdMember_zyC4DH0NSunf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table represents the Company’s investment in NewStem: SCHEDULE OF INVESTMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20230101__20230630__dei--LegalEntityAxis__custom--NewStemLtdMember_zwDVqp4h6eUi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30, 2023</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_499_20220101__20221231__dei--LegalEntityAxis__custom--NewStemLtdMember_z5SHtYFdsmPj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2022</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_403_eus-gaap--InvestmentOwnedAtFairValue_iS_z8Pq36wFMrIl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Investment in NewStem, beginning</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,090,286</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,435,155</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease_zgFi67ae0N2b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Allocation of net loss from NewStem, Ltd.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(185,022</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(732,393</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--GainOnDilutionOfEquityMethodInvestment_zDBvhKqhLivb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gain on dilution of equity method investment</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">387,524</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InvestmentOwnedAtFairValue_iE_zmPqHU2n1yBc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Investment in NewStem, ending</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,905,264</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,090,286</td><td style="text-align: left"> </td></tr> </table>

2090286

2435155

-185022

-732393

387524

1905264

2090286

<p id="xdx_897_eus-gaap--EquityMethodInvestmentsTextBlock_hdei--LegalEntityAxis__custom--NewStemLtdMember_z1QJatki2ABi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The results of operations of the Company’s investment in NewStem is summarized below (unaudited): SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20230630__dei--LegalEntityAxis__custom--NewStemLtdMember_zZ42ND0OKKxc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220630__dei--LegalEntityAxis__custom--NewStemLtdMember_z3YSz7vrFCR5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20230401__20230630__dei--LegalEntityAxis__custom--NewStemLtdMember_zCRMRWDdzGwc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220401__20220630__dei--LegalEntityAxis__custom--NewStemLtdMember_zbzhd0qCFmXc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed income statement information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zEvfelDVVw6e" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 2.5pt">Net revenues</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">95,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">95,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GrossProfit_zkJwYeStpWp6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Gross margin</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">84,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">84,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zqHqim0Yndr9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(605,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,659,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(342,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(431,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromEquityMethodInvestments_zOW0Xdo47Tyk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Company’s allocation of net loss from NewStem, Ltd.</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(185,022</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(326,256</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(80,431</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(60,647</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The financial position of the Company’s investment in NewStem is summarized below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20230630__dei--LegalEntityAxis__custom--NewStemLtdMember_zfCmFCqrDe7b" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20221231__dei--LegalEntityAxis__custom--NewStemLtdMember_z3WLk8U1Sbqh" style="font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed balance sheet information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsCurrent_iI_zynGZcbBUcD2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">444,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">911,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_zAkvWyc8uSYk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Non-current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesCurrent_iI_zHY4tJmxCkb3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">97,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesNoncurrent_iI_zfLroQnlhkF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current liabilities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">126,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">121,000</td><td style="text-align: left"> </td></tr> </table>

95000

84000

-605000

-1659000

-342000

-431000

-185022

-326256

-80431

-60647

444000

911000

15000

23000

76000

97000

126000

121000

0.50

<p id="xdx_897_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_hdei--LegalEntityAxis__custom--NetCoPartnersMember_zWm5SsDfZgFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table represents the Company’s investment in NetCo: SCHEDULE OF INVESTMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20230101__20230630__dei--LegalEntityAxis__custom--NetCoPartnersMember_zAe8kqFiMMn7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30, 2023</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20220101__20221231__dei--LegalEntityAxis__custom--NetCoPartnersMember_zzvs4egSJi31" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2022</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_402_eus-gaap--InvestmentOwnedAtFairValue_iS_zIVZ3mHbrzk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Investment in NetCo, beginning</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">137,011</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">137,011</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease_zkFJxsULIzLf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Allocation of net income from NetCo</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,591</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossReductions_iN_di_z2TRBhprQTSk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Distribution from NetCo</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,875</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,591</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--InvestmentOwnedAtFairValue_iE_zVvNxqoZUIKh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Investment in NetCo, ending</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">137,011</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">137,011</td><td style="text-align: left"> </td></tr> </table>

137011

7875

12591

7875

12591

137011

<p id="xdx_894_eus-gaap--EquityMethodInvestmentsTextBlock_hdei--LegalEntityAxis__custom--NetCoPartnersMember_ziA5m9iZJBU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The results of operations of the Company’s investment in NetCo is summarized below (unaudited): SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20230101__20230630__dei--LegalEntityAxis__custom--NetCoPartnersMember_zLAxcaebKt87" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20220101__20220630__dei--LegalEntityAxis__custom--NetCoPartnersMember_zvHO8mLLCzl2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20230401__20230630__dei--LegalEntityAxis__custom--NetCoPartnersMember_zoHUpaXmnaT5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20220401__20220630__dei--LegalEntityAxis__custom--NetCoPartnersMember_z5YnRcTqL4Cc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed income statement information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_z4bSMDJdGVX7" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">Net sales</td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">15,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GrossProfit_zm329bzNQdZd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross margin</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,750</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_z0J6xunXvSy7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,750</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLoss_zv7WGAFDAB4g" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,750</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromEquityMethodInvestments_zwuPinx8YSrk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Company’s allocation of net income from NetCo</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,875</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> </table> The financial position of the Company’s investment in NetCo is summarized below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20230630__dei--LegalEntityAxis__custom--NetCoPartnersMember_zaCfBUshMK5j" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20221231__dei--LegalEntityAxis__custom--NetCoPartnersMember_zFZ5l3ZStVOb" style="font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed balance sheet information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsCurrent_iI_zcjC29eUH4Sk" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">4,197</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">13,475</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_znlxGjRLUKVh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">272,799</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">272,799</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesCurrent_iI_zIlQqKGNMxZ6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,974</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,252</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesNoncurrent_iI_zFmjD0eQkdR3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current liabilities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> </table>

15750

7875

4197

13475

272799

2974

12252

NOTE 4—NOTES PAYABLE Notes payable are summarized as follows: SCHEDULE OF NOTES PAYABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Notes payable related parties:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; text-indent: 10pt">Notes payable director and Executive Chairman</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayable_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zUhNItP1jJI" style="width: 16%; text-align: right" title="Total notes payable">355,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesPayable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zsYSZ8U7zA75" style="width: 16%; text-align: right" title="Total notes payable">280,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Accrued interest added to note balance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zOLd18GPrfsc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued interest added to note balance">24,298</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zF95A7yv8c61" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued interest added to note balance">8,450</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 30pt">Total notes payable director and Executive Chairman</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_c20230630__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_z72vdgSOHrGb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">379,298</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_c20221231__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zmZAD7Ww8Tsb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">288,450</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Note payable shareholder, principal amount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwMlcKsifska" style="text-align: right" title="Note payable, principal amount">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4KchljZtu48" style="text-align: right" title="Note payable shareholder, principal amount">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 10pt">Less unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zAvY7Ra4MlVk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less unamortized discount">(138,493</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zv5CYGj43pk2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less unamortized discount">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 30pt">Total note payable shareholder</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zWgo1Xz0lqwh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">11,507</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zmzKzb3RM9x9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Note payable, litigation funding agreement:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Note payable Omni Bridgeway (Fund 4) Invt. 3 L.P.</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--NotesPayable_iI_c20230630__dei--LegalEntityAxis__custom--OmniBridgewayFundMember_ztcRE0N8VfD5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">2,332,663</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayable_iI_c20221231__dei--LegalEntityAxis__custom--OmniBridgewayFundMember_zkt8IARISu7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 30pt">Total notes payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_c20230630_zu6v0b9b9nz5" style="text-align: right" title="Total notes payable">2,723,468</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_c20221231_zoPlHe2bUzbh" style="text-align: right" title="Total notes payable">288,450</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Less current portion</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--LongTermDebtCurrent_iNI_di_c20230630_zcdq0SqmOZzg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less current portion">(962,464</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LongTermDebtCurrent_iNI_di_c20221231_zKpTArAVs91i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less current portion">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 30pt">Long-term notes payable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermNotesPayable_iI_c20230630_z3RaKXdFAu76" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term notes payable">1,761,004</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LongTermNotesPayable_iI_c20221231_zKDsmCqozGU4" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term notes payable">288,450</td><td style="text-align: left"> </td></tr> </table> Notes Payable Related Parties On April 12, 2021, the Company entered into a promissory note (the “Note”) with a related party (individual) for $100,000. The Note accrued interest at 8% per annum and matured on April 12, 2022. The proceeds of this Note were used to pay operating expenses of the Company. Interest expense related to this Note was $1,198 for the six months ended June 30, 2022. The Note and accrued interest of $6,752 were paid in full on February 16, 2022. In May 2022, the Company entered into long-term notes payable in the form of finance agreements (the “Agreements”) with two individuals who are related parties, which were amended in July 2022, to borrow up to $600,000 for working capital needs. One of the individuals is a director and shareholder, the other is our Executive Chairman who is also a shareholder. These agreements provide for funding through January 31, 2024, provide for interest at a rate of 8% per annum through November 11, 2022, at which time the interest rate increased to 10% per annum for subsequent advances. The Agreements mature the earlier of January 31, 2024 or twenty months from the date of the first funded amount (May 2022) unless the shareholders agree to extend the due date at that time. The Company received advances of $355,000 and $280,000, respectively, pursuant to this agreement through June 30, 2023 and December 31, 2022. Interest expense related to the agreements was $15,847 and $8,768, respectively, for the six and three months ended June 30, 2023. Pursuant to the Agreements, accrued interest is added to the note balances. On May 5, 2023, the Company entered into a long term note payable with a shareholder for $<span id="xdx_90B_eus-gaap--LongTermNotesPayable_iI_c20230505__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zmF3W6SoSk7f" title="Long term note payable">300,000 in financing to be funded $<span id="xdx_902_eus-gaap--OtherLongTermNotesPayable_iI_c20230505__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zLEetJwe9cD4" title="Advance of long term note payable">150,000 at inception and $<span id="xdx_901_eus-gaap--OtherLongTermNotesPayable_iI_c20231005__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zgToUeN1NVAc" title="Advance of long term note payable">150,000 no later than October 5, 2023. This note bears interest at zero percent (<span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230505__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zRl7ypX4saJ1" title="Interest rate">0%) and matures on <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20230505__20230505__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zpG3urtL9LL8" title="Maturity date">May 5, 2025. The note includes a guarantee which has been identified as an embedded derivative with a fair value of a liability of $<span id="xdx_904_eus-gaap--DerivativeLiabilities_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zLufwXw8WEFk" title="Derivative fair value liability">204,795 at June 30, 2023 which is reported separately on the condensed balance sheet. The fair value of the note exceeds the proceeds, and the note has been discounted at inception so that the net liability is the fair value of the derivative. Accretion of the note discount of $<span id="xdx_90F_eus-gaap--OtherNoncashExpense_c20230401__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zogz092AxN4g" title="Accretion of note discount"><span id="xdx_90B_eus-gaap--OtherNoncashExpense_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zElt1U9LPcrd" title="Accretion of note discount">11,507 has been reflected as part of interest expense in the condensed statements of operations for the six and three months ended June 30, 2023. Note Payable, Litigation Funding Agreement On February 11, 2022, the Company entered into a nonrecourse litigation funding agreement (the “Agreement”) with Omni Bridgeway (Fund 4) Invt. 3 L.P. (“Omni”) related to an arbitration proceeding disclosed in Note 7. The Agreement provides for Omni to fund all costs related to the arbitration up to $1,000,000 in exchange for an assignment of a certain portion of rights to and interest in claims related to this arbitration. The agreement provides for specific calculations of the portion of any claims collected to be received by Omni with the remainder collectible by the Company. Additionally, the agreement provides for repayment of funded costs pursuant to the same multiple calculations in the event of a favorable outcome that does not include the collection of claims. During the six months ended June 30, 2022, the Company received $310,000 pursuant to this agreement for the reimbursement of legal costs and working capital expenditures, including previously incurred general and administrative costs. During July 2023, the arbitration was settled with a favorable outcome for the Company. As a result of the favorable ruling disclosed in Note 7, the liability became probable and reasonably estimable, and the Company has recorded the full liability due to Omni as of June 30, 2023. This liability consists of expenses funded by Omni of $<span id="xdx_902_eus-gaap--OtherLiabilities_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__dei--LegalEntityAxis__custom--OmniBridgewayFundMember_zY3FmOOSWVC6" title="Due to related parties">933,065, including $<span id="xdx_900_ecustom--WorkingCapitalAndRelatedFees_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__dei--LegalEntityAxis__custom--OmniBridgewayFundMember_zCxApXVP2hmj" title="Working capital and related fees">310,000 advanced for working capital, and related fees or investment return to Omni calculated as contractual multiples of funding totaling $1,399,598 as of June 30, 2023 for a total liability of $<span id="xdx_907_eus-gaap--Liabilities_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__dei--LegalEntityAxis__custom--OmniBridgewayFundMember_zHHK2et25053" title="Liability">2,333,663. An additional fee or investment return of $<span id="xdx_90D_eus-gaap--InvestmentIncomeNet_c20230811__20230811__dei--LegalEntityAxis__custom--OmniBridgewayFundMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z6nCvrGLp9Tg" title="Investment return due">466,533 is due to Omni effective August 11, 2023 as payment of the liability was not made by that date. This agreement bears interest at 5% per annum beginning January 2024 and is payable in four quarterly installments beginning April 4, 2024.

Notes payable are summarized as follows: SCHEDULE OF NOTES PAYABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Notes payable related parties:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; text-indent: 10pt">Notes payable director and Executive Chairman</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayable_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zUhNItP1jJI" style="width: 16%; text-align: right" title="Total notes payable">355,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesPayable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zsYSZ8U7zA75" style="width: 16%; text-align: right" title="Total notes payable">280,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Accrued interest added to note balance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zOLd18GPrfsc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued interest added to note balance">24,298</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zF95A7yv8c61" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued interest added to note balance">8,450</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 30pt">Total notes payable director and Executive Chairman</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_c20230630__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_z72vdgSOHrGb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">379,298</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_c20221231__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zmZAD7Ww8Tsb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">288,450</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Note payable shareholder, principal amount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwMlcKsifska" style="text-align: right" title="Note payable, principal amount">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4KchljZtu48" style="text-align: right" title="Note payable shareholder, principal amount">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 10pt">Less unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zAvY7Ra4MlVk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less unamortized discount">(138,493</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zv5CYGj43pk2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less unamortized discount">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 30pt">Total note payable shareholder</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zWgo1Xz0lqwh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">11,507</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zmzKzb3RM9x9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Note payable, litigation funding agreement:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Note payable Omni Bridgeway (Fund 4) Invt. 3 L.P.</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--NotesPayable_iI_c20230630__dei--LegalEntityAxis__custom--OmniBridgewayFundMember_ztcRE0N8VfD5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">2,332,663</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayable_iI_c20221231__dei--LegalEntityAxis__custom--OmniBridgewayFundMember_zkt8IARISu7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 30pt">Total notes payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_c20230630_zu6v0b9b9nz5" style="text-align: right" title="Total notes payable">2,723,468</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_c20221231_zoPlHe2bUzbh" style="text-align: right" title="Total notes payable">288,450</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Less current portion</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--LongTermDebtCurrent_iNI_di_c20230630_zcdq0SqmOZzg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less current portion">(962,464</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LongTermDebtCurrent_iNI_di_c20221231_zKpTArAVs91i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less current portion">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 30pt">Long-term notes payable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermNotesPayable_iI_c20230630_z3RaKXdFAu76" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term notes payable">1,761,004</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LongTermNotesPayable_iI_c20221231_zKDsmCqozGU4" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term notes payable">288,450</td><td style="text-align: left"> </td></tr> </table>

355000

280000

24298

8450

379298

288450

150000

138493

11507

2332663

2723468

288450

962464

1761004

288450

100000

0.08

2022-04-12

1198

6752

600000

0.08

0.10

2024-01-31

355000

280000

15847

8768

300000

150000

2025-05-05

204795

11507

1000000

310000

933065

310000

1399598

2333663

466533

0.05

NOTE 5—EQUITY (DEFICIT) (a) General At June 30, 2023 and December 31, 2022, the Company had issued and outstanding 46,881,475 shares of its common stock, par value $0.01 per share. Holders of outstanding common stock are entitled to receive dividends when, as and if declared by the Board and to share ratably in the assets of the Company legally available for distribution in the event of a liquidation, dissolution or winding up of the Company. (b) Summary Employee Option Information The Company’s stock option plan provides for the grant to officers, directors, third party contractors and other future key employees of options to purchase shares of common stock. The purchase price may be paid in cash or, if the option is “in-the-money”, it is automatically exercised “net”. In a net exercise of an option, the Company does not require a payment of the exercise price of the option from the optionee but reduces the number of shares of common stock issued upon the exercise of the option by the smallest number of whole shares that has an aggregate fair market value equal to or in excess of the aggregate exercise price for the option shares covered by the option exercised. Each option is exercisable to one share of the Company’s common stock. Most options expire within six years from the date of the grant and generally vest on the first anniversary date of their issuance. Pursuant to the Equity Incentive Plan the Company’s board of directors approved on November 12, 2018, an aggregate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20181112__srt--TitleOfIndividualAxis__custom--DirectotAndInvestorMember_zZ4NFdB1Yzpf" title="Number of options, shares">5,760,000 options have been issued to directors and investor relations professionals. <p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zYJb8u8CrVr6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company utilized the Black-Scholes option-pricing model to estimate fair value, utilizing the following assumptions for the respective periods (all in weighted averages): SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630_zAJPxbnj1cxi" style="width: 16%; text-align: right" title="Risk-free interest rate">3.5</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630_zfYwY4N5noic" style="width: 16%; text-align: right" title="Risk-free interest rate">1.5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term of options, in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.9</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected annual volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630_zjvAiOpDFrBh" style="text-align: right" title="Expected annual volatility">191.1</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220630_zjie9hGlGW0g" style="text-align: right" title="Expected annual volatility">185.8</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230630_zr0o2s2nQp5e" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220630_zCnmnVBm6jjg" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Determined weighted average grant date fair value per option</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630_zw5rdgGXTNxi" style="text-align: right" title="Determined weighted average grant date fair value per option">0.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220630_zXeaXBZuausg" style="text-align: right" title="Determined weighted average grant date fair value per option">0.27</td><td style="text-align: left"> </td></tr> </table> The expected term of the options represents an estimate of the length of time until the expected date of exercising the options. Options granted have a maximum life of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zhBzy0pX8aae" title="Expected term of options, in years">7 years. With respect to determining expected exercise behavior, the Company has grouped its option grants into certain groups to track exercise behavior and establish historical rates. The Company estimated volatility by considering historical stock volatility over the expected term of the option. The risk-free interest rates are based on the U.S. Treasury yields for a period consistent with the expected term. The dividend yield of 0% is based on the Company’s history and expectation of dividend payout. The Company has not paid and does not anticipate paying dividends in the near future. (c) Summary Option Information <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3hMBaRMnIe8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A summary of the Company’s option plans for the six months ended June 30, 2023, is presented below (unaudited): SCHEDULE OF STOCK OPTION ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Options</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(in shares)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding, December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zG79w26Etux1" style="width: 16%; text-align: right" title="Number of Options Outstanding beginning">5,400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCSi5ghV7ZT4" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding beginning">0.14</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4u592MbU6M9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Granted">360,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zr5lIpJsMALg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Granted">0.20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, June 30, 2023</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWuZRD0b4fg4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding ending">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zwHkexV1KfO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding ending">0.14</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, June 30, 2023</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFtx8QdtWjPe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable">5,400,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zftyzU8BYhli" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">0.14</td><td style="text-align: left"> </td></tr> </table> Stock-based compensation expense related to stock options was approximately $32,000 and $15,000 in the six months and three months ended June 30, 2023, respectively. Stock-based compensation expense related to stock options was approximately $123,000 and $74,000 for the six months and three months ended June 30, 2022, respectively. The total compensation cost related to non-vested awards not yet recognized was approximately $50,000 as of June 30, 2023. As of June 30, 2023, 360,000 options were unvested. These options vest one year from their grant date which is March 2024. (d) Warrants The Company has issued warrants at exercise prices equal to or greater than the market value of the Company’s common stock at the date of issuance. A summary of warrant activity follows (unaudited): <p id="xdx_899_ecustom--ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock_zMawxWOhzMw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> SUMMARY OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">shares</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">underlying</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; padding-left: 5.4pt">Outstanding, December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpMgQgDU5jja" style="width: 16%; text-align: right" title="Number of shares underlying warrants, Beginning balance">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBiAcO2wLmp8" style="width: 16%; text-align: right" title="Weighted average exercise price, Beginning balance">0.12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGl8D5uixlK1" style="text-align: right" title="Number of shares underlying warrants, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCwDlnl7YJE8" style="text-align: right" title="Weighted average exercise price, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBZaAJRFY4T" style="text-align: right" title="Number of shares underlying warrants, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6SNtIUFNIqd" style="text-align: right" title="Number of shares underlying warrants, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zL0cCDNNspZ5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares underlying warrants, Forfeited or expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsKf4mYRix9g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares underlying warrants, Forfeited or expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Outstanding, June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpj0rXnzN1z5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares underlying warrants, Ending balance">3,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWJ6HQNnlP8a" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Ending balance">0.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The warrant agreements were amended on May 12, 2023 to extend the expiration date to June 28, 2025. The warrants outstanding at June 30, 2023 have a weighted average remaining contractual life of approximately <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dc_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeRhflU3YKhi" title="Warrants outstanding weighted average remaining contractual life">two years. The Company recognized $243,000 in stock-based compensation expense related to the increase in fair value of warrants pursuant to the modification of the warrant term during the six and three months ended June 30, 2023.

46881475

0.01

5760000

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zYJb8u8CrVr6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company utilized the Black-Scholes option-pricing model to estimate fair value, utilizing the following assumptions for the respective periods (all in weighted averages): SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630_zAJPxbnj1cxi" style="width: 16%; text-align: right" title="Risk-free interest rate">3.5</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630_zfYwY4N5noic" style="width: 16%; text-align: right" title="Risk-free interest rate">1.5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term of options, in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.9</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected annual volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630_zjvAiOpDFrBh" style="text-align: right" title="Expected annual volatility">191.1</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220630_zjie9hGlGW0g" style="text-align: right" title="Expected annual volatility">185.8</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230630_zr0o2s2nQp5e" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220630_zCnmnVBm6jjg" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Determined weighted average grant date fair value per option</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630_zw5rdgGXTNxi" style="text-align: right" title="Determined weighted average grant date fair value per option">0.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220630_zXeaXBZuausg" style="text-align: right" title="Determined weighted average grant date fair value per option">0.27</td><td style="text-align: left"> </td></tr> </table>

0.035

0.015

P4Y

P3Y10M24D

1.911

1.858

0.19

0.27

P7Y

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3hMBaRMnIe8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A summary of the Company’s option plans for the six months ended June 30, 2023, is presented below (unaudited): SCHEDULE OF STOCK OPTION ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Options</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(in shares)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding, December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zG79w26Etux1" style="width: 16%; text-align: right" title="Number of Options Outstanding beginning">5,400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCSi5ghV7ZT4" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding beginning">0.14</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4u592MbU6M9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Granted">360,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zr5lIpJsMALg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Granted">0.20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, June 30, 2023</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWuZRD0b4fg4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding ending">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zwHkexV1KfO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding ending">0.14</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, June 30, 2023</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFtx8QdtWjPe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable">5,400,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zftyzU8BYhli" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">0.14</td><td style="text-align: left"> </td></tr> </table>

5400000

0.14

360000

0.20

5760000

0.14

5400000

0.14

32000

15000

123000

74000

50000

360000

<p id="xdx_899_ecustom--ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock_zMawxWOhzMw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> SUMMARY OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">shares</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">underlying</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; padding-left: 5.4pt">Outstanding, December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpMgQgDU5jja" style="width: 16%; text-align: right" title="Number of shares underlying warrants, Beginning balance">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBiAcO2wLmp8" style="width: 16%; text-align: right" title="Weighted average exercise price, Beginning balance">0.12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGl8D5uixlK1" style="text-align: right" title="Number of shares underlying warrants, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCwDlnl7YJE8" style="text-align: right" title="Weighted average exercise price, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBZaAJRFY4T" style="text-align: right" title="Number of shares underlying warrants, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6SNtIUFNIqd" style="text-align: right" title="Number of shares underlying warrants, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zL0cCDNNspZ5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares underlying warrants, Forfeited or expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsKf4mYRix9g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares underlying warrants, Forfeited or expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Outstanding, June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpj0rXnzN1z5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares underlying warrants, Ending balance">3,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWJ6HQNnlP8a" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Ending balance">0.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3000000

0.12

3000000

0.12

P2Y

243000

NOTE 6—INCOME TAXES The Company’s income tax provision differs from the expense that would result from applying statutory rates to income (loss) before taxes. A reconciliation of the provision (benefit) for income taxes with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows (unaudited): <p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z6ocJryxzbz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> SCHEDULE OF INCOME BEFORE INCOME TAX <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20230101__20230630_zZH8kauV62Wh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20220101__20220630_z61eT4qOiqXf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzO6C_zkZrczruihn8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Computed tax at the federal statutory rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBCRUZPUkUgSU5DT01FIFRBWCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20230630_z7iiEPnncIie" title="Computed tax at the federal statutory rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBCRUZPUkUgSU5DT01FIFRBWCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20220101__20220630_zHaNeSlnnkW9" title="Computed tax at the federal statutory rate">21%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(609,122</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(81,073</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzO6C_zqjescyKL0Qi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of federal income tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(126,030</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(16,774</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzO6C_zriavUvvSz62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in federal valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">764,756</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,930</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzO6C_z6FHJxBf79D2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign rate differential</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,604</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(52,083</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzO6C_zKuga1r0995c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total provision for income tax</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td id="xdx_49D_20230401__20230630_zQjlrBwUAuL5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td id="xdx_490_20220401__20220630_zNi1WSHPMrVb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; width: 60%"> </td><td style="text-align: center; font-weight: bold; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 1%"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 16%">2023</td><td style="font-weight: bold; text-align: center; width: 1%"> </td><td style="text-align: center; font-weight: bold; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 1%"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 16%">2022</td><td style="font-weight: bold; text-align: center; width: 1%"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzO6C_zKPZdGHqGqz5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computed tax at the federal statutory rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBCRUZPUkUgSU5DT01FIFRBWCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230401__20230630_zCS16Isfu1yg" title="Computed tax at the federal statutory rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBCRUZPUkUgSU5DT01FIFRBWCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20220401__20220630_zbuHXmsryU92" title="Computed tax at the federal statutory rate">21%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(56,452</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(76,345</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzO6C_z3lO3BfncKm" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of federal income tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,680</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(15,796</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzO6C_zuX6seNCPSpc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in federal valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,972</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">154,045</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzO6C_z1DvD68CQLL3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign rate differential</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,840</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(61,904</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzO6C_zpAC6VjgExNb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total provision for income tax</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> </table>

<p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z6ocJryxzbz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> SCHEDULE OF INCOME BEFORE INCOME TAX <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20230101__20230630_zZH8kauV62Wh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20220101__20220630_z61eT4qOiqXf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzO6C_zkZrczruihn8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Computed tax at the federal statutory rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBCRUZPUkUgSU5DT01FIFRBWCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20230630_z7iiEPnncIie" title="Computed tax at the federal statutory rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBCRUZPUkUgSU5DT01FIFRBWCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20220101__20220630_zHaNeSlnnkW9" title="Computed tax at the federal statutory rate">21%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(609,122</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(81,073</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzO6C_zqjescyKL0Qi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of federal income tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(126,030</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(16,774</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzO6C_zriavUvvSz62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in federal valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">764,756</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,930</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzO6C_z6FHJxBf79D2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign rate differential</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,604</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(52,083</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzO6C_zKuga1r0995c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total provision for income tax</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td id="xdx_49D_20230401__20230630_zQjlrBwUAuL5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td id="xdx_490_20220401__20220630_zNi1WSHPMrVb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; width: 60%"> </td><td style="text-align: center; font-weight: bold; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 1%"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 16%">2023</td><td style="font-weight: bold; text-align: center; width: 1%"> </td><td style="text-align: center; font-weight: bold; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 1%"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 16%">2022</td><td style="font-weight: bold; text-align: center; width: 1%"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzO6C_zKPZdGHqGqz5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computed tax at the federal statutory rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBCRUZPUkUgSU5DT01FIFRBWCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230401__20230630_zCS16Isfu1yg" title="Computed tax at the federal statutory rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBCRUZPUkUgSU5DT01FIFRBWCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20220401__20220630_zbuHXmsryU92" title="Computed tax at the federal statutory rate">21%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(56,452</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(76,345</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzO6C_z3lO3BfncKm" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of federal income tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,680</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(15,796</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzO6C_zuX6seNCPSpc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in federal valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,972</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">154,045</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzO6C_z1DvD68CQLL3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign rate differential</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,840</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(61,904</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzO6C_zpAC6VjgExNb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total provision for income tax</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> </table>

0.21

-609122

-81073

-126030

-16774

764756

149930

-29604

-52083

0.21

-56452

-76345

-11680

-15796

87972

154045

-19840

-61904

NOTE 7—COMMITMENTS AND CONTINGENCIES The Company was the claimant in an arbitration proceeding against their <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NetCoPartnersMember_zkQTlDFoMDO3" title="Equity interest percentage">50% partner in NetCo. The Company initiated the arbitration proceeding in an effort to maximize the total potential value to be derived from fully utilizing the NetCo intellectual property across publishing, entertainment, digital media, merchandising and other ancillary markets. Arbitration hearings were held at the end of July 2022. Arbitration proceedings for the joint owners of NetCo concluded during 2022 and the arbitrator rendered a decision in July 2023. The Arbitrator ruled in the Company’s favor on two key issues of the arbitration. The Arbitrator ruled in NovelStem’s favor on the issue of contract interpretation of the Netco Partners JV Agreement. The Arbitrator also found that the Company’s joint venture partner failed to use “reasonable, good faith efforts” to license and exploit the Net Force concept, in breach of its contractual obligations under the Netco Partners’ Joint Venture Agreement. The Arbitrator confirmed NovelStem’s contractual right to use Tom Clancy’s name as a possessory credit in the Net Force title (Tom Clancy’s Net Force). As a result of this ruling, the costs related to the litigation funding agreement disclosed in Note 4 were recognized. Total costs related to the litigation and the related litigation funding agreement of $2,332,663, including a reversal of the prior period contra expenses, were recorded in June 2023 and were separately stated in the condensed statement of operations (unaudited).

0.50

-2332663

NOTE 8—SUBSEQUENT EVENTS As disclosed in Note 4 and Note 7, in July 2023 the Company’s arbitration proceedings were settled with a favorable outcome. Additional costs of $<span id="xdx_903_eus-gaap--InvestmentIncomeNet_c20230811__20230811__dei--LegalEntityAxis__custom--OmniBridgewayFundMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zq87viQbOAP2" title="Investment return due">466,533 related to the litigation funding agreement were incurred on August 11, 2023.

466533

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 131 174 1 false 24 0 false 7 false false R1.htm 00000001 - Document - Cover Sheet http://novelstem.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://novelstem.com/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://novelstem.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://novelstem.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Shareholders' Equity (Deficit) (Unaudited) Sheet http://novelstem.com/role/StatementsOfShareholdersEquityDeficit Condensed Statements of Shareholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://novelstem.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - NATURE OF OPERATIONS Sheet http://novelstem.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://novelstem.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - EQUITY METHOD INVESTMENTS Sheet http://novelstem.com/role/EquityMethodInvestments EQUITY METHOD INVESTMENTS Notes 9 false false R10.htm 00000010 - Disclosure - NOTES PAYABLE Notes http://novelstem.com/role/NotesPayable NOTES PAYABLE Notes 10 false false R11.htm 00000011 - Disclosure - EQUITY (DEFICIT) Sheet http://novelstem.com/role/EquityDeficit EQUITY (DEFICIT) Notes 11 false false R12.htm 00000012 - Disclosure - INCOME TAXES Sheet http://novelstem.com/role/IncomeTaxes INCOME TAXES Notes 12 false false R13.htm 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://novelstem.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 00000014 - Disclosure - SUBSEQUENT EVENTS Sheet http://novelstem.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 14 false false R15.htm 00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 15 false false R16.htm 00000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://novelstem.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - EQUITY METHOD INVESTMENTS (Tables) Sheet http://novelstem.com/role/EquityMethodInvestmentsTables EQUITY METHOD INVESTMENTS (Tables) Tables http://novelstem.com/role/EquityMethodInvestments 17 false false R18.htm 00000018 - Disclosure - NOTES PAYABLE (Tables) Notes http://novelstem.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://novelstem.com/role/NotesPayable 18 false false R19.htm 00000019 - Disclosure - EQUITY (DEFICIT) (Tables) Sheet http://novelstem.com/role/EquityDeficitTables EQUITY (DEFICIT) (Tables) Tables http://novelstem.com/role/EquityMethodInvestments 19 false false R20.htm 00000020 - Disclosure - INCOME TAXES (Tables) Sheet http://novelstem.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://novelstem.com/role/IncomeTaxes 20 false false R21.htm 00000021 - Disclosure - NATURE OF OPERATIONS (Details Narrative) Sheet http://novelstem.com/role/NatureOfOperationsDetailsNarrative NATURE OF OPERATIONS (Details Narrative) Details http://novelstem.com/role/NatureOfOperations 21 false false R22.htm 00000022 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE (Details) Sheet http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE (Details) Details 22 false false R23.htm 00000023 - Disclosure - SCHEDULE OF WARRANTS AND STOCK OPTIONS (Details) Sheet http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails SCHEDULE OF WARRANTS AND STOCK OPTIONS (Details) Details 23 false false R24.htm 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 00000025 - Disclosure - SCHEDULE OF INVESTMENTS (Details) Sheet http://novelstem.com/role/ScheduleOfInvestmentsDetails SCHEDULE OF INVESTMENTS (Details) Details 25 false false R26.htm 00000026 - Disclosure - SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT (Details) Sheet http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT (Details) Details 26 false false R27.htm 00000027 - Disclosure - EQUITY METHOD INVESTMENTS (Details Narrative) Sheet http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative EQUITY METHOD INVESTMENTS (Details Narrative) Details http://novelstem.com/role/EquityMethodInvestmentsTables 27 false false R28.htm 00000028 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) Notes http://novelstem.com/role/ScheduleOfNotesPayableDetails SCHEDULE OF NOTES PAYABLE (Details) Details 28 false false R29.htm 00000029 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://novelstem.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://novelstem.com/role/NotesPayableTables 29 false false R30.htm 00000030 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS (Details) Sheet http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS (Details) Details 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITIES (Details) Sheet http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails SCHEDULE OF STOCK OPTION ACTIVITIES (Details) Details 31 false false R32.htm 00000032 - Disclosure - SUMMARY OF WARRANTS ACTIVITY (Details) Sheet http://novelstem.com/role/SummaryOfWarrantsActivityDetails SUMMARY OF WARRANTS ACTIVITY (Details) Details 32 false false R33.htm 00000033 - Disclosure - EQUITY (DEFICIT) (Details Narrative) Sheet http://novelstem.com/role/EquityDeficitDetailsNarrative EQUITY (DEFICIT) (Details Narrative) Details http://novelstem.com/role/EquityMethodInvestmentsTables 33 false false R34.htm 00000034 - Disclosure - SCHEDULE OF INCOME BEFORE INCOME TAX (Details) Sheet http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails SCHEDULE OF INCOME BEFORE INCOME TAX (Details) Details 34 false false R35.htm 00000035 - Disclosure - SCHEDULE OF INCOME BEFORE INCOME TAX (Details) (Parenthetical) Sheet http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetailsParenthetical SCHEDULE OF INCOME BEFORE INCOME TAX (Details) (Parenthetical) Details 35 false false R36.htm 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://novelstem.com/role/CommitmentsAndContingencies 36 false false R37.htm 00000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://novelstem.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://novelstem.com/role/SubsequentEvents 37 false false All Reports Book All Reports form10-q.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm ex33-1.htm nstm-20230630.xsd nstm-20230630_cal.xml nstm-20230630_def.xml nstm-20230630_lab.xml nstm-20230630_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 1, "axisStandard": 12, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 481, "http://xbrl.sec.gov/dei/2023": 28 }, "contextCount": 131, "dts": { "calculationLink": { "local": [ "nstm-20230630_cal.xml" ] }, "definitionLink": { "local": [ "nstm-20230630_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "nstm-20230630_lab.xml" ] }, "presentationLink": { "local": [ "nstm-20230630_pre.xml" ] }, "schema": { "local": [ "nstm-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 290, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 86, "http://novelstem.com/20230630": 7, "http://xbrl.sec.gov/dei/2023": 4, "total": 97 }, "keyCustom": 13, "keyStandard": 161, "memberCustom": 8, "memberStandard": 10, "nsprefix": "NSTM", "nsuri": "http://novelstem.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://novelstem.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - NOTES PAYABLE", "menuCat": "Notes", "order": "10", "role": "http://novelstem.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - EQUITY (DEFICIT)", "menuCat": "Notes", "order": "11", "role": "http://novelstem.com/role/EquityDeficit", "shortName": "EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "12", "role": "http://novelstem.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "13", "role": "http://novelstem.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "14", "role": "http://novelstem.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "15", "role": "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "16", "role": "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-06-30_custom_NewStemLtdMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - EQUITY METHOD INVESTMENTS (Tables)", "menuCat": "Tables", "order": "17", "role": "http://novelstem.com/role/EquityMethodInvestmentsTables", "shortName": "EQUITY METHOD INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-06-30_custom_NewStemLtdMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - NOTES PAYABLE (Tables)", "menuCat": "Tables", "order": "18", "role": "http://novelstem.com/role/NotesPayableTables", "shortName": "NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - EQUITY (DEFICIT) (Tables)", "menuCat": "Tables", "order": "19", "role": "http://novelstem.com/role/EquityDeficitTables", "shortName": "EQUITY (DEFICIT) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://novelstem.com/role/BalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "20", "role": "http://novelstem.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - NATURE OF OPERATIONS (Details Narrative)", "menuCat": "Details", "order": "21", "role": "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "shortName": "NATURE OF OPERATIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2018-09-30", "decimals": "0", "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE (Details)", "menuCat": "Details", "order": "22", "role": "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails", "shortName": "SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SCHEDULE OF WARRANTS AND STOCK OPTIONS (Details)", "menuCat": "Details", "order": "23", "role": "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails", "shortName": "SCHEDULE OF WARRANTS AND STOCK OPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EquityMethodInvestmentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "NSTM:EquityMethodInvestmentDescriptionOfPrincipal", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "24", "role": "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EquityMethodInvestmentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "NSTM:EquityMethodInvestmentDescriptionOfPrincipal", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31_custom_NewStemLtdMember19021015", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedAtFairValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SCHEDULE OF INVESTMENTS (Details)", "menuCat": "Details", "order": "25", "role": "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "shortName": "SCHEDULE OF INVESTMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_custom_NewStemLtdMember", "decimals": "0", "lang": null, "name": "us-gaap:InvestmentOwnedAtFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT (Details)", "menuCat": "Details", "order": "26", "role": "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "shortName": "SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30_custom_NewStemLtdMember", "decimals": "0", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-04-30_custom_NewStemMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForProceedsFromInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - EQUITY METHOD INVESTMENTS (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "shortName": "EQUITY METHOD INVESTMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-04-30_custom_NewStemMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForProceedsFromInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details)", "menuCat": "Details", "order": "28", "role": "http://novelstem.com/role/ScheduleOfNotesPayableDetails", "shortName": "SCHEDULE OF NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - NOTES PAYABLE (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://novelstem.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://novelstem.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS (Details)", "menuCat": "Details", "order": "30", "role": "http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails", "shortName": "SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITIES (Details)", "menuCat": "Details", "order": "31", "role": "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails", "shortName": "SCHEDULE OF STOCK OPTION ACTIVITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31_us-gaap_StockOptionMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "NSTM:ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SUMMARY OF WARRANTS ACTIVITY (Details)", "menuCat": "Details", "order": "32", "role": "http://novelstem.com/role/SummaryOfWarrantsActivityDetails", "shortName": "SUMMARY OF WARRANTS ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "NSTM:ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - EQUITY (DEFICIT) (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://novelstem.com/role/EquityDeficitDetailsNarrative", "shortName": "EQUITY (DEFICIT) (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30_us-gaap_StockOptionMember19022203", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - SCHEDULE OF INCOME BEFORE INCOME TAX (Details)", "menuCat": "Details", "order": "34", "role": "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails", "shortName": "SCHEDULE OF INCOME BEFORE INCOME TAX (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SCHEDULE OF INCOME BEFORE INCOME TAX (Details) (Parenthetical)", "menuCat": "Details", "order": "35", "role": "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetailsParenthetical", "shortName": "SCHEDULE OF INCOME BEFORE INCOME TAX (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "NSTM:LitigationExpenses", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-06-30_custom_OmniBridgewayFundMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "menuCat": "Details", "order": "37", "role": "http://novelstem.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://novelstem.com/role/StatementsOfOperations", "shortName": "Condensed Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Statements of Shareholders' Equity (Deficit) (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://novelstem.com/role/StatementsOfShareholdersEquityDeficit", "shortName": "Condensed Statements of Shareholders' Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-03-31_us-gaap_RetainedEarningsMember", "decimals": "0", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://novelstem.com/role/StatementsOfCashFlows", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:EquityMethodInvestmentDividendsOrDistributions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - NATURE OF OPERATIONS", "menuCat": "Notes", "order": "7", "role": "http://novelstem.com/role/NatureOfOperations", "shortName": "NATURE OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://novelstem.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - EQUITY METHOD INVESTMENTS", "menuCat": "Notes", "order": "9", "role": "http://novelstem.com/role/EquityMethodInvestments", "shortName": "EQUITY METHOD INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 24, "tag": { "NSTM_AffiliationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Affiliation Axis", "label": "Affiliation [Axis]", "verboseLabel": "AffiliationAxis [Axis]" } } }, "localname": "AffiliationAxis", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "NSTM_AffiliationDomain": { "auth_ref": [], "localname": "AffiliationDomain", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "NSTM_CashPaidDuringPeriodForAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Paid During Period For [Abstract]", "label": "Cash paid during the period for:" } } }, "localname": "CashPaidDuringPeriodForAbstract", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "NSTM_ContraExpensesLegalFeesAndAdministrativeCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contra expenses legal fees and administrative costs.", "label": "Contra expenses - legal fees and administrative costs" } } }, "localname": "ContraExpensesLegalFeesAndAdministrativeCosts", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "NSTM_DirectorAndExecutiveChairmanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Director and Executive Chairman [Member]", "label": "Director and Executive Chairman [Member]" } } }, "localname": "DirectorAndExecutiveChairmanMember", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "NSTM_DirectotAndInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Directot And Investor [Member]", "label": "Directot and Investor [Member]" } } }, "localname": "DirectotAndInvestorMember", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "NSTM_EquityMethodInvestmentDescriptionOfPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity method investment description of principal.", "label": "Equity method investment description" } } }, "localname": "EquityMethodInvestmentDescriptionOfPrincipal", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "NSTM_GainOnDilutionOfEquityMethodInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on dilution of equity method investment.", "label": "Gain on dilution of equity method investment" } } }, "localname": "GainOnDilutionOfEquityMethodInvestment", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/ScheduleOfInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "NSTM_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment": { "auth_ref": [], "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income loss from continuing operations before income taxes minority interest and income loss from equity method investment.", "label": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment", "totalLabel": "Loss before equity in net income of equity method investees" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "NSTM_IncreaseDecreaseInAccountsReceivableAdministrativeFees": { "auth_ref": [], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accounts receivable administrative fees.", "label": "IncreaseDecreaseInAccountsReceivableAdministrativeFees", "negatedLabel": "Accounts receivable, administrative fees" } } }, "localname": "IncreaseDecreaseInAccountsReceivableAdministrativeFees", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NSTM_InvestmentsInAffiliatesSubsidiaries": { "auth_ref": [], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investments in affiliates subsidiaries.", "label": "Investment in Netco Partners" } } }, "localname": "InvestmentsInAffiliatesSubsidiaries", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "NSTM_LitigationExpenses": { "auth_ref": [], "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "LitigationExpenses", "negatedLabel": "Litigation expenses (contra expenses) (Note 7)", "negatedTerseLabel": "Litigation expenses" } } }, "localname": "LitigationExpenses", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "NSTM_LossOnDerivativeInstrument": { "auth_ref": [], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://novelstem.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Loss on derivative instrument" } } }, "localname": "LossOnDerivativeInstrument", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows", "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "NSTM_NetCoPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Co Partners [Member]", "label": "Net Co Partners [Member]" } } }, "localname": "NetCoPartnersMember", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsTables", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "NSTM_NewStemLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Stem Ltd [Member]", "label": "New Stem Ltd [Member]" } } }, "localname": "NewStemLtdMember", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsTables", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "xbrltype": "domainItemType" }, "NSTM_NewStemMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Stem [Member]", "label": "New Stem [Member]" } } }, "localname": "NewStemMember", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "NSTM_OmniBridgewayFundMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member]", "label": "Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member]" } } }, "localname": "OmniBridgewayFundMember", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfNotesPayableDetails", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "NSTM_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note [Member]", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "NSTM_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Share Based Compensation Warrants Activity [Table TextBlock]", "label": "SUMMARY OF WARRANTS ACTIVITY" } } }, "localname": "ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/EquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "NSTM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options granted weighted average exercise price.", "label": "Weighted average exercise price, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "NSTM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Weighted average exercise price, Ending balance", "periodStartLabel": "Weighted average exercise price, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "NSTM_ShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholder [Member]", "label": "Shareholder [Member]" } } }, "localname": "ShareholderMember", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "NSTM_WorkingCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital.", "label": "Working capital", "verboseLabel": "[custom:WorkingCapital]" } } }, "localname": "WorkingCapital", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "NSTM_WorkingCapitalAndRelatedFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Working capital and related fees" } } }, "localname": "WorkingCapitalAndRelatedFees", "nsuri": "http://novelstem.com/20230630", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r511", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsTables", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "http://novelstem.com/role/ScheduleOfNotesPayableDetails", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsTables", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "http://novelstem.com/role/ScheduleOfNotesPayableDetails", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r508" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://novelstem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [ "r179", "r180", "r182" ], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r191", "r192", "r193", "r194", "r245", "r325", "r352", "r375", "r376", "r434", "r439", "r440", "r441", "r459", "r472", "r473", "r480", "r486", "r487", "r489", "r539", "r550", "r551", "r552", "r553", "r554", "r555" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r191", "r192", "r193", "r194", "r243", "r245", "r272", "r273", "r274", "r324", "r325", "r352", "r375", "r376", "r434", "r439", "r440", "r441", "r459", "r472", "r473", "r480", "r486", "r487", "r489", "r492", "r535", "r539", "r551", "r552", "r553", "r554", "r555" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r191", "r192", "r193", "r194", "r243", "r245", "r272", "r273", "r274", "r324", "r325", "r352", "r375", "r376", "r434", "r439", "r440", "r441", "r459", "r472", "r473", "r480", "r486", "r487", "r489", "r492", "r535", "r539", "r551", "r552", "r553", "r554", "r555" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r246", "r530" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r142", "r246", "r521", "r530" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r179", "r180", "r182" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r142", "r246", "r521", "r522", "r530" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r532", "r546" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r16", "r488" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r175", "r176" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, administrative fees" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [ "r110", "r111", "r309", "r310", "r311", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r110", "r111", "r309", "r310", "r311", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r54", "r488", "r566" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r276", "r277", "r278", "r363", "r527", "r528", "r529", "r543", "r568" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "Stock option compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdvancesToAffiliate": { "auth_ref": [ "r546" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients.", "label": "Advances to Affiliate" } } }, "localname": "AdvancesToAffiliate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Stock options" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r80", "r102", "r124", "r157", "r166", "r170", "r183", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r293", "r295", "r308", "r342", "r399", "r488", "r499", "r537", "r538", "r548" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r99", "r105", "r124", "r183", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r293", "r295", "r308", "r488", "r537", "r538", "r548" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r124", "r183", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r293", "r295", "r308", "r537", "r538", "r548" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r28", "r101", "r474" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r28", "r68", "r120" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash at the end of the period", "periodStartLabel": "Cash at the beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r68" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r23", "r44", "r343", "r386" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (see Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r73", "r189", "r190", "r471", "r536" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r490", "r491", "r492", "r494", "r495", "r496", "r497", "r527", "r528", "r543", "r558", "r568" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/StatementsOfShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheetsParenthetical", "http://novelstem.com/role/EquityDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r53", "r387" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r53", "r387", "r405", "r568", "r569" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheetsParenthetical", "http://novelstem.com/role/EquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r53", "r344", "r488" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.01 par value, 100,000,000 shares authorized, 50,316,672 shares issued, and 46,881,475 shares outstanding as of June 30, 2023 and December 31, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r74", "r122", "r204", "r210", "r211", "r212", "r213", "r214", "r215", "r220", "r227", "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "auth_ref": [ "r14" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the total principal payments made during the annual reporting period.", "label": "Note payable shareholder, principal amount" } } }, "localname": "DebtInstrumentAnnualPrincipalPayment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r49", "r50", "r81", "r82", "r128", "r205", "r206", "r207", "r208", "r209", "r211", "r216", "r217", "r218", "r219", "r221", "r222", "r223", "r224", "r225", "r226", "r316", "r481", "r482", "r483", "r484", "r485", "r525" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r21", "r206" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r92", "r481", "r544" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r22", "r128", "r205", "r206", "r207", "r208", "r209", "r211", "r216", "r217", "r218", "r219", "r221", "r222", "r223", "r224", "r225", "r226", "r316", "r481", "r482", "r483", "r484", "r485", "r525" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r39", "r41", "r540" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Less unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r106", "r107", "r307", "r365", "r366", "r367", "r368", "r371", "r372", "r373", "r375", "r376", "r400", "r402", "r403", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r476", "r562" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative fair value liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r106" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability, guarantee" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r115", "r134", "r135", "r136", "r137", "r138", "r143", "r145", "r151", "r152", "r153", "r155", "r305", "r306", "r339", "r350", "r477" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share - basic", "verboseLabel": "Basic net loss per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails", "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted net loss per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r115", "r134", "r135", "r136", "r137", "r138", "r145", "r151", "r152", "r153", "r155", "r305", "r306", "r339", "r350", "r477" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per share - diluted", "verboseLabel": "Diluted net loss per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails", "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r29", "r30" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Basic and Diluted Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r125", "r281", "r289" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Computed tax at the federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetailsParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r541" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r6", "r97", "r110", "r111", "r112", "r129", "r130", "r131", "r133", "r139", "r141", "r156", "r185", "r186", "r242", "r276", "r277", "r278", "r285", "r286", "r297", "r298", "r299", "r300", "r301", "r302", "r304", "r309", "r310", "r311", "r312", "r313", "r314", "r317", "r353", "r354", "r355", "r363", "r427" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/StatementsOfShareholdersEquityDeficit", "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r2", "r4", "r60", "r347" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Distribution from NetCo Partners" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity interest percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r163", "r177", "r523", "r533" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r94", "r181", "r184", "r520" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "EQUITY METHOD INVESTMENTS" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r2", "r38", "r180" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r64", "r409" ], "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r62", "r124", "r157", "r165", "r169", "r171", "r183", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r308", "r479", "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r59", "r85", "r157", "r165", "r169", "r171", "r340", "r348", "r479" ], "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "NSTM_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r4", "r60", "r84", "r161", "r177", "r347" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://novelstem.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Equity in net loss of equity method investees", "negatedLabel": "Equity in loss of equity method investees", "verboseLabel": "Company\u2019s allocation of net income from NetCo" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "http://novelstem.com/role/StatementsOfCashFlows", "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r125", "r279", "r282", "r283", "r284", "r287", "r290", "r291", "r292", "r361" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r89", "r91", "r140", "r141", "r162", "r280", "r288", "r351" ], "calculation": { "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://novelstem.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "NSTM_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income tax", "totalLabel": "Total provision for income tax" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails", "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r542" ], "calculation": { "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in federal valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r542" ], "calculation": { "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Foreign rate differential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r281" ], "calculation": { "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Computed tax at the federal statutory rate of 21%" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r542" ], "calculation": { "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State income taxes, net of federal income tax benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r3" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r3" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r3" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r146", "r147", "r148", "r153" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Add: Warrants" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r146", "r147", "r149", "r153", "r249" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Add: Stock options" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r40", "r88", "r113", "r160", "r315", "r412", "r498", "r567" ], "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseLongTermDebt": { "auth_ref": [ "r87", "r95", "r96" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of interest paid or due on all long-term debt.", "label": "Accrued interest added to long-term note payable" } } }, "localname": "InterestExpenseLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r116", "r118", "r119" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r19" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest expense paid" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": { "auth_ref": [ "r559", "r560", "r561", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.", "label": "SCHEDULE OF INVESTMENTS" } } }, "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r65", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment return due" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIssuerAffiliationAxis": { "auth_ref": [ "r358", "r362", "r369", "r377", "r390", "r391", "r408", "r409", "r410", "r411", "r413", "r414", "r419", "r420", "r435", "r436", "r437", "r444", "r445", "r446", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Information by affiliation of issuer of investment.", "label": "Investment, Issuer Affiliation [Axis]" } } }, "localname": "InvestmentIssuerAffiliationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentIssuerAffiliationDomain": { "auth_ref": [ "r358", "r362", "r369", "r377", "r390", "r391", "r408", "r409", "r410", "r411", "r413", "r414", "r419", "r420", "r435", "r436", "r437", "r444", "r445", "r446", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Affiliation of issuer of investment." } } }, "localname": "InvestmentIssuerAffiliationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r358", "r365", "r366", "r367", "r368", "r370", "r371", "r372", "r374", "r377", "r378", "r390", "r391", "r433", "r435", "r436", "r438", "r442", "r443", "r445", "r446", "r447", "r456", "r458", "r466", "r468", "r469", "r492", "r499", "r562" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in security owned.", "label": "Carrying value of investment", "periodEndLabel": "Investment in NetCo, ending", "periodStartLabel": "Investment in NetCo, beginning" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/ScheduleOfInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r524" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investment in NewStem Ltd" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossReductions": { "auth_ref": [ "r457" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gross reductions to the investment in and advance to the affiliate.", "label": "Investments in and Advances to Affiliates, at Fair Value, Gross Reductions", "negatedLabel": "Distribution from NetCo" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossReductions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the investments in and advances to affiliates.", "label": "Allocation of net income from NetCo" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r63" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal fees and litigation funding fees funded by litigation funding agreement" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r18", "r124", "r183", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r294", "r295", "r296", "r308", "r385", "r478", "r499", "r537", "r548", "r549" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liability", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r58", "r83", "r346", "r488", "r526", "r534", "r545" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r20", "r100", "r124", "r183", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r294", "r295", "r296", "r308", "r488", "r537", "r548", "r549" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r14", "r45", "r46", "r47", "r51", "r124", "r183", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r294", "r295", "r296", "r308", "r537", "r548", "r549" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Total long-term liabilities", "verboseLabel": "Non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation settlement, expense" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r103" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.", "label": "Current portion of long-term notes payable", "negatedLabel": "Less current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r22" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Long-term notes payable, including accrued interest, net", "terseLabel": "Long term note payable", "verboseLabel": "Long-term notes payable" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Ownership investment percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r90", "r93" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "NATURE OF OPERATIONS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r117" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r68", "r69", "r70" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r61", "r70", "r86", "r98", "r108", "r109", "r112", "r124", "r132", "r134", "r135", "r136", "r137", "r140", "r141", "r150", "r157", "r165", "r169", "r171", "r183", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r306", "r308", "r349", "r407", "r425", "r426", "r479", "r498", "r537" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://novelstem.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "terseLabel": "Net income (loss)", "totalLabel": "Net loss", "verboseLabel": "Net loss available to common shareholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails", "http://novelstem.com/role/StatementsOfCashFlows", "http://novelstem.com/role/StatementsOfOperations", "http://novelstem.com/role/StatementsOfShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r66" ], "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other expenses:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r14", "r82", "r557" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Total notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r157", "r165", "r169", "r171", "r479" ], "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Accrued interest added to note balance" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherControlledCompaniesMember": { "auth_ref": [ "r455", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Controlled affiliated issuer of investment that is not majority-owned.", "label": "Investment, Affiliated Issuer, Controlled, Not Majority-Owned [Member]" } } }, "localname": "OtherControlledCompaniesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r43", "r341", "r380", "r381", "r499", "r565" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Due to related parties" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermNotesPayable": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.", "label": "Advance of long term note payable" } } }, "localname": "OtherLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r70" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Accretion of discount on note payable", "verboseLabel": "Accretion of note discount" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherShortTermBorrowings": { "auth_ref": [ "r15", "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.", "label": "Advance from borrowings" } } }, "localname": "OtherShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromInvestments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.", "label": "Additional funding" } } }, "localname": "PaymentsForProceedsFromInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r104", "r187", "r188", "r475" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r26", "r359" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from long term notes payable" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r244", "r318", "r319", "r379", "r380", "r381", "r382", "r383", "r404", "r406", "r432" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyMember": { "auth_ref": [ "r126", "r127", "r318", "r319", "r320", "r321", "r379", "r380", "r381", "r382", "r383", "r404", "r406", "r432" ], "lang": { "en-us": { "role": { "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.", "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r42", "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related party amount" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r244", "r318", "r319", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r379", "r380", "r381", "r382", "r383", "r404", "r406", "r432", "r547" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r27" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-Term Debt", "negatedLabel": "Repayment of short term note payable" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r55", "r76", "r345", "r356", "r357", "r360", "r388", "r488" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r97", "r129", "r130", "r131", "r133", "r139", "r141", "r185", "r186", "r276", "r277", "r278", "r285", "r286", "r297", "r299", "r300", "r302", "r304", "r353", "r355", "r363", "r568" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r114", "r124", "r158", "r159", "r164", "r167", "r168", "r172", "r173", "r174", "r183", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r308", "r340", "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of stock" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF WARRANTS AND STOCK OPTIONS" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "SCHEDULE OF NOTES PAYABLE" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r5", "r33", "r34", "r35", "r36" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "SCHEDULE OF INCOME BEFORE INCOME TAX" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [ "r124", "r179", "r180", "r182", "r183", "r308" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r98", "r124", "r179", "r180", "r182", "r183", "r308" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r12", "r13", "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "SCHEDULE OF STOCK OPTION ACTIVITIES" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r3" ], "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation", "verboseLabel": "Stock based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Warrants outstanding weighted average remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield", "verboseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected annual volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Number of shares underlying warrants, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.", "label": "Number of shares underlying warrants, Forfeited or expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Number of shares underlying warrants, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r7", "r8" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of shares underlying warrants, Ending balance", "periodStartLabel": "Number of shares underlying warrants, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Number of Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of Options, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Number of options, shares", "periodEndLabel": "Number of Options Outstanding ending", "periodStartLabel": "Number of Options Outstanding beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Outstanding ending", "periodStartLabel": "Weighted Average Exercise Price Outstanding beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Percentage of outstanding shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Determined weighted average grant date fair value per option", "verboseLabel": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails", "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term, in years", "verboseLabel": "Expected term of options, in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Options unvested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfShareholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r48", "r81", "r488", "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Borrowings" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtInterestRateIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument.", "label": "Short-Term Debt, Interest Rate Increase" } } }, "localname": "ShortTermDebtInterestRateIncrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r71", "r121" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r6", "r24", "r97", "r110", "r111", "r112", "r129", "r130", "r131", "r133", "r139", "r141", "r156", "r185", "r186", "r242", "r276", "r277", "r278", "r285", "r286", "r297", "r298", "r299", "r300", "r301", "r302", "r304", "r309", "r310", "r311", "r312", "r313", "r314", "r317", "r353", "r354", "r355", "r363", "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/StatementsOfShareholdersEquityDeficit", "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r129", "r130", "r131", "r156", "r326", "r358", "r364", "r377", "r379", "r380", "r381", "r382", "r383", "r387", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r406", "r408", "r409", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r427", "r493" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsTables", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "http://novelstem.com/role/StatementsOfShareholdersEquityDeficit", "http://novelstem.com/role/SubsequentEventsDetailsNarrative", "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r129", "r130", "r131", "r156", "r326", "r358", "r364", "r377", "r379", "r380", "r381", "r382", "r383", "r387", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r406", "r408", "r409", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r427", "r493" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsTables", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "http://novelstem.com/role/StatementsOfShareholdersEquityDeficit", "http://novelstem.com/role/SubsequentEventsDetailsNarrative", "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r52", "r53", "r76" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Shares acquisitions shares" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r6", "r24", "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Shares acquisitions" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails", "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r53", "r56", "r57", "r72", "r389", "r405", "r428", "r429", "r488", "r499", "r526", "r534", "r545", "r568" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total shareholders\u2019 (deficit) equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/StatementsOfShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 (deficit) equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r75", "r123", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r303", "r430", "r431", "r470" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury stock, shares" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r25", "r31", "r32" ], "calculation": { "http://novelstem.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "negatedLabel": "Treasury stock, at cost, 3,435,197 shares as of June 30, 2023 and December 31, 2022" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r490", "r491", "r494", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/EquityDeficitDetailsNarrative", "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails", "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "-Diluted" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r144", "r153" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average number of shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r143", "r153" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of shares outstanding - basic", "verboseLabel": "-Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails", "http://novelstem.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-26", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(11))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13A(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 6)(f))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r501": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r502": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r503": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r504": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r505": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r506": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r507": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r508": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r509": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r511": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r512": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r513": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r514": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r515": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r516": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r517": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r518": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r519": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(f)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.8)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "https://asc.fasb.org//323/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 56 0001493152-23-028259-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-028259-xbrl.zip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
'#L>X/Q:KV9,N)"Q3.8AL1_,9/;(;*1#[^Z^&G%N MW+!DG]A[\A-3-B^G6 Y;Y'S&\V-V^QC #+HA[SG6,;OB0Z'D@ 6NURYC>\H$3UFGE*+%)Q)PVP8O <\YGOS; M7M"L:>X'C73>)ZWUX%^(?LX_?$R=^A. +QI_@2&HPC.#-]C>/)[83 M"_OUK*F89]:6;P MU@@B"0 4%QL4%P?N]MJL$ZKLVO(X>32 MEGST;*_PP@@BN6XF0237S22(Y+J9!)%U 6O1IP=UGM6Q-DER730,Y6 M#MZ3TP__'.N%5 ;5!C*:(&PLA,'Z'LVWOB^ RX1?8_&[?=AX>SC_RG7=V/R: ML$O819H/V\9;7EI*,:-&L7,> M4"WOV4,*\1)=X44$AZUQV-[ MKZ0-0V9PDQ"I/2+)0A(>=<*CJ1:2ENK&673I1Q'\M-!U375:,U"-*^UCN%)% M-ZLC([DFPC1A6B]N$Z8)TX1IPO2F8WK[H+6O/ZQ+.8A(B"9$:\/PU^M(JO5> M5Z4-#QIM)J -#P1 J");"0 $@ )@$9RC@!( -1(N 1 +5<\MJMJ ?O-JJ_K"P@-P'V]O+$?\K#O MP!#PT97PI_CO5(?7:]*CRH(]_7EHF+X?-8YV.V3^";9FP7;[J+%_:-QJ$T'V M!4.VLW^H/U[IZ"F5QS3D')7'"( :"9< 2 D )K(1@(@ 9 :"3G"("T1+H8 MGSX5#X5&S@_69$/XS" ](,J$9XOYQT1)CTF/-6ZK0=JR"*J\U"=QS V$@ )@ 1 (SE' "0 :B1< M B !D "X?C;26E_&G%G];+B7\/"1M1=8^R/-)<1+[KV&I4G>&YLKF0JR)L$[8)VX1MPC9AF["]D=C>;C<.]JEK#F&;L*T- MMFFMEC;JKYMSM%&? *B1< F !$ "H(EL) 2 F 1G*. &C ZJBV77<23YA] MW\;,=](M>D2J1*^JA2:;,Y;!SMFWHVBQ!."%]@->NPT3DZ,@'B&[12 M2^A>$;KW#TI*$M=7$'ASVSV]_ A?UVNEAHA_)5'LW#U6.(UK(XC^9[WV502A MB(071XQ[C _]Q(M!QE'$X@'\X+B7N,6GJ+FWJ/C M]4%-8Q@!3UF#.!PO%OT0M#;@88PU(=P[;_F>+;Q(V/+7H3-D=X['/N>1],[HWXG@C/@@?WC]F?W$W@JPYK M-C-G='[Q9T:0(CXWX 7EYWS\\OKOYXO]7:DM_?7'?/ MLN_'G83ENRX/(J E^^J8/3AV/,#YM5[-F'"A]CE9T8S]8":S1_8\'7IW]]6( M<^,6/_O$WI.?F')%.<5RV"+G,YX?L]O' &;0#7G/L8[9%1\*)9"A+X(J5HE(QPZ'$1/,F% M(O.0J0K5)BJNSN6=K0_PR1NPD?7:93SMXXI0_.E>O3&: V[;8+_A.\>3?]M9 M+6G!)3;-/=7):2[LTP^&>5F@_:3+KKJ?8: P^D^KLPL_>]/]<)9YTGKM(G6E M-[D#17=[QJ,!^^3Z#_+XFO2^LZ:?JK'FN@I[$:N;L-#[_=_)97#:.7 )JR)[PP>IZQSVW. MK%2H+G.=.Y7KA/Z0^> ^>8PE26[%SKT3.R*?ZVR.SV" &GK!$M0B'YPUH$[4 M/$N43YTG,XD!>E%3M6:E">,!YHO3E&1];\9:WLRLU'9>+6[8)BJ,LYZ<1K8$5LP:*&-&>D!V,78\3=%K MLAX:4E.U]9A^>]?&\J>J/X;B>^*$PF:Q#U];OF$Y7#5P7QZY\P2+OD9?G@QWWNTY&.KE':[ MI:7B?17WW$VD='%%!\RH?$L/3.EHVX3C17&8H-G5'0%3H9=&"-ANSRT9E1?I M_)*>%ZXNF+BU0&^)M_<.-)9YN]$Z.M12\;EU6HW.ZT*T3.SZDL;[ZS)K>[(G=#4;YI4?Y"(+]:)(-^$59B[W"3S<3^ MVP7\%-D)':G1PDY,+HPYD$%&M#!&=;87*X[*// \U=ID#]RL.L-?LP^>FA_9 M"H.HT<)63'KAM'A+7I@TZX6*8UG-RG8?J*,5\:,KYNU(N Y]2P@[BWFC*,'^ M9+B$ @X ="]\9!%6U*,&+D63DS;?2L2&L[SW.]=5D M,.-5E"E7>>>K;[ W8GWW,6MBB_! MEF_V(DFG-34Y,AUF4K,B'WOVE#%@/);G'7JB[W@>!GUIWZ+9!R VT58<'5:^ M47/-]N* [ 79B^>&&C\U(0)^5[GQF.[I6*;U6&KT5(I[K:D=E2LQ'^.TECCM MF:GCW&/7[/^\C"[CV+531G-8\A8 M<] ]U1P4=:Y>:[,F^T-X B+>PL2J"@33'SJHWS!D<_]@YU %=68$G[,]V5*1 MQB^UX!R/;UKYMUF,VAH+1!8?=4;(@L6.B<1\L;'2B;5V]AUOZQFW-4Z,4Z8> M='?&E/=7*:P89'GLP9;X@W$*V_[=M;\G_K%RHC*__3V4/WG-'L!=.I[EAX$? M@@N5VY%O1 OZHD0G&?[@"6@EJJ7C\L?HC3W78X,Z9[QR8LHY,)5U2]_.,0@ M'UX)7KN71(Z']S&DIY%\#^D"-^X^(A5'.U-79YA?$2$#88B!.#7"0-PNJY6I M+6 .!,W,%O?"]0.,H;%VU1R/> L?\%8V([O._YP%P+KWI9EHP!&)] )/)I?%L?8B#X1AHL$3C9M[83 MX>Z B*P26:6U6:4S(ZS2C9/?[[SH'WPBP!"@P0HA"QB("+L9),-$&AC9$DS( M>.3;S6]'C?W#_=$E3JP[705H+&T+1M%2A-%2]/16(-93%UFC+05J]EJ'.2T- M^0".EO4N6XZ.><>TF9U(2XRC1UFO=U9L #[!@HR^PUD77I$-*]6&(1WSJL!/ M]]5,K<7$2N83%?@\AZ[,U$QGJH@OOC!<5U0(M4:T._%'-N; MV+:#I@(BD#M(5&2/0 O&<+Q$R'BED$_X]VD>XP'9K-UA4EVB'?:9>Q#P8#B1 M:WH ZAS!&T&=0M'G(;X3:8#'(P'"CF,(.M!2N8DM\C?:Q="D@9CX6RB5!1/@ M.I;PHG1GD RE0M].K!@F#Y;M 2(<_#\2XF_Y1&%BV3YR)("'(??ZZ=C)Z DE)8K'J3;#S)[*]G= \.2 M6!9D9G<)-@Q#$A3KD<@HN;MS+$>^51Y4PT,S$9A$>$MANF%A*[SO@4D(A]*4 M@Y7'EC0L+_#*%^\ %@3C;N0S+$:Q_6XJ@LS2G16:F5WZ$"QV^Z%0'S/Q0U@)N(H==CO#F!=8)EV+[0"'&,Z.C <:8F1M#ST5FEX\=>C8S9<(D M;S+&D%4AJ[)(1GD^E5$N8E[*)4& .LK )YK*;E<%W,GEJ-)97<7.A_QOV_$J M5\<+B -52#G3>/[NV1#YF+:%3&,;HTLYK*UG,:R]HWL5[)=K\ZDJL73UCXUM M/"H810+(//9WM ?(UU]9-;GFN."20>1_G'B S:3 \%]]0*#>O>G+&C_5:# MI8O Z8O29V\A]X^XRCW3-6&SZX&&W]>K=M]T6).=\LB1->SK$/RL%W/5M-NX M254:ZTA#L8:C =-)9%;EB09"Q+/V((Z6 :8?CL9N7QY5+!O,&F"Q3VZ%D&UG M!KYKBS!*:UCU&BY!@!KG2Q)W8YSS] M*#P60$[+0[5J@6P+;T=).6F1QOAUW$6&R*DCYH5"Q_ MH2K>T<)5H9Y@H> 2V/#$7XDG/6>])J&-I&3,F?DT:NF,$T8YH2DO)NO4JD*4 M*_6CX&&JR.? &KE/:[,X+? !VG[(98]:!VPK^)>8*53+C>= 5M""&'3U;HSX+,//B)J &\B M-4-)OB?7DDXKQ6D%F[2?C&;G'W$[I"-NFAUQ.Z0C;G3$3?^#8G3$C8ZXT1$W M.N*VAB-N59;4=EF3%4N?LA6G<=/9E*0E2PN$UP?+8*O('0O7Q2)7>@&PP&04 M,Q/<78)[SD1X[T#&JO;4\1[#&^W@%R4[JQ6S90,DBXO"V:[%\9W;SOBMS@%_ MQ"T_(U'C]A^U71!R.B%D(R3.PO3,6!+@0^W.*_QF],G-*#AHL;Q7',Z858%CJ]7-O*BL7BS.JK/ZXJDXS3NU,TI; A-:S MG>IU^6NS+0LW2]Y(K@D?O]W\EI_5G&HYO[GPJ6#:53=C3H/= XQU)W$WS=>. MXNL9GC6#Q#94:YI34TT'[;R:R;@G!IW7 S<+R5\]L=Y76F/@[$4'I;PIA45[ MJ@%W83XSN5'&'#I/#5XFJROBZPPF3EW0\W,>:M%\7]]NXGI1L^JN\T\JQU<1 M"1Y:JF="L6M+=MCM%_S1 GIG2,/S=F?JAO;R+5@U[*NV2WI[^B(),DL;9)8, M.D_P,JOVJSYX.MU@;>4'3T_5!O[UG3I=V2F8#:CM+Y7)KZHB]NM)MR84ONPZ M"U7GJ#JG19GJA4Y;R^K<%]F?R4I"W&24-G&A"MU<:$Q=XD4%NJ438#5N\5\J MV;V0W'C=);NN.D\6X2X]["[ULBMT4ZL-5*";N8#P/!-453VH]",F&]%=8H\U MQUIHCHZ87'A1'"98H#=P?ANR@_K*O\_NWNBTQ[=11_!>/+?-;IQA ((;M3W% MX[*?5#?2CZHC1';GQTWWT\?191^XS5[V,KT740S/I*=Z5>M"7(5NMUIY7%^O M_1$*'K/3T(F=:,"NT>7D _]Q>IV/N\V#(/1_.$,>"_<1&TRW=_=&^<'KS=BJ M;124Y#$+JZ#EQ28)F9;CQOQ"/P# $7="=H_GAO-FF7,'4(PJ=+65\+S$A3ZV M6QBM7AL*'@$\\2%"PYK0,.HE(SND.EECU50V$PB01D7U4Y[LPB\[ F12=KP@ M4?TA;(&=G1U/%$>1]^=B.PH76].\VPC9EUQ!?[O[*PM#&$_EJS$OMP!'95LJ MVVI1OWRATUY=V78K6Z/-SK]S+\&V4.VI=:YY%=F%"X(EU547W0HT;U]C&?71 MA>?]*Y.<-:/=O3DSTJ V^:12GLDX"<.D41A3LHJ7I=9+5W9^P6;L_ZJ=^/42 M6"FL*X]/,YBRW5XTZ)@FXW6UAE/C(K=>U%1B99ZHYDYXKD7W9VQT;;US0,7U M!6,!/[;,F^WBO[K(;78NG.GA4/:_5[KM8S/N??OEZ_O'KD^=R%FC M-PAAXTY MF_-DFZTY!)5,PM,7OJ[^M(Y)>XI6O,K\Q:O7/LOCOIW\UXR;$#BX<@>\G\[\FYY]6GAV?)FS^QR%?BZLY?>*CCVZ;L*PPR>ZLP'EDW/N2Q'B=JKPQN2M9DC&J7HL&>!5'NK,#'_55*\;) MGOWY_1/P,P^F!<-'PG. 1GF[J6S&J)Y+N1>$CB4]C/JY8EKO,;UP0.TXRG8? MU&LP1CRZ%IKVA*Q^L]F=@F>FG>I6[ZAP53=VX?08Z(OK@% 1Q@T%!GQL&F)L M:6050%6O*53Q*!VFAS<#1PK=> 7YH$!8/&K)V%"]0B>Q)[XGD$$ 8?[K[*W MN_X#ZLA",*W7 HY.VPEXG%ZD5KCK@O"ZKO:R $>TBBA2U_F>. !*>16)YSZR M;<".C=?'CJXKR?W$Z\;HWA,$@;3T"FB.9X6"1_*JZDZK8/;7T5 XDY.) NKF M>FZG?C2]U07<&RAC^OUB-RTI<;G8:1 O%[>]U&;$2O?O1)C[142%+>U&DKK7 M433Q #_&*X[$#V$E>+N986I+><^+[DEPD_2:EVE?[#6F/&9=T[F&I">_UPHS M'G6OU>U C,UQ>@__+-FR;;1?:1 _E>0TTA1"MK]4!M1GXNY.6!AMU6O9ABB5 M>>'V78[]TIM9:_4GHC"TPZX+@V#(!,8:'&#\R,+TL@1XQ:>0]QU(E_X_NWGT M[- ?BCS1N,@/ 9AF6C% MW7B=0NPJT8]UY9?)KIL, QACR%2*_79_E&'7:_A^O PP8NWF?@Z23_(2MPSL MUY*:$:9AD/U1FB[#+WG%X6BL@^:A_%CQ<,KTY]B1[#+F>P\\M*.=>NUV_ 8" M[D;^:&[X5"B<82\)(Z5Z,!\(]O$K"]*22-T.^0"*AA$B'@ ?78*'J:O4CZRL M.E.%&C D!"=C1V-^ZXS.Q4AR)=/G4W6G#O84B.YT0Q NA>Y'W92)LUNCYCEF*&_B-W\18;E@2H^ HC M$7>5G@+F4. IBC'-[7&,N?W95XRF:FZ/ 1ERX,P9C-W'L;LSRJD]$6&C,Y,GA_D(/"(]9 M0"S>-8O'4(#3N&J8Q.[,A'"'??9#X4.(.G5529'-V8B*O_4:B!8+!)Z0YZ/3 M5 5+!:#;.8<50Z21FOA-B/88C<;U #/.BXL+9@%]&"1#8@,ID-+LT;69:+/2 M.W P:)#%9[EXFEV,PY&'HW)'JR ;*[T),Y>R^.'$X]S+3?1'_-4G(29#C0QZ M.0T2;9B&PP/U6IZ,%]\G&?]4(KZ#%YN/@ C,E*;1'LL99U.N7I;=HFT[D31R M$CGUFCR2A +CKI5@Y)(.I!IWJ*-(Z>C97-/+@T='E29^GZXZ*_N.MY0BPXID MCN>9HR-P4D!8OQKBU%"L.QCN17('3,PFSF'-(:# ?5R,EEEN\1@>ZM,.Z\ZZ M;%S66.<-/48QFR*8[/]Z[;^Z-UW&%[A3 LQ2CK8&H7+K/. M;4>NLA,+(3A@E 3R3NG,O(5YGU8($NX=]"OUVC;8?KQ.6]CYS=6CH")=4\9D MYW5C%,EP2U[SE ^<7]8EK^HMZK8<93*HPWP&\9KI;PR1D^7$C](%!#X&0(A\ M.TSZ %^L/J,^4K2RIA.E&=3N'?$0J:0#02&+L])7*R\X\MU1ZI/EB5'X&%[Y M)F&.:6LOBL,#B38/D[IMG)Q8?,A<*#]1H\F;G0DS<7'\:]>7X^MJ"MN3K@N=I<9:6? ME[--1GG[Q77FE3&>NTLOGY>.@'DLE%/#E^+,8'!Y M-YSE]ST EYTNYO@.GDWWY+W?..=TR2GG57<_2S607UQ/\=FR<>+T& M\O=0 >1"D3]T5+$_77;-8^?,5$V&+ J$ [EY5:X2*^&D4TAYA"+!+^5*1,II MN>/?!^SW9; %2)V*A@S;;K7JYB>FFL90;EANC"MB >;990^H2<422FZ-LMNU MV.C*)53!B2 O*_?,*K! R#G*P^JU4;Z(K\G3F#R+ >,4X&K+6,E!)3+%*#2E M7V8!$NZ6"K$M::5X$( ]X+);1&&$!DOD.HZ,214ACQ#2IR'U#E--]F;0A$J5 MAO"@57>)ZRI[#K986M%\6 AR(6K%]XZG-WU<(03BC-*SI[;USCG\\/:8?9', MC-ZQ2ZQ.T0D('4Y O/W5$Q!&[OTWR254O:>OR(IGDEK1G"Q]:W.BRM;P]U3E/W!RGGUJIDHS@/?,[+QEO"3FHHZ:9#)?+(16F2 X M7)+HKW^[FXNHH*B@8-CG[)U$H7OUZG5?JU?_^'\?(X%X [+"2^*_9]0Y>48 MD94X7AS\>Z:I_63^[/]=GI[\&*KP.?BLJ/Q[-E35\<6W;^_O[^?OJ7-)'GRC M"H7"MP_TS)G^T,6'XW,T25+??CWXA&BF3).DDG;4-DE0 M.S<0_/M\(+VM'2>?3%'F.$N;,[]2]'6/42R,:<\ OX!ITR'Y1!WW78 M[#?XK?F@IB0'##.V'NXS2@\_:'PQ-RK\3)8$H#@^C;^9>YQ3Y:0Z&0/%&13X M]3?T-7J'3I(I&UI821-5>>*\5N/+N:D465T&"GXX]U"]W7FPGA*E-R H*AB= ML]((/T9F4^09YDO 6!P%T0;:!^)^K,"%P0 M']S'=Z)6QK]T2;K4?6S_0Y>OB\4F_(' (Y))KV^GBEVTUN[<&KOF&C<8*%W2 MWZ)(:IO7,V070,J$"X#_KX@0A9,2Q(W,"#61 Q]W8-(EX3\%BLZDTYN,6["- M6QP!D8/_JE6!&73[C*" 38;*VX8J2ZR&1^(5EA&:0.8EK@H_4[H_Z4W&I&QC MEC19MH9\ 8Q<$;DRHX*N_O5]F_QXX,GIP\]__]U@BNP5I(]RE^H:LE ?#'ZT MR1ATMSUD9*!TZ2X6_?H@"OYLDW'*"):F,59J":3=!B]TFYH,NFG[*&/XR68 MUN[;77(>,OC1)F-4T1CF(I>'VFV15/?ZJKDX*OS(&*,G<1-"42<"^/>L#^7+ M!4&18Y7H\",X31V\$RUIQ(@)_8,$G$?F^UB276!@$,I&KI#B[_$D',J.; M'#F[3"8I&NK.%;-6989%!H@QG*':+XHL5J5*"[" ?V-Z J@#U9CG; [$HM+H MV\'BN7_/(.72/*)ZDDP7S@A-Y/5G(<=#A:M;#V-PK(((^[PR@H_!= +&0/BB(ZS>YX-\F;XE#8Y-=,9@] M- ;74&'!?RJL,+((I9T";01L/%XQ"L]N!QZ=6I!_ACD: )1E7M!4P&T+9RHH M.*&!HN\X$D"K.%G_#<44NL:[7:2%)+&M2NSK QCU@+P$=]8__>('P$6.X]&0 MT,!D>*XFEI@QKS*"&_#^FQ2[ -^1 :-H\@3C6T>]&^#^R]4B]T=3=(.C([F@ MT>1& V2$9(=V!# X#;&Z%=H%__5>(57 72HWG@6Z&8^M):E@8A'])\ _9<_ MX41%"Z@,+P+.E#MN^/#?L0@G/KQS2\Y_\]P3F\^K]@UH.I\*%<";"=6\_[)I M%^"]DTG>?U/KP)RS/0$>G1!Q085'H5KPW\H))SZ\2*BF*/]ETR[ >R:3%)4_*L[9A0#IXQ(B[JCP)E13M/]63CCQX9U; MZ$/83DO!B0UH.N6_][4+P)L)U93_LFD7X+V32=I_A^; G+,U ::/3HBXH,*C M4$W[;^6$$Q\;<(O_ME,%KD6=/ !U*$$> R"D-N1!R#MWX'#!?\ M5XPM,&8F6/@U^NVA)*LK\>LA*9HF [&92I"EF[*$)!!W-7F$DK@F5GF1$5FH M+8KPI3=^5K-^./!V%=:S-;J?G MVA7* M:"4#_-X.C)*-T((\\$LN0LOQP#;Y""W' _<4@EB.CU4D&7+!<@MI%4F&(OV& M$]MPU]#SA,8Y @U^T^@[NS_K\[?8@6.A,RF-NG7PWE;!Z%[EG-VV3#8(6^X- MB)I7(\@[I/X[:NL@36\':<[_$/2U##TW:'AZKL'S#JS_-J<'8+?%K/]!AFVI M52U)349612"[!(FRU)X)=CG?N &P]/[E@!L-> V5 SF =[]\]ANQ.!_5&<' MF> !WH/G;3>&V'_9L$WYS@80IPY1WK4352P6)8>?*E+A*.K:!.(#E7OL0!5! ME?HC9'EQR@-.UEVOA? G^60!49% MD1L9D9PC^+F@P7^$7TJRRD\!5^85G GR#?8 $BN2"A2(8A3\VA),DWAP*&8H M"1R07>#W,?6V,?P&D(V1R%_)/#< [\RDJHDN[FXV'T!V=;?CR]F"_Y3K7-5@ MBWA>39;CH>^,S$&QHN<6=/$^HW[E&J497.)[R[$RDZJ,],1,5-)T9BGZEZ=] MC7+CR-_N&#!7_ SXP1#^++X!F1F R@>065X!4(ZQSC4(.V.C$%3,-@"R,-$1 M#&&D DE[1@\-@60; T!#59+[@%#&4T"^2Y49(VNI>=?RA0'NM?H^9S_YXI_&B,[,EO MLZGF!]>G4R1--F>#C^%V3Q<&"O B5]"YV4S.? W@YDC6I];GJ.!2Y?L\D F\ M%.#87[!4NYMOI+3X\FRZ;X[S&;.-<='J,A2*"NU]U%KH5LW;/IN;E7S,_G # _-%#JCN>9%YY/4NF(X59OH:E>SA9@36%\XS>2(DB M\TBR4U(@2#)]L,@BB38;@ 6!)%?=&"UTS0DU>ANA1@UWT[Y!E*(NYQ]\$K9Y?VYG=SZ_[QS7$*.WC?G.$+MZ9PV??5 MQQ@_!PVLQ,$GHP>7LW^?@Q"<%__)*,#]M./G( +7]1\Y':SOA_8Y]C],%H&Q M)WO=]]@B"*]%< AZB"V",%D$AZ" V"((GT6P1SJ(6/QESTBBXD!*Z,PF:@_F M\N*^QV93>,VF0]!#;#:%R6PZ! 7$9E/XS*8]TD%TS:9](&E]3]//P21A,IOH M/9C+F_4F_APT$%:SZ1#T$)M-83*;#D$!L=D4/K-ICW007;,I4"1M<7W1YV"7 M@QM0OA1DVPDGJ-K%K>XQ^QQ$%"H++.H$%9MP!S?AHDY"L0T8$ALPHH04,2,R M,ECV?,O;YV#3T-F>X3S1L>UUCY^#B$)M>T:-H&+;,W2V9]1(*+8]0VI[AI.0 M-KFF\7,04+BLHFU/$P=N3F][7^OG(*+P6D41)*C8*@J7511!$HJMHC!:1=$A MI"A'Y,*,9<^WV7X.-@V=[1FR[A\[7FO].8@HU+9GU @JMCU#9WM&C81BVS.D MMF?("&GA!HC8%@K/T8)]=(J,DXLA-V4.3 ^Q)7)P2^3 %! ;$B$Q)/;>0SBV M",)F$= 'V/?8(@BO17 (>H@M@C!9!(>@@-@B")]%L$1V] >;K3][/2PA)'C M)@DJGR0+41:BY@*"YIM,].H?YBDI$WRG28I$U4:0%;MM%H@,'*LJR8!E%/4( MA(MIBYE+TZ6&+G><%GM0N8%W(IC=WNRZQ*ANN>5IPW$Y7M!4_@VT :O)^!KP MR@RF9C26X):X>6 M MCC$#V&+$ 9@%8N?6NYX\/(=^CRG/:!)(D,%AE)/1+3V+'(^0^(Z +.PBS=RT MC43:(C4%*M*.D(8:[RC1/.3'(2**_.S,S[OHJS?D<\NDF&H/1[4F?%L31)]0.KR(JK8D<_\9S&B,L4V (;.QM0XSI_:>/C\P.XP!_ M<0\&C%#!$;($HM&HG<%@1S-@8-5-'+P,P0A)Q-O%A/RU2F2RAPCA7PJ?XXZ M3F\]$OL;Z#70#G4]\4X?U&#[_+G4NKQ M?L>JW7M' 5V[%U(QD00K% )5\*X5_+&E'R%Q<(A:^YA XJKXE57Q,8%$*;ET M@$-BL=T9*YI-%$U,)K&Z\:!N8C*)E8Y[EWD!SL$AU$WF3T^5>1FPJB071:[R M 5A\8JTT9'AYQ!S)83[[VCLR(RH,BPJDE*N)_9O%-K2+^%I/9UY@6E>LLWXW MCM4A7XBXQX0;$ZYOA+O/&F]WPHW),99?,1D'55I/7" 4H(8DH( M)26$PT(PB00W$1E* @?D:--$%"W9)>1_$@$5DV5,EB&4E@;M-48B?R7SW "\ M,Y.J)AYM4LUEH9]$",6[?>C=WL>!3 J%S2EZ]INY[TWX/:\HDCRI2RJ(]J:; M"J,,>FH-8E'6T""VO7=:[$&S&<9F;);-6'@ID&Q&3"6'I9*Y2MVY[=YO45Z\ M\7'IA/.U>5!K96,J.;QX,+8B:/&0L\1#+GJW6"TR56X;ILH%70=/1_V&,#K( M&\(L4J0H^/_9;Q%#UP(IXB5L2HIS+P55\Y2Q&#Z"1+G($EM&,.OZW$1 MZ]-#6EWA:W:Q[CQ=3"\1M-+W(\PQ>33B#9 +.,U#DEF1YA!?# M?A**]3IMY.[(#8I99C8B8LA8FA\Q;P1KR]KEN6=;UO[2GF_4BNDZINOHGA9S MOQZ#-N"O^+2X<"0&Y&'NQ<6B3#BR O''E[9'13QA%8.AI>L\M MB%SC[D=&BZ'?]VBH/CA'7E=]QF]KR.4(@U0!4-+1!(06B3B_L4)>>"FH"Q I M6T&?<31(+8K&-2I2Q%T/CV>AEA=\.%UG[LF>==W2K;Y1WO+=;N_]I-K,)4"Q M=#LV:KM)TV1DVVY:=XN_,S+7F8Q!F&\##S/!N$1J8X*)0Z">BLG7$ R5CPEF M#P03OFIRUPYK:P@FE8X)9C\$$[)>:VMMF&=&EJ$-;2>6#!EU8K%<8/WV2W25 MI"3"/Y5YXIE;^Z%54\AL&9>3]TO\%G52":M<.7#CCWB?CRR2[\+/7VS']OEI;T< 4;19'#)*U*:IG(7\!ES,/.K^2G0:"[C MXY(/Q74* U_XH:WG@/ U7>;!T6D'6PB]6]=&0&94R2%3L@$.%F%T&M4V:1F( MTH@7UTV['B^+\SH-;'X_AP4/"&W":=9LV1C^NO6&U>[;:XD./K/+^($3A"M\ MQT@0UU?-M1L&G_&X83^^\1\7)BJ_2C?%^G6%*#4>'FKM=JU1C^@*:6.% MSXPRY,6!*HF)TY/R>>F)8P MK/D6Z"]&:%5IYBB<$2*#7"U42V2?[^R2(I,_L;:=C3DCE)AF#@/](JGD%TCE MI\;(<$IAT@)C25:=J>;^[:;,:N_O#T];$TU?DD>,^N\9_Z%>]"1) -#)E#7@ M1$T+(*$=*.32V>\NM'5Z\O.QV.I46O5J&ZI7?-86J=8ZJ!E4854.JKKBCBC0>$LR:]M0B5H;C2[HJKTRK6VS6LG@S-]5@O5UK+.JMLZBQB)OR) M6/:'!7I+\*L6"9B2OP^)B^@N_D.HTO*'45U]M/>N)(U0'R*X9:ONJM9C4SYHM<4Y44:+2E+I%$V[ M*J]H;D=DBE*K0]^I7D0*IWA/E!JMYOD1&D1?*A\,JYZ>(,004I^0+800 MC$(H8\"B9#!'\'#O5(5@A]B"_QK5Y3JSD'/Q[!FD%_3UF M.,[\>^,5VB+[5L">E02!&2L0(/,W/5=W7C/ MZ,"W;(&YG* ^#EI,S]%BA_FH&54S+-[G5?9/J=)1E7Z>EU.OOBDQ%P#.+K.9 M))G*9[+YK <*@_^1@Q9%7L>#J(F*1OF"N5I?J203$G1W9.*/)O,*Q^.>"'/* M!N,C*DN3^CK O%V(X47* T;DI_AONRFPJZ0ZN'@Z1OJLG;?.V^?Z4BNCL2!- M4%U=5&ER7M#IP->E\R4JG$FS;]BZNXR-U-A(#=PP*,\9!D6.DX&B&#_N>1%0 MSD;! %SG[PNU]Y]M_SQ;A\G/+FDZD]%1?RTP'%QJ2V(X%]M@.8UQM69UM//J M:M33S8>DEOEJD*NCSR[;&J\"@J:IHNA>=%_3X)W/]4?W3 M?+BB_5[0;.JSRRN)98@6HR(3PN-R,D[+P09*0VY"-P5J\E+4P/G9[[O?D[AF2TQ H6*"&P,XY#VA6=J*TI0:=8^,V/W3WQVY?'UZ<, M2TDTYS>QS,0 #S!FW#D^E#$PLH M7WUBR8,S7%A _0))DT"T^=69_&)C-0K&ZL8 YTDW9>3G5LR2&?_[;YZFX*JD$V"_UGN:H\,3XH*/M\9Y=IBG112%\-M"^ G3/ OH?FH-!$V[@JOOC8 M?GJA:C=3N;9]<<<,],4YSRXSA7P2FLWIC91JT%+MCZ:H?'\2U7QK ."WH3:7 M>94'4 3H*3T@ XX8:[*BH=R>*L%7<7B2H.@OO:_(&$"%&D56O8AS>]'11 $X M$JE\X*(9=S(T#4T",.R08 5&40[B 8O//;D 5)[V#B90>C45].>C'J2\,4W M)^&3;ELZ>%,(U;;,LQOX8(>HMR0!%<#[D(>?S+3$9W6,Z]#,"<")/ RAQK!^ M.EAC>_MPX*.FS"RN ^A-"'8(H%: @+Q"V0IP00"RK6VE=5^HK\2040A46,L1 MC"# +U%IO )__M5X9*I#"[T'C ?@F):UGD()>/VXEF&SSVQ]HF*(]=,3:,BC M[U'M.\'!KZ&KCYX=RX %V/&G: (?<%&(+W# /OQ7T: :4(82*O SR[35(:,N M O_.S(.)JX/QR\8BOB8(1N2(+S3T:-$J>P! +&N]/W -Z 7\+'P+@6$,A,X) M*!@*#"6CJ$2!)#AFHIP3+W!AQHF!)>"+FFR# ?2CQG T5'JP>UX36_Z MIU1ZF^;>>OX5XCC/CS2+B[M,6$?X(DKWGXMM$3%#.A[QJ@I)'PB0GF5)1!:. M,"$ M'8F1 U9)>@RE#= E!F5(5!Q^B)7S\:P.^2H \/I29K,(,9M@8$FX!H' MHIWL$%\0HG/?Z11];CR@#GEX8PGM7FL*+0''Q>,;/5%\0AV.UD0NR78D#/.M:E7P&MO.W^MPW ML"K.]H$;TS?^ M^Z.O;1H680)>QB:XINH<,5Z*UG'!H30",?S25, M<*+KG8=S(X80X0(D))[?> 6K&I$169X1D F$CO0A4%&+8(Z1.85 9P)YSBWC MGOK"?'4RMM>4)U<^9JTT]-8SSKS&-RDV-7G^<_.R?6C+2X,/-ZC6-?B(+&E& MG;.V<*N5(?27+*WP!;(4]F[U$^&K7<>O@?F.CI@R/H3B :#!,[SH)^Y>4"6- M6Q1ZOI=!&Z%LI3+,Y JW5P\WO_[6P1X8U Y/'(L.+?@S[D2,I%=J(K;2&U 3 MDJ9B]8+TC)G%-YB.5Q0-R&;-IUY* W#H"?+M2$+@2>QK C5T,-Y %W$K*M12 M*$#*XC@)ZGBV7X:-(T"AJ_W:PR&24ESH%8%=:LRDC;XB1B6*V@!BD*#2"4)O M&AA.IWT?C;%05DZ7J?]'GI,4I#Y9A_>-$32 7 E=;$>UE"2TR'=K%6KDW_'6 MX)W1[Z*PD7&7KQG&6)Y*=Z?Y=H>3*@K/M/Y8)E@5JT.XMTMY_17CGLU9;$7K M(I]\DDK/6VE0I7.2R@&6'S'"&6'\HOQ[5JM7SPAT50,>PKQ%(YU-Y/-4(IW+ MF :;"=]A(Q;1SE8&0)(+)X6"<]CB^&,.\WL:T.K>L['."O!D06 MO:@O$DN_98RON&UC80.SF#)F]J?=WERT1^?G6#8D%PS.90*I#[H'IFD6KRMS;+)CD,'_K8Z23WZ8;5QU0F6;,%$/$O) MEC210T) DB\(>=#[0I/I!)W*)^A,YNN^=IDAAC)RU?\K*UV2I/RF?:C0B1JT M@LT,>#_E;^8(U:8H@--7=\4(4 0 MHCT$0%6,[/RJ$^%(& M?9[EU:\[BQP="%WN,)>1IM!,+'=BN1-QN3,O+;)[,V)*C#(DJH+T[FS$?!;3 M)1N+D%B$')4(R?G;FT^%SZL28L;R(KKPH^"XO4N>H(!(=VF!P"S[$^O #P?P;20Y!4C1THK+8DS05BA?Y M%:A$BU=>HR\.8O,A%@>1%0>4K[7Y6!RDSY$9H,J2H&!1T)0E%G"(^V->CWD] MC-OZ67C=UZ))O6*R1C1P&Y.YQZL9]K6/= M'7-Y*+?ULW"YKT61.I<7S[$'3E095I7DF,-C#@_EMGX6#O<_D)\])RH?0[[' M'T&2+F;NF+DCS-R^1MU_]"[;<#9&U8-J>SB=&#AWYX^[$_3J!CCT=Z(QQLG1 M"S21T;+X._&$&IO!KS];?YQE6EMLS&1#IHG&[T1G,H;S%V6FQ[/?"73_IH[J MNH002,^UN3'?PDVBXMX[N]!V9-IHS/K864?(C96@W@>MSNE)[?BZA&P-_5*O0U_J];JQ7JI5KPG MVITBG-^E>\SGI8P-H+>V-#5C-C_W[ZA[:5DD>7IR5;R'-%DAVC>5RG'W,EII ME&@C"/,$]R&]F%6@$DE;A>K\ =\SJVUIBBQW*8KJ3M_2M9\/3)UIM9@MNB-Y M,XB6NB-QO#(6&(@N41*!>UYKR6YWV@M[P\#5-A-&_CO@!T,5S2%PZ4+(USV=H^27[\M9[>0!G&\YHGAW8'>! 5YM'JZ4I.@5)Y/'U M1N.S:NN!&6RZ6OMA<1]6[. +'XIV7!MMK49R=M&76.&O>$10$564>EF#2W_R MZ.#< P4?$3/&G+83I]'^QS(H1HLR6NA8_FS#M%\>K=.& 8N@74#?NJR*5;O\57=:IX9\ M2R@7>K>]L]6+WC(X[X3T8KN-W:!5BW9X70\TKM];&1&=!@P3-,X[2B_M MJ'%1^VQC2>IJB]UTRZ(M VE,2#!X^HLPXBY]WY5Q4&S_L[M3TLMKL_5"3460@!]):),QXT+5OG1V029S:TE20^W$J["U>?=*-]D1YI,9+)4,!OE+%)2;BX- M$B4=2Y:HABR!0F4*:*4[%>^;J=MB(WV]E>7K37O2+MJS(ZF,0+!SGM"!M8T= M<\'R64V!I)U,UL0WH*BXFT]-+/;[ MO,"CRXK;6D_A.9Z1>:"@F(!-)^OLDWY[D'+#UH#,9((/_NCKFH&*NB9":XB5 M"'04403R@;BGWNX\7'C 8+ ,1:5R"9):+W3#Q5$[XM[*_&B^@0?1W6^S@PX[OP&U_);F:<"C->Y&KV+S/C>1L<.[E7NV(VJ MG78R8$$ %48F06?3L:%\Z#WU34!!7[Q )NC\^EB4CS8UN613(Q%D-Z9U&:15 MVZK"\.-4D=V'7^YL3B^+*%HG1]W*GK>NW9!%;TG!^#V"D[2> #S%13<<90.C M-& //$&1="*[A1-.[R9;CG5G?)004#HD(",%LS.>,]M>S(P0I]G"!8VS7"[9 MY/(]S_2@GE)YK)':JL2^&CWD]=;QME3]_K+S][7B5>V^UJE5VD2Q7B;:-\56 MY:9Q7ZZTVF9K^\K/QUKGA?A2KE1KI5KG:QC1'RYHG(FAX$P,!TOH"S,8XJS^ MEGM:=D@(-ID)ROXX)DCN2]/AH-:=CH;CEY=?+[=T,WVX!(DM*SC68=X2\4NJ M>>ODV3SN O:^ M^(Y2C'='ZA,"A#L)%>J($'$C]MW8R:?0MP,R@V6H0I9. MI#T$,PX6U_18>Y#+;5M[L%[Q0^:5-< MZW]G.N_]?OM@[P3EJ79 />$:4S06 M\VD2Z:Z;%S!?03\^L[Z^(XX1[K!9_B744XEL;KVF#"BA[BQ7;(% 0[! "3,= MMZK0$"7?:H.;5_E)*02@2!=6MTVRW>:E'#O%[ENN4 DR1R=H:GUN/Q8MVVR4 M?[6MZ40^M]>$0L99IM0ED74(5QC295HH/%X5AV2Q?9_;5XW!3H?ISR[O+<-] M/AHRO@S:&#W6B$C)P9W#MU,9[JINYT+]4Y\*;TIWFBKQ6DF]N]7N]^[(W3M[ M;0F"%UE!0P/H Z_\AS%L8!X%5(&B)@@1J(%[,KM1O3>_T;YK_BBB1?63RT(5 MY)@'&8?':0P%JC=6)0OAFWP^D79T(39%M#/3YVU,7X8X>,,'"AP5QR+_/Q<: ME0 MRFOM"F6O71& K:+O#$">?4H@$?"P[0<(]\U)"'@N1 MC7;(MVA7*I-*I.B]AKOLC5-*TFC$Z[7%Z$@[7"B9Z#AZ_I8.W#$%P4 GF21"[P&JTY2W*A8Z(/C7_7FJ@42=I- MU' =$S\X;J@=<;.^%\VJ\L7MZM>VBOZVAXP,###,2<2[[M"LF?4:HO(K@ MG9]TS,C$&VY>DD]VV](%=],V0F" 6]_#*>0_UV8J:.I1D*'\Y!](1^Z.G MOT\/CW79;>\4/ C!6*,LDU!Z\^D-TAG1-5(@![\?:_P&TWO=OT4 ?+#(Y[=T M8XKR!-%F%J@S1-"P0,U47!JJK":T)90O$QRY:L=KBJ(Y$AOS<5VN_4E5?XOT MZMWF\0C+A%;<;%J#R-JEC"3V*(K'IL M2"<8U,U;M\_,[M0$PATF27N39\+>=O901GU^6M4G\8OO<;;1'LRWF=P4>@ MKD])7B18'<3#4H,+W@(^KEP@$_E<(9'U<' ^G$RT"=K\.Y<#T98E4:?1P!H/ M6?S4 BK#BX"K,+*(KADOLJPVT@3DY97UD(M9VV$RE5"YE0J5\:A_YV?++L=C M;"8DA!']"9H6OJPFAO6X\HF=($S_GB67R8).D/ET@BQLTRDG\.AQ,,C;G*E< MD)?/)PJH+QZU34_-KUY#J!T9,(HF3[#:U36P%5JKFPJ*X[LCQ62G_*,L_P%I MH*8"[MZQ6-M@0&J:XXP*T8\J'1>=@.KJY>E&J8,+4LQ=WV8F8UJ@\I8'L#BI M8AK9"W/F-IW3\#KDW[]^#BOCZQN973_G2G)UG?5 CL9F\/CA9:02Z50F016< M=)"WD ER+#;Q*:*;9%TC^]RD0L G00J%1"[C8QNJI2M#/O=&^=?^+J"-TM75 MO+*JK,SW+9PK,W24/2N>_G4W^OW<%_(WPSV7]J^ITE,\9 V/GGZ7=]1O$>-B M7A6@JDBE8UGCW;/TN%7^"9E$(45#;WQ];XS@3[$ZMDI::&XW$SF](:,]/?&Y MZ62;MA"!'9>?ZV]G*^K#-HZ3--)ET$PHK<-[I'NNK=OMN$_>D>Q9Y#KH?<-W M'5\>P:7-48&^,P2G)PS+2B,X(KHYR#B:"44D@=Q^.-] Q@%S644NHSH$"D"T M9EPIW>=%1F1Y9.295TXKYU%%AN-60OC_DTP251X(W 719 :0?=M07P"1A2^F MOA/8"X&43B23ID3A^#?OYHF^5.N)+*X\]'CI]]P<:R[>=BIP=&]9J4IC)[9U M"<69EU+.W?-MQYN)L>]$9S*&\Q=E*,_8[T0=2CD=JW4)(3!E?^F;^1;Z9B8J M3#'QXQO$LQ/*H:?XFNP!*/7@V&.\8P:2X:I,#%M$:2.U&0F,YT>W X6 U??: M1]*.)=)\T2VR4V6E2Y+I,RN$U;NL-YXJ]^U.Y>'TI%;O5%KU8J?6J!?OB5*C MU81BIW<9V57W+DN->KE2;U?*IR?M3A$NLE+OM(E&E6@T*RV\T';$5_CEL5Y\ M+-<+78Z7BBW#_%ES);G6TAW M<2:$(JEN=Y83Z60JN<[?8<\6/-O[7>%[OU9^AI0\0@5M(84VD/)2?V ?L^6' M3BX0K'BZ*OR 6*GH!)*>)Y5?3]/JW1_M^K:?^I2T0NL4DIZGE5?QY\"[(Z91F19O.MWIA!9'%;'^]CN3"KC6 MQXC^I%$"87F-!M0XL<[,P>W:I-X8D/YG=2[6C#HY3KN4KG MY=:<+C;_'GZP$KP\XN9[!:^HCX@K9#9JP/ MOA)?-NGB%,K217Q9^/+&^*^ZW,[P)%(I5-6UZY55X<:]2XGO)LCW3Y=1;DTS MUN'[\Y#YMKKL4Q.YUZYG&9]O[:)6!01P!7)WI!KJ!>J9VOWTX>??[K32K' ? MMSU:_;W-C5V[]"8V"XREI6!!)+9YI4FSM %!.T%T(I]/)?)4P*?1CP#IOFF0 MC#=GZ+/CVS>?B$[DJ$*"I .^L/$(4+YWYV@;?95WTE: MXW8..Q* ,[3N[-TN6BT29KI/N["#3EN[!UNKN<^T ;LX2^N98'N]]YGV8 >M MMWX/ME:$GONKU"51FE^IH>/MR5SCXL*;\>]1(_?K^?FOG^DKASRN.@1RG,.- MH0DNAUNQ!<8A9S?$V25<-1$2OC;2+U:B3&M0J=*SB MN07CP>UVLW"0L==872ZS;:PN(CN_ MN_%RG/ON8#*)4/568@WGF1D2KD"E:U.U[RWP++;)AZKX9^_.(PZ*Z3V$"!ZOCE#1\H+V M[-?D$@+__9-B'@-&D!72Q2B/?! M"S,$FBHMY+F2I?5*D2#83M< 1'TT74N=?LU%#.M."W67FN_'OYF4JEM MPJA;'8%MRM(;KZ"MAIBUJP^.%=$!ID:BL/ZBT4%36G_WDZ_>_A-_, MA6^A$1YX49)Y=6)*_J+(S8^BMSI^ .I0@M^\P4?TW/K,D:C7[J=5\L%R([#P M))5_J$VB#9K<29%[#?G6@.I\/M/3H39INBMQ; MJ;#-D<#=/-6ZH46W)ZH]792TALGGD'P ?9B"VC"5R.3WS-%107Z@&BZ?A5Y+ MR>N]'LZV:V+4Q 3XP0F*-(90N)5,JI3&<#4\]SS]L- M7;H0G_"*H8D*-.LC&15&%J'5HS2!C*]-OV(4GIWK*]R:R/7,\RC'_=TF:.'] M$"J>&7=(Y7A!4P$WBUB,@:S?1QH?38VA\8D=@J])7^="S,B:2,+Y%J@__/K> MNH$.297"7)=F1ZF"C[ZQ3I=*/?]]>M0ZI2*8$RJL(*'-NWD8].B7 M02=U);"C*LD\%S1V4I2>GC-#[KDUAF.\WOTL=I<7=[5B<65]P]R7]_HG=_?T M]E+BB_3JY1E;OX\%KC','#?09S>Q5J^ZF&9-/*>R+BSBLA'[!Y,\=RPR7OK MJ"#P6$@0 9-_@4NRGD7 TA5JKZ\U:I*^ENC*(*0B(+^!"%A:7O_V_;ER_9:> M/.2.3P1L&ZS8JP ($$C(_DYAK$_'_IM8 MW!=Y]5*66II9^W0Y#RO[T1A; MXO(>7W.IOT7Z^94Z/O;?-F2V;_T?%)"0_9W2A9^._5?9R(O:?^%2S&R[SY:D M/\6[W^P1L/_2\J26.'[A[DOU?'BTO\?B5SI%;?!LREXHZ_AC\R3ASB&GRV=\ M81G@" 8.@JZEA]S>@UB7^CKB%4+25$6%SC?J3KU77WR#%/+&_&C/J9HH*.H8 MJ&,$-/JZ"&O,5K_&47]+]>MWZ=+SG3 CY*VP>P@6SJS'A\')2VAQQ\@P-52% MIU]WO1*S-4;VR?4K%>I&5!*$FVWI5V\&P(:[N!>(T]E$/D\ETHY=)'>T"78] M6G%(:53:61HM.=4/\FTZ=]U0&KU"]*01Z8,T6L)(M?_T\Y?P]Y8>YV-IM*// M?P!9Y"^\L21RED1Y'^RB!?^^.&(5(%;+*:X?/4GDP4[T8!2!P%T03\NAW.,!?#8@L?#']G7AB! W^1A/)I*E/.?[-^U$7?:G6 M$UD$R0_,$G")@F 43.$B7?0W!(XU_YZ?@Y4$@1DK$!;S-^O.=8I$EZXO+7A% M[%B5QDZJWH6[];V8FPX^:\.;B;'O1&4WJK1(N( VC'3.0#%=E8GBY%-M. N/YT>U M(6#UO?:1M(]#-B$S15:Z))DYLW2";\OZT;NL-YXJ]^U.Y>'TI%;O5%KU8J?6 MJ!?OB5*CU81BIW<95=$#%U=JU,N5>KM2/CUI=XIPD95ZITTTJD3[IMBJW#3N MRY56^W__S=-4[CM1^?E8Z[P07\J5:JU4ZWR-^-J_/-:+C^5:IU*.^DI,YEM> MA#>1;EKZ*3+5I:AT=_IP!:AB0[MFJ#P4^-H(+FR"'X%"U52YT/PN62K9^A0? M8\=6W5 2H()0_L>,)072CGZR_4L9]'F65[\27QY-S?[U;'-,>],^9XO)2HY7 MQ@(#D0SM2?BH<^[2_;#'W'Z]8R,:O21P9\[^+00*;<>_9_2BVERAFI<&=R8@ MW7+>#+(=EV"=5+C*="U_T-IY?8=+T+R#N(6$4/S@E=EC\/.1)+95B7U] ,C= MZ$[3KX^I?.&A..KT T /FNE V$EMC)TBY$WDVS!"D^&YFEABQKS*"":F'O\\ MW-]5U'(6I0_\QI0Q5V0HJ054AA8$[6Q8>YU27I1GI^*64%0!V7Y"ATIV_C9^7NKL>6K@,@ M 1WC&R[.<]%/H(K3XPKK9L#P$*SJ5>)B8@XQ@#-U1"!]E*R%&EB6U4::P-CJ MP4((I467A"G70@QL!$!<#*7H419R*;)%FG?-S/DDND.K>TG$SO]L (LI@)[XOGX]8.][MC%(U59*DA/ MI2A; 05F%<,0T9MW:M?KM-\S0/31",N&@J]P_JZ2$P(@L2 MQ"TC:HP\(:@$@4!=)'WC'?H?%X:W.W&H&VEWQSSGB$NO MH825T<=>2LG=*<722U&PRD^N #374% )8MA D%YVG!U%HY[[VE3?227I4-P.Z%\B=<"Q?GRC:#9?")/ MQ;A>@>N5H>]M\4X7R$261 W US?$C ;NUYP*WA+YSK'T#5JYN334R^<3A;2W M6XA7(FG)%CL6A;0BN,W]T2;9ZF^JH&5#K9A:BZZ]A]DS,SIT#2=! AWZ"^77/7,/AO=>3U\GZ4"NJ5K'[#3X8/=KP;:^F^I?9A#R N@ M@^NH_:FX*?T9*/+P).>L9\HV/5.$AJIQQ4%'RT,*V^,6.H'$QE;1@*& MD) PB 1K ]T3*1WXS@I_>?K0%W!XE0M;WP49\O6O%"U[XL$-U6@@(1TJDR!S MVUQO$J&]]DKKA>.D]4\IN'+D<6YFA 370462ORW5]F/PKG\P[!WG8VAB:*(/ MC7,!0L:Q\\O: @2NW*H*+Y*8J_CL9LVJ#1X8F1T2J85B@]TP.DO?E+RG;^91 MXTL]0;\L_6V!S WY1&^0M@DH5[-HD1^LB,!G;EK* 005^/<+@5M7!!P+XH)+ M[U.%1)I#\:CCI\%MT_AMJW@-\^)9[-%1)4:E?!O7$>7/O[>U1KIAZ> ME6RTT$1(K<(!GNQT49LU1+:G6JI1)LOKPZ>7^:#G(_'ZY?K11+1;_7P2V_ MLN7E'OZD8.:L^FCFTP]Z*:U/N0=?MN$P6?FC0W]@N?U\KI#(YITN;SZ2[? M MG[F7L'V!3I#Y=((L!%AHMTD<'QL79T M2Q6.9B]VQG0!DGXJO0.F]WAY%0I(\?V)\2&/KGF @Y/G&5X,_M:8C>XA"OS. MB&@U\YO;ECTUB=YL[BBM@1 M=.SE'D$)%G>0/J8.TG$[]7"L(6:&$*S@4#<-'=;[BE_?\G7GW&W)N#F>LFZ. M]]1*?5*XUJ[[[\\MACM8*W5ZD?0#[5Q+>STUMXA+7U*Y[8>2^M+\R(B_J%!U MK*7B5NJ.@P;9,=4OG,>MU#?'=6#YV!1-);+98\&]/UF!1>0'V$J=0@=8\I%J MI5[H;]&(_KTE8K17I/ MW6JH7"*=W6=CC2/FIOQGH,C#DYRSGJ$/<7R\)-\HI3]$]A.FN1@,)Z:0+"9+:II8[0GOME=:#:DH4"ZX#;&;Z.#0Q-#$T.S#33.!0@%(T>1MG(4GEJI]Z_?OIE'C2_U!+?]ZU'OKG\CO.4/WWUWT2*/YM%O#SF H +_?B'PT[52WXLO MB-/[.3*1S05\W'H[1/IU??*>6JGG$ZD"G:!W.>3GGQ#/[D^(K\C!TW^*MQDJ M/Y3H8?B$^:$3[T?#48?/HOO'4/L6\-NGQ.ET+I$NI )II;XB#UZN:GR]J8G3 M22[.@Q\BZ MTU0Q5R]-'E.M#MA'$W5O:7!_6\VN.7E?"393SF2KE2Q=IG[>4.%O,;MHTT6U4^G,PF2+!SO=OB6R=Q+$_5\/I')4HE,;IL=.403 M]<+^--N*\H$7L?/KS^_'YY^#7/0T7*3+"XZ/M:-;I' L6F_[4@C=''D']6"69/;V\P_ZSA"/J&8JD8YCRHR'+<2PO^?9)*H\D#@+H@F M,X!,V@9_-0 UWP61^4X\,8(&?Z.)9-*4&QS_YCW.JB_5>B*+(-FL [^WOOH. M"UX1GU2EL9-(BZ.XTEWVXR?P1"R,> MG4K21A#Z"7X$RD=3>Q))HF1I5^M3!>G>$J,,B:H@O2O$ET>1T3A>!=S7_=W# MPO'*6& @$J'Y!Q]=VQC875%XB8R;*F6;7LI6W+Q0UJ\6H^8N&9L^OTL/G>GC M[=]V;H/&RQZALU\FNOW"@L>*O?$?QLKCVR\V__'ZUK@*!"E+#7FW0,HV_:D/ M1(99QZ,4*X9K\Q_$ _QXJ! 5* "6+M'X+.CRC>;,S-3G0N0FK>2C+M&.2$IY M"@P>L!4\F9T_CH*,D:8LO?%04EU-'J&U4A,;8R S*C1_BJS*O_$J#Y1B3U%1 MI*C+7W6GE;<[YGGZ^%I(9_=5](MMICZVF?JR-"(D$T2"L6"\"&,90+B@<2:) MC.L))1Y:%N,Q.2:[(Z9>:EX]3J51JSN]_?L^>1D]J_W?/AY;,DSP)():MW\M M,S9+.O8@73S69(X49&=7*KM53]WUYPQ2>@<85=KJHDR(>; JKIY*4.E4(I-? M'_<-3Q/=P% ]UVS';T3GLXE<87UJT@N:G;G5?F_';*%H:7K:X &H0PE*\3=@ M%'$B+JX;;,SQW9%BX^3A_:^:UGPEKYEA,*)\GJMIS-7+"]8A)W@1\S-RDH'^ MR0@O!GZ!5@- X"<85Y.6)W0?@+NI7 [R]]Y/21\660BIS3D,@]-+[ZGX:IJ-XW,@:8BLVGMC=RF'ZDWE>S&O'8 =>L, MV942T61D503R@7EV,_P&R;P+!>J)_/Y[U?A^Y#-;V/:$A#-GV/LE-=0AD.N2 MR$+;O_*!#AD -_(O3)^%SG Z+=WRAU1C19:5 :9!J,$X7F'A+"J!2%)2 3%F M)BC>?%AV<$#J_FB>HA(9,L1JRB/1YVA_B?ZJ"UA-@<293"(MV!#+0.;?H'O[ M!FHB%$X:DEANI)_ZG7=\WITUV[Y+_'AMK(MQ\$UYHJ9D 'X;.Z^W.PX4[ M%O='ZYDT] .B+^!S6Y]G7.^]W(,!(U2A5>]&V\+5A_;PRN7O7P_JG6 XB3Y M]30B1PB\R@\8W=K1] I*_!WZ W!$;^+T!#.0 3@<6YCBWT+Y_AB!3J12="*; M#?A\\#YX8>N.*\Z\D)_SY%4@0^/4T,GWDCCH 'E4!CU7R<\\'_C9 M/6(; )^!;\4Y6@ P]?AA^.0F3TK$#N'HV?3"*?SD>>"?);7VK@ M:OS,5\RM_2.V "W>3/03UYNU( B-Y9U3N4>KG,HE4 M)N!#,V' GB\QJ 5)0:<2J:U:7ZYGM_)\]!@5\H,RT'_:,G_&X:E9VH^DKKK3 MAY;4^V!NWJK3;=SLW31.:KP0YP%WM$=,/W29-*#& M1]$,I058 -TJJ-.+W(@74? ,^UB&'4_7EW(,V2DM/E),3F-\/KSL3$ I=Y,% M+X"0K14DH-EB7P.VXP_HMVZ']0"$NDN:@4Z0Y/K;<\-NP12V;E.WOO':\@XV M93!F>&X6P'3@D%(FW[NOW^7>"]MPB#>YZL86!GP$T $\?(9M)?[V1^OI1+JP MJPH.#HMK6>A]N?OE5J^ M N^%;:Z<]5\)[>XHZ MKA0%@>YGIO3"*#W0@XY=*E59IJO[^VQVI-B&@9>\F MKTJO\WJW%P_0+82 ZD51WIOXHBDX=OV5&!MK0UD;IYKB VL7[SNP/\.XD$N0 M]#;] P)7U8'BTC?FS9&)]%:]:[8ZFA!WI@P\;)9:+S*K>GL%UQ,5\.FK9E]K ME]2 4AD.\=2%$Q5]$\3X1(6_4?86=+PGN(:UT6\/)5FUYW7G8D%7W$MW^L0U MR\V&4$K]>@WX<,7RPBQ04?V:@F E]I_)]1;%2Y,AO+IEC39WI82 PS$DN67< M=J5O:"]BAO*.!8##!=PU1=%0.[%&?ZF(P?0,,:'?OTD-MO>[I%UM4[ZPL5'H M1O,FZ+H41-4+,YK?+$P3:J=E_0X%[3?2=";X],$Q[D$(!($O?J.#$:3[C69M MQ[+WB 7%WSKUYV?K(\LTMKD$>+>LL^4RNMI(T2=+[]NUQ_*1SR L/%HZ5'H3 M2\<'_W!5O_#P6N+A@F;]26O$<^A?=$#I#7(!SO*CHTBL"CCT15'DYC^P/:G? MIK$+RV5:C HJ_3Y ;J8E9]69G)T.?Z6Y/^G64_&GG^?&7.2H M5<&#).IA@T'[1?X^R^X2A9V#2Y]X4P*HYMLZWN?5^=H);1:"RKPREA1&N(8< M/H9OE-'Q-5'E10UP1HP4GS]M&V)D^O!X>_=0_LE=O05TYLXE9L6HJ'LIT;.N MOM;;F1)C3 "14/S!<<&&V^G28IBB-[I-V8WRLXE4>M<#U/%.[K"3E%\[F4]D ML\$]>.?@^^F=V%1)4>IM]C!WH4$#CK"YR]M-BVG@LX#.UC( H$;74K8DZW<"M MGDNP%C//D^+OM]O)[W2@,MX.DQ$XA%!!G]<"*\ZI;KGUY.QT"@Y7,CQ7UF0H M;73/KRK)"Z>5TN^]MWNI6?@ 54=N:AX7$[/8=!L"AX)M'CO?74G]*I"H%GSLTMS^BV1MZ3%MR@_G%M_X.6>V;V?6=X/COPK MZ$KDLKX=U@S^/IT]W;<2&>CCJW-VNSHG&U^=,]L+'Z[.R<97YWQRB?2CMW@/ M3\ZZA^>HK\ZI-SJ5]NE)IT%8E^@0U5J]6"_5X IGM^E$?)FV6U^BO!)G)M/- MH+HV@F^QGFU3H+#,&$E468/.VD)]"J-J,FCT;9$C)+M,[R _7X"]]'!WRI;D M$OET_?-EYAL$<4-A ,QP>D+][[]YFJ*_SP0"7C.=[4ZE1_#KUUVQD\NDSBZA M''AL5= U4XUFI86%0MO:FGW1V!%>U1C,WI8AO,$R5)'I\37Q!STN1WZS'\-_6=D&0< M^3&^+NFNA?'E5X*'S@6!KGI%SH;A=Q#O0PFZ%6.9A[[$&,Y@]K9!7@@QS_V% MN7B(SIL@,$'BBQT-GE!U:9&*1G/Z\25,)W 1IF5#H'0DE M*!)12Y+9'MRDDJNWGUJN][=Q^PK"1R5+\/I#*!FG"M5]U&"_!C MDQ+.3T\L<42\,PJ&$\C"A'@5I7<1RA7B!OK&DW=)XH@'P/&,(SGV'XZE\DD5',&2"D[4!(C1>4=$'B=,31A"D=]S9%ZERB"B N,!X7)4! MH]]*@:'".1Y(:'! 2,R0[.",&@ML Z(/H> <2:CY.C.>G%OB'IH".%+5DXRC MY^^\.B0$O@^@U.!1X$B7&6D_@(= M 3%[A<@(A\[%M02WY_2D)"%BA6_<\U"3<$B7( IY8$1((HAR#$Y0B*; B+'K M$3(ZG.T39#UH"4*.5S#OSZ4J5J#;FHHXVL-8%LEUL=B< MF::Z@,%FUF@L( O"J :R9+AJLSVPUA](QNH0"9\3;1Y)4?0?[#-# 6U_8XA> M85EMI G86&&@?.SS+(]E(S,>R]('-,=4 !?X?ZL\J190&2@;N0HCH\)BI3@; MLZP/V.7KT#06LQPZMCVSC:?U>I4MU\5V>4);MJOM;1.>=4;K>@!\J'U+9EU[ M>] %W.'1Y>059B[=3F26U[:XC8K64W#N0D7:SVZ[&6K>,-Z03,(&XNQXR((9 MB'38ZDTD-]]$??^H/%E ^]=[FEYQ]^"7G"_L?_^H?)(L^-&:)9-(K]X\@Q.Q MT3&"?(WD!OP!A1X449A9H-G#XA6C>]B <2C:]%?G+F.;V3^&^- ]T/E^JBRT MR[ GH',N.42\H) B$!O\B_U$*&CIO^\X<.A>RZPSV46 M>F*6EZPH_+F3X3%&AH>N@V1HH\IX;#V_#OE 13XNCVM*48;>-M?L&"XD.32S MS/ *^ANI+ '/;'G/)JW:@RR0 : \Z?,XB7I.% 5(U]I@""?:&Q>1=2WAKB M< MB!Q9%>VWT;=X:8S*)KHY0*0JODR9T'&7IG=#&Z \GQ6C&W)XE^776V-TX M^Z";,!1)=;LS8^;U.0>N\V3M>4I9RM!X&Y(H?GUE%^OYF?9W]C&[1ODAY_E] M?AU8H"G$%P4 HHZ:W*2_0G%@21IADL V[P,S(1"DB3G.Q@E5_0X4:=6N,=#2 M@:8W"OBCX(&U9TN[59V["L/H#W.%'T;6! [+VK8MDZ*ZTU_/OX8W5_>CW"MO M;=;LE?7W'"S-XF9A9GPY2)1:LT=P;A0T,8[U,=P;$JK8Q5C"5G'QJD"O*&O< MJ:FQ.M7^=)B9L:?/I$O?GF?\N=C]_-0OI#V#/2*1(B'0'7=88M M\/U HKW!JI+NT, MF8F; A0W5V-A" %#1(PL'6PLR4"1- M9HURQ9DM@7PL/50X,\$6/33=6"I"!T! <*5C>SSD2ZJ)IR=O/'S76.(6G4$C$BL1!UG,*Q7$2JBLV_1D"1[HX1#CZU]BTPT( &_?HDA*X ME;() %BK>Y2],\#="=THW1V_O?GY/\7S9Z97"T M2QEBJT75 ?7KEW7:]5:J5CO$,52J?%8[]3J MUT2S<5\KU2J?K#C.?[J]8J"AWN@OD-Q$_Z\+W:;MM[]Z&Z [E<2?@BB,VL4/ M*DITNT"I6;H[?>; +2/UFZ^WJ;-+O'Q<_->$1ARJ1=$O#3P,5<:6UX9GA#2S MA'N[%!P:2^:P]X,-')0PPP$*G)7G1[:Q;&>'D1F@I[[T:[99W:Z'RABZ-",( M:_(GMA2*Z" +U-(4B91]"PQ0#@*]WT[^.B>*>&ZX"&&"3<7)DFTB"*:)N3 Y M!%%2\?&HTQ/#;,11?0M\TSIT/A5%U$3#)^%%PQ*9A5QUL]4S7F70%P"KXE(- MNR5EIAO-Q4BB,(&K@XL0D+VDR?A)BQXCZ-$(O= " ME259%1FG)_HI7Q18QMP,N'.B!&1L![LAD>!XA14D18.O&" *$Q-PJ^9JR2@5 M16UF4<\A!4*QCL9FY#C#+[+81[R*8>XLG&Y# 1ET2 O''1WFM!"!_$]$1"8V M(9^A0 2'K. M41^;@?E9Q:+.0T9VU<8&#N(2$R\NLD($-,(5 +K7HBG(_=79\_1D,Y$L P93 M/OZ#P;D9T_F),1%H+Q@Q^1\ 4<;B47=&43;8K;*0T./>.@Y MPNG,PHYVI625L4LHRBC#"5)4P@B/XTB>/JL]0T5PD(#> &<7HW!]* P!$<"@ MIDAEB$V<\C<&HX^,T74;''Q@V7ZYZCQM+CY/Z^MYVEQTSM/B<(-)(_'AVOTI M,L-20P;+MJ;:&IVSC6$&O4/+,M-K$!B]FDK1H("5-<&R14T#7YGS(>"4DHP\ MZ_GB_OE4 BXGMBT.Q09P$1.!ZAL0M#*.]4*^095[*'S,O((EY\ R>[$1"-6& M )46FOJHZ.1004+GTRR*'BM9B+&DUA[Y,=[K3GN#K/B@2 SSFXMR:(7J3E,U MYIVF2H_9/]S99<6H5[.M.(ZKA)*?S"-B]C,.6"J9WJ3=3$X0/0TZX]"LF)F8 MLV*,#W0P!)4L*K-X.))0 E;W"?T@I1YK-'Q.3<3U&*@;IUXLIM I1!0LX" FF#6@'X=0C#6I M9)X/A+;I&Q 2LX)9JT8>ZD+HG_R#=C,#?]B/YR'$OTDXBZ?,7"HKDC8/RI+6 M,.NK'YW)DIBCRL0<*2VL3O?)<2K0Y",C6F;X@"Z1I3G/#*<1;08,G'Y62O"= M&$KOB$:=<\VXW@GS$5Z&40V-!C3*BEUP@A ]@]2 $FI%3-F&!VH="25$@$.6 MJ,CQ"QKW*SXDZ( 3Z*U:1Q?<5C1G(ED+81E9QG$-Q)TXTXE8U8'4O:WA],18 M1&TNW^VRCVX!P/EM.C(_.=KZ;*ZJ4P:H6,.A%-FPTN%3O*P'F#%=&8'='DH, MX9I>R#C04H=/]J%Z $9F7X_-X'I1EI=9;:0?,40?X%BK7H*L9PDL\C4K _0T M/Q((/5N)05P:'%XB0E6CJ.)DQ$.O<[FB'8DCJ!#42<*LD;'IK'ESQ^Y KM$N M2S6P=IL''REUL"^BTF?@][U"C29OY5$Z&_<9N/P'%Y.+2,J8_06^[$Y 7\\A M=1LUCJDX!.!+","PHIJH]A6:5ZL++>S%T6O>[$[_5*_OVU.::E0S40X#E+O3 M4H[Z]>?GY'>:X_4*"U:O@"OS@H;(&!ULOX>F(@%Q06!D?*XRH$@OR=A/9/8C M]_8P 3RP]J$C6MYG,\ 6U =F0WRI!]ZL#O(?7-10H6"O4]UNQ.ZTG_F9 MF4R$:^DY'ZAZVHM=W[=.>^#,MQ6],WH[&'Z:IIA))<0?Z&DKB#+C!+/WC,D* MHBY$S(_=IZHL(G*CU/RFR#9N+V T5?I.K,_K%U!:WW@3]]K7 M7SU;O UG#A??">?+%M9V^-9[X=+2^.'/GZ/:6U+?T?3\WI+UZM_[ M0OFC_9<.Q=YZOC!KOS(AZS]R%NM\]!(@6S8(30?D5N"*1HZ!;PZ79@ M_7W;=:#6<' "11*[TU&VU7D5:FGR)1?,-7.&89Y&AOER^6S=#!XQ;PPOS [G MSH(^>N,191$/QK#T/R[[,O\8Y3CYTDU=YM.+CQNW=GU9G4R9PVP C6.*W$Q=>C0/ .MZ*YH3>?3>0*A1BYF&+3.G+]HETZD<^E$[FL M4W[OTZ&7MM#K%^U2V4(BE5I_B[ 7Y.YTH_#B#94AOL$SAB8JT*R_:_79B"$7 M]1!R'4>0&WT& MQG>^H+?E"W0==7=*I^GK]/M/B56W<1.6Y#]NG\$&C;W5&GDC+/ALSN.")TM9 MZU.BRXH3^3R52.?6J^Q#$630*-W6@(\1ZDZC6QGM,4+=*70K,SU@A#I+?6KN MYGE6;Y/'""4<7]%A**JJS/EO8UT=T/3&V6:H$N"8S00\7$5/IO8L,_A990%Z/XJ/RCS_1%D73W_Y$&Q1-__T3;5 $X@%QOBZ&YO#0[$216T6/H 5XO9^9Y'QT-$SOUJ^N35];N6KM]W!K,[DO#*EE=SIM^6 MH,\X'D+3MW4M3%_HCS/ZJU2N&Z5N6J[4>N!C^I MU"K5Y];3[56+?!QTA*?ZS]>GMOY,O?;SZ;;Z.+EJMOBK2OOQX^FI(CRWVD6I M=?U$OCP+"CMY+2XON;)BR8:\=5[T,WRPH=[?U>LI:]'NYQ,/O>PUM1^.FQV$ MQ>Q8!](T=8-%SDF7]668UZ;+RQ:R^>G/^6;+"L./A.3[^2[[U&7!P4D9/)L MM)D\OY;)N8][0[$MG'#\U7GK%&O7[U526,OH%Q>_RK\N+I*'IOS%Y1<\,+PK M FK9Z?7S1[,VLEU4ZL[TX4+!VC1'ALQ[?Y8BH5!)+M+Y5E1O.=%&RW?']DVV M'A;%:G>::4WRM^K'=7'XZE<'"M3.( 1]#S:^G2 ?WTZ OO3M=H)\?#O!/FXG M"+)!3M'6;6AVE4K%:':$QB_-VAPM=[_I .?>.57'WCE^3=:=CD="A5;N*EJ] M%^FV.F9QF][I;;X%U7+'*7Q#+@'YGK6N3,"]=%!/5M291_E$76XJW6FE_*?R M>_ N//.?6L&A0+W,?QX(NML*,Z$^[7:C&/?&JHB5>N I\>O MA:/:V[1CWYHQ"S79_>1V7.="L;?;]-/P"UUQ0._&/RL^UCTULQ$_/1BD MZQ]7*ED4@FZ<,_,2%[?"CT87SL2WIMO%ZOR#+QN\JO+ =OF ,6=W;GO^/WM? MVIRVLBWZG2K^@V[>WK>2NL2;>=@Y)U488P?'!L=@._87EQ "9 L):P##KW]K M=;\-LK!2\7B\3C^WV:-,^;"]<_!V%00^8BQ/[N-2#QD!Z2:'SIV%@]B5]Y(%=7[K[R0,KIXYD MGL>#7Z7:S\>'R_NWP(:7[%?JR/0D;)?^185)1I) MQA/YF'=,/)DKBA.=< 8\'3S(W9B:T.5UD2MV-)%TD:'CXAEFZ3QR,GA>$V4> M_,EJ6U=?)5#KGE]>#S$]Y MX:CYQ4G=_F?VF\R:R']-)+\"".!TS]X#V[-:O7M=OM>PM\5P>HY7@# &HIM] M#$?O2;J-ZB%/:*$I6N2 @[_ [.UTZ:AS7A9M&^N#',)ZVB:#.#D?RO18A?I7S^6FJ M0 W,6K/I8C,JF*&GSJ<#[R!'.+LE*=@\7F?N.)LI1Z9#3N+=DU9HM[3"=T4 M 7[0U=?J=#3=]6K(:RUGK'&M[2KT)Q!FW&)-=C9Q O$.B.;G5;\DMRIOA88C M.9QM(_C<+OY8450,$ M5-CS-6L)1P">CJJJ@J?75%F&+]%'4.]D%\:D^FFOL0B'PN.9)-W<7EW="9.Z MHKW_OKV/1:A<^RASUR;B=\AO? G=7S_F744^]>SOM[EIX)^.VXS\>HO!. M)&.9Q<);Y(4N-Q)YC,WU\]HY:\ZS^9W);T#Q^N4]$XL ME-Z2RT5DH_;$OI]U56X1MI;($2TB(-:#I%'WPH@MHFI,$B03EB1(LGGQ* C@ M3UZ+0U [BC0F%P?7X>'/ %P:-% 5,AI>G&&T$\&DBYSA6& Z^Q =@>W^3I&^I.3(WV#,E MU[ET+[21T7_7F^+URPIGVM[-:P?W9G!C J@DGLTE@KF!MWFPY%8LPOA))K]J M!X*_L9P.V-'*YT?ID4(Q$HV.L;R'^MHG'.2QI1 M YA_W"/_0])J[+\4VVU)EJBKR9LF5Y71#&@JLK9,)(QN*%>"R9]^NL0P@CA@IH M7Q0PXT4>4=,9!8RNLU"<#J)(!9I!'WM;HH$]7NE(6/+,I(VD8'X,@E.6X&[7 M,53'PGP@;'%U">3X&-X=JMHKGD00N<\=56T-)5G^0FC3&*J<+H):CO&]OJ:^ MP)9TBAC\$3<4C:"KGQ1LD2Z=(NQ8[1/I^!G=M,GXM\K-[?_RO?ZW,_)SXML7 M.YX(9]!1'&)5]M+ MFA*DVC30?'0YIS#:J=.9UAC2,NE6_!8"2/ T#F-'*/HRF)4TKHYQ;K&J:*_O8:,88O%51*LW1DY-V9E%VG$GP(DM4T"N!G@,@97POW51 M?"6FJNLTR][-3?'7YFXI3^U]T:2[>\.*LR?2T?K6IUI2>'X8FV4?$'>27:^!$A50- M8,!K(QJA_Q-NB&43'1=KQO/3'QT"^:'*2&BZHWFZB*=!QE;-:"Y4]M5R5UCO MN=L2I:]?KT"HRF603<9HD:=H5$J?_8A7ZZ;2/NA^0\0@ILV"4$A1<6?G7.AN MAZ4M^GR-UM Z#6VM@5#N>?PRT(?O2EV][[XLTT#(+ZTTW(Y!J[4'HHV%&,VL MVLA@=J.X99+QK99RFS5=R?FU#WI>E5>'9_=O_70W*]Y)P5?$3_4=:6K@H?S(P;VO!">"02?I6PE;\;M48F#<@R=&8":.J>:H'LK5H?)V"YF#]9AC+ H&4"<,QMA=,'$2 M=J7D@L;V@8!UR8+MC6,Y>;,BE4]C\].!]V?;]TK:1#PL-?9 M1[B82!SBYN0-+45KAS'P-Y.-?]"!Q[[L6@7[_]_EJ'!;S.CEP50^%\LD_<+& M:Q6+>Q@QN:1R77X>]V[>?MPEE<3H5 CUS860DA,WUAXB.O3%W FX+47@>MUJW#^7'S3-)%-(WTS"M9G!?5RB^O[-XC?)7Y=\L:KE"R>AML$92OQ.UIA M0 /5=B8)_K1T] YS+72S!^J1:KI4KQBKNIU2OX>U?\;Q<#0UCKI*5"@EN;#O*- M8P>V[S!ROZT4C2H%$O5[2B>K9_':SY_OX8S=F(KI^1Y\A3!*>+"<'$FR,BQ3 MC_5Q;J"=EVXSV^DIOI>PS/H-/%D9EJ7;Z]N'L];X8O@GTV71;YS*RK!LCKNM M^%OIO/=[2Z-UUH,EM:G"F"*Q)BI"F!(RF0?!T3"],P5E/XDR!$A,#T$)!19A M#B=9G\/_,(&VOS+G4(Y[Q&ZHS!]8.*NDH@FKD_(@0>V)6&9AB,R,I"Y+L#K_ M#3MJNOC!;?8:/NXFV-TLSO6X924YS^/RH"W*9_?WPZP88$3)F;(S[?&<%B1) M*DBJHF'7"LW,%)KY]H;1C]5RC%98<*VA%A9^MI7WX0V"%&9U^9J9>^2+DS7R MP#X,=I>-\A=F1_F/X V)>=)'YMEO["[)/+E$>,SC?X6Z&Q=>:*JNWVAJ6S*> MQZ^7PT>Q;O0?^MGM)$;-Q#79%O-P+U*2@R&/'>4-N."_FULRGUZ*T3?D[D/# MV;*\FY[-NW\8Q#:E\G"OLR.5;T+EV8"IW/]:XK];:CK7&+WNV,"<3(3C_>OP*%'.KL;[F#2]%#8/I)CO**GV-(=4 M,@N,O;AHX8C3 /AT2_I$/AZ#:^F(TFVPZ9;4C&P\EDWGPM,R7,5&'[.=VD$? MB38)HQT2>9GKJW1TQ,85!J%5%>P1XO>^$5A8E0 KI0,G-TBH;I=ZYZ4W[4S, M-3_-W(U_0M:LC,SUD\U6.O7Y!LVV4@]7K_F[1+WYUIU]ZD_?W3VR5CQE>%G+ M.TC*+6(]U%H ""?#-O#F7CLAY1#I;M=@#S7'=1M("35K]2!0N'E;O(5X6KB7 M.<_O-(FWR%<5C!F\06:H)EV^T2,8FE+#QO&+@=(WQ2+EX$IJG=\)9 M,OALU:Q?MBI@FWZ?#7&8F7VUOVE6V762Z#RPWT5CE'1ZN B9XQ/)Y0R-)7E[V2:-J>?QPYG^>E%.-WYUUP@W[7N4+=3 89#;_T_3U:*6 M3!^KBD9)_<\_S>\'>Z8/&/&NJ@-1ID,FU:&BD^K#F M+@,QW?":@9^V0H6]]J5<."UEAD-GJCU=#D>]DN'M*PRT7_JPRUUS4_L-9M1[ M9N;(O[^=0UO<%P/\OJCP:VX 6X?WZ:A)@GDZ;]+@SLE,VS[#1"/CAKICB9R:F)@MI1@!AQ_&5/PAF,FCKB9;R\Z)0( S[+ MN<9N3NP YYSBJ%._D>;X<=@92!YX6-+('\@$5/A?Q81/-7E=VO((W/UN<>I# MH&'/,_2?WA[H/$,?,?'0R]3UL_93Y_RP-80@1AH">#YR#Q8OCA<%,Y"NNU0/5AZN+8O[U[5RZOE9RP:<&3#;.ICVU MXU-]S.,^%#4W,9^S/-<'V8$9C9JT9C3X4,1[H:;%3OY12B9U2 MA&NBXZYIP6>29"#TL%&&QS(US.&)I=5R:)9NQ>=+,T%:UYYL'I=1O=;.E@7K M?!@&MO(*3VXVL*?^/*[[/S_Z&XD93,%_/+]_UNZO*^*H=8M\-ORF8K*\HJ[PE3M%P M<__VP[BKK<@]'7P;'^LE8IK"8\]=A]\+Z[$[:,=V*+9/L M1G^6JL\MZ7F<;-R>=OO:KT9]2]7YH&M+NJ%)33H3[RL]NJ%J"KQEP'.;I1TLT,Z&0 M"EME_: 9(@=GL 6<(9)X'M>[[9^U7N:Z53GH^(]O"'#Y*9Z)^'&,I]MAN/$8 MST3\.,=SW^=XKACD7G&49SK049X^(0VIF.D5I*?+T[OL08NNS:=Y8G['AY_E MF7D>B_++:UYNO/V0$LO$JX^S/,/NX'$65,#ZJO@N\&+SIY$/(6"]]6)\!T"Y MM29Q^@!H\*.6[UU=E<;R?A3[!P6@Q%KC-7T I/ZXZ_._>PK?"&=:Z:XH:+V9 MF3X RCPJMT+C[2I=VM+8S#UN%Q%"KYF/D!7CEP 1'IGO%@G3 SL/&0W[T7OE M<.7M'LC#O3O 'X>!XWS-O8@3'W<3[&Y6F:^9;M:OSRY;%_>_UZD!7F>^)IVZ MHO/RG"F:^]OX9JOC,H.+-F1B.=]:J6UEA^TCRI8;DI1-+#<#\P@P"V#)^!%@ MJP%LN4&1ZPC]F1,A>ZEDH3FN_FH]M;:5$N0W^O% P\@;#'?92JH;][4Y MPQ:/8P>/8P>WD"!V'#MXS-K;0Q0>QP[.SFT\CAW<[MA!X:64+(AW/])K]77;UMS! /L\Q-)+N/#"GCBHR.\7+[=7=S_O MU^GDLO&H'Z^0V%^O5 CC P-G_V0N&5&]?G_*AIJ'-&>ZWX'2S;H3_(+GWU@AE_Y3N7?=@7Q!]E1+9I*AL.]R0_?. M>R]GWOS=#.XS-4O"J&V MX FX7;QU[.GQ:Y/G7;:]DJ$ZE\7\+DIG8M,XDW1!5G53FS4,R-.S?<8;S^-2 M:I3/RN-?YUW^D*!?K37*T4B:A/&2WR;:_"3/0"8..G?I=++X*][]1)ZNH%3WW.&"FDJKGSJ-SJY[S7GL=/@ZMF_>U7YZF>"I4. MPY__9XAZ--+G1R2:RFNB.Y;,XW0WG"^E;S>@O+4&6R#/4P^U1UY)I.\27?^< M76^#+0]O'D)(^AA@/(PPR3' N+_QN6. <9\YY\,&&!> M $_:VC@'J.-*WDRMA(XG%#I7'J8C<66I(F"H6ID3&[Y711,0QJ(7*F+DVQY M9?* PG%<8YU=/54(\:&;:M30>$6GKB7]=.3^"TV^ M\GV))5_10=$-'.",LU];TD!JF;SLS=HZ8S J*BT;0A: K"2NNVZU8MPD7BXK M]CSHAFKP,NAU+G!_F@306B$V-X#F^E79"\\^!V?.OL5'6]?WE\ID8O'X+MN@ MK$R$IPN(D*7X[2\1ZH_UI_Q=;ES,9?: "BV_\BZI,)F/!TN%V\[T\17A14'0 M3-+6C$U=!Q,0?C14@FSQ>2%3S(T& M>2&;.&SR6BRDUR6O?"R]<4USZ,-^?41LBA;+3%^;R^K*VV.(PG):4_$L]S#,-_3]I9:) MU(R\%.7VOHK;Y.X&SS3(/DTQZ4TGY:7 M.?"6%P"0\8M21?<8F;N1];(LE_WGCV?289W MSN[/V.:?I6H%QP:'*J>*@\?<+9^^EN]?;3J<"<[-+N0%PV$7PF/;(@PNPW0A MM5"$+4FXK@F^^T*-J76I,32I.,B4'B]>TJG^:S)L:EQ:3.9FB\FE4;]'FMJD M#>MWX6S? ,GL"^$2'=+BL9\(#TM ],@ETY4<&PP=()V:%^U MMDGFG'-\1Q/)()ACUL(!.AUJ/47B3C6IU1&'_(C[? X?Y-)?N(HR,$ZX%'=U MNE'=]YLPE4[%T-N1X2("0IZPW5F_D'V*R>3=N+J?CAQ:#.$86 MJ(?/JIWLHR= W4%0U1UEN%*53D/4>N@XL5,+)AUV8Z'U%J^_]6I/XX[7H3%Q MEE ]:SY;#8/1"]DDL/DZ)=4;M(I?%Y7YY5')Q,'/?J.H%>_U0D(*$97+7JJ% M_?+>+W6I(IR_&@#H-2[6#4N _3U-%N+G7+^I6_[G[]9YT\D=P-+<[9>D7W@2,G;'JK M*=%(L:]),I=(QCB0 (F8NP&&DM&%Y]VE62/NLV2[GK^@A.'^\M8F%^(9S[1B7^=WD:0D@+AR M_8[(W$0\G4@^/SO_FI6"X?%IW-@GPOU;#HV,%-<'R?10R#IF\*WG+"PS8N$( MX*7/X#MM(O$UG@:1[/S+G1?;(+WNB(J^4^S3N/[_4:'!(KU7.XYT")1KT]Z<(HPN[3=S_O!T'FWWA8 MCE=@89(\#%\RD;_AI)-XG.Q-XIS[&E^2C-$9'/FYU0J<^RJ=<2Z9DQK2T$G8 MM+Z)^Y?4UJK9LP#PM.%D/5NRV^-%(Y,'@\NOOX@^13]\] C4YI;JXV H% MJB"*+9W./I! =".;#8&L.%.G.?N@('(JG)HW,& DOO>QVRZ^$(VX)/4)9U&C M]8@M?&$-U]*\/BUVO6.*Z#)EN@I59^.)>((@-SD1&5\=N?F1?/WSM-&\O7>0 M.[GUQ>-[/'OT%9U)>U!/TAL-"%1TQA*^F=<$P^2*0Q3ITCM'J$F'^Q0K,:R^ M!X0^*"%0\0H<.25B$=%3&"OY8(RI7).5)T#^V8TPUNO$E:>'Q]:/!#\38T"E M4FM9M'DW.L,0B8,MD@T#9]E8SK<5',4983T\#,X::9NRC*+Q7&QJ)@]*3R++ M<';48?='AZV #GL-0A(1,T=[E?T-;\0SOH/$A%*8SJ41G_U;EA5R6MA2:Z$\3@#Y+0I70&W$'D 6SATI3M$ZC8_493AYS9QQ^F MF!\T+(MC'U3M%:Z%$M^7#%YF#)^SA76.1!;N*E>UHBB/!IE9'%JM-Z[_]:XU M2ZCF;*&:V\!3D)VAD1.P:OWA*N!-&:SA]P8 MA"N3]Y9:>;*D\7$5Z]SP0=74? JQ"!'@,K(.Q!"-N-XG4E_WD!GH O!I0HEV M?HC1U52ST^4N>84(H%2""*!TS/.T6QT'HPOH#<\S23;QX!3S9#R#E#6H%]J] M9CP]?A%"UIR!W#++D]NZVG'@5/=W-.+HVQ8NJ^J MAE*4&0"RP/>J%@P8#U& MB RE!)N2(F@BSQ3"2;R6W1WD'^-'^ZU0?I7 MK54MR8NPNO!S,Z1((@'_Z_PK&+0F9IJPX>(5.5 WF[KX9I*NYZT!7B ZU>N< M^X+96@2[8%+($BS@PZ6SD_;]S"Y@1%O8$Y;D;Y.*_*,U++=>EK&1"%]9 GV: MPS:S@YC0BD8LJ37#%+)TK^#P@XKW$/8SLO1N,KD4(=^BPI':3FU) PY#68N- M_XA3AOMLJ1)?@+YDC+@1%=Z1W#J5VZA/ M+Q9&3&=6OY70KG:XF7TLI-QR8&21FM;O="HIE*[[PX4WV;)@W#B6,M.,+R']BJBJ.5N.S8%-&0W"WTF'4[WR_AT8"& MO.Z#R>P"[T3*]DY,YNVO;NL*YW=76K=W5I*E()P0,Z<%!^J$R,3RZ>DT^"WS M6W)Y'])$EOOJ6*I=/5UG)..RF5O(K:NZBCQEV$%B*1_+^2:E;8F;W;XHGMQ9 M>(?-]$JE3K@;#_^[-9G8M),*Q8/59 0?=C<:T;?K+?F (=IM1 %1[IAVQ=K;_FVIY4CFE0!)E; M [IY9IL55:GYH4#T<#$'&7%.J%Q3M-3GN1<"Z0=T2.B^*HO&Y5 L"&=.Y@Y3 M_-!H\V>"I;HB[3/Z9_=18.CG<:ZC(/;)X? :F<)Z8B6L)^+[A'7Z&O%'X3U7 MQZ"P)JGT-?HW]JMS%8PY7C%X7=D4LBOB:YX-F>_8\6&B4I M*H?[0Z4$Z*E G$9<+J$Z8<.72 L\?#/IZ>\O()OL= ;=+YWA;"6_&D/] M'A)!_R)E:L95X>HJ/YTY740&2)B'CXBM24ZT@-( ?=,3!0X@#3@2:"&::UM M7M*X 2^;1%KS]KBLD;^'+NTA)6LQ5Y_#?>TC<&6VA[^'^8?RN=-^Q3F &PPV M!!:+%)_S[TN# *P%RA7\YK Z^HS7AT6)".X>3<0""Z 67>SS*%OE$4H5-(P$ M_XG7E#Z]I&2;PN([3?,Q7#D_,8YX4NQG;-*U6HX@Z;H5+EUEKF5\0W2FNHUP MPX;OQQU:/^$P[TTD"[EV%HU87^/\2/U\4IW#N7:\WO7ZW](S_&^[IG>U,XX7 MDL7W:KKCR?ZSH4#@;G=X^3[/6)U]^EG>QUV?OBP;B;O"U8V@M98[_6)MU'O^ M62[/M-?EN46&#^P(B9T=8693D[F>PVC$EAZ:V)9%P:#W'F:=(*JE22>\-"G+ M=,OL(;F(+.$0J'45SV$T0K3W#^4;^Q@5&79!1HR[]#E&7,G M/AXT#:)_ULE!M+-&YGAI05* &:^:FB[.;3OCG]OF36WS=CF)1GS;G'"?V2+X MM/V^*]0'H."UIF10L6(I0;B9%AUZ2?/@2!YL;B)WPDIVHL((OP!JDTI.P_&R M#%),-_2IN*+K:S,2Z3SE?#:4ZJ(!=R5^UQN_2EII,O1?:_;*X*NGI7C\XO7) M51+H($BWOQU;-AEZSL9G1;N25O8-^5=(;5*PKG.N$PC1#7IQEUOI4XKN+$BAA\?Z$A?$R ML!C!8N9EP939_<>49=<.D-_8IW J(;ULB3,,F\)@GB[_8:DGX'2#K4Y@>J1D(ZJFD(*DE'X['V5"0.."W!8AK/Z%LG['0 MGIM-N])&EZM@6#NJDYC/AW,R/2SE3Q.E7A-O$XOB*'@HP2%\6&IM-&+EUA)0 M BVC/R[&J ;)HJ^) TDU=;"G)3HBO<5U1 7437DFH#^61GD\S+X>Y@.&]JDP MCD:L^@(6W'_5X5JQKDCG+ZV)AW'##( 4X?A"FS"EN%J![%&#!>>I5I:]P5:O*CD:B3O M!+^/Y3K.RIB2"1*-W,(\+9B;2'$A42;G!9#!NJ13 ]B^"=C5:EWG?DZRZ4CW M%EW!:ZJACZGS7JU6?[@O.9U&SBC )BI6E@M3!N;\#5@++:12L7AVI@LXAGJC M=35-(38^J] &;G%V KS3]Q7'I?=B__?]3;+;>[%Q_#!1 D/9C2(5@*=HO(M8FRH-@44#A28S, 6434'TT$K4:Q98NE4%./FT#T/L$P M ;B6SDV%CUW3@UW=?.FM[,FAM+Y745 "5T7#W]^\)G%<_ZJ\I,S?B<*MNPYW M\HP@0Q=G6$YM=+5WLIU;,*:FM&$E86+BPKFI#)K&OG8GXW]4'RV M%"/F$Q8CYM=W"*V?=)152@/MXJI?:'2VQL%YZCEB_UJ VQ#RBM+9;"R3FHET MN,UUC]XGMMLT!YHKFAW8K.4]3='@B.U \>JDJ!&CKZ/'MYB'!CT@@"&F,CKV M\71VTOQD@0WSD381^-([?_[4[>?K>7%7V4/!2?T%B4(S]3U/X5Y3!"--P9O8 M*J_%(C7J5O34A[>QO/<-GH C$[^%#K>$3(-ESB*T[4>:EKI]L X!< J/A. M?'_?__,_7[]RYY(HM_[E;@#?WV Q+'X4<)'$-^X>4Q#^Y9+(!?X:="M;/WF^@@Y+OZ[ 7ZU_?.&O"^>3I;^@IW%]ZC>=QNO:BB!DI MG:^G0^V)&'2XNM8H1R,9C"$FDM^\UVD^67@>%V\N;GJ7X^O&^:?OY5]WE<8C M]_FL?%XI51I?;*1^L CP@6JI"A*2E]_Y,GK_73XU65W72X.AGV8:G\_[<-02N%>E;->=H[AU/=D;; M8,=GR9]21DW+#[]?7 %*? SP"\_%:)F=[H;R]"'.EP#S9"GN!IL^'5_>URJG MO%Y,+POF\CI@#F['#VJ!+^2'K[>NJ6I+@'E!0Q0'T$LY3*;VM8H!9%L]]+.+ M-C="1"5(JXO\XHW+1/YKZ.Q9#JUW98$D$4QNXVDCE:3I%E= MY*U@L:I104/[2;9-TBCN51QQ(J,4VBN,?I7DOO9-3>CRNNBZD-T2CG67MA[J M:[ /@"RFV]C=;;$,!@1(#,4;:69)SR3I5CXX.@>[XE=85!RQE&[,EZ#=7DQ# M18H5B# 3WT5-D##1A[VJB%82.3: PH1TT;"?HCFT['M>,]).,]5$D'C8(G4R M2F,M$HW00ZF>S=M]WNC/P&(@4V&QEBF(M$8.KJ0F[;SG#SG+BC7[K-S/O6O7 ME^@] +<.7&@RAE"<^R;SHOV;NCI&TJ&/5Q2XG34=9:?K;4DCR,)$CJEV1=$(-0B!^M 3CY?[#3*K MWVF:Y"Z'-6TNY?@^7"UJM$L7F%)MWXG=%12=ROJAI MF/>.E'TZ',*.Z.7@-BVJA,1)QW'?:6Y3M4261.[R Y&4WV$$FL@/($,7.9%*!;HOFEE$W@(::P.7DP2%#Y;D[*\. MA!!3$;H@W)'N_8F*&#*,LM"(H<0(*.K1WS50YLT(O!3U>RQ[TQ"JWDL2!42+#WV@Z+@GL(MQ4D@%'P/ 5KRVT5GIJ2R37'4WP-=S% MZS&VCE5%TE9E61V2NC4'GJ[2!*O/'8GM2RI8;Y^Q*@QN'SJ?'7W2<'WP'5'_ M\N\'YC)OJ.ST['D\:+\_5FOO=W+#&8L&YB.HK? QX$3QT_=ZZ4?Y[.ZJS-7. MN?-BY9:[+U[=D9]J-XU*K;T_D%TT%[&L^/3R51Q '5H(M=TV*L,B:U4[QQ ?]GA0U942:: M6^ %N2]\?:"RYKC1[>$\&3S.\7(,!EZ'G23!QE41Q-9PK=2OKK MUS9V3_!T]Y\\&ELD^?<,4'L?2_A^:N8DXJFHX#J:^CEWU'=F7,\ TZ?)D^>G3CZ4K-00S_TO.1WKUX;1*9C MZL0OYN-+4/Z4\O=6R2^S6_*;J@5N/PX?T]6,HDK"1R:_=4N)%TW<"(CXMC(D M_--W+,:FM?HBG?5D>S; 5"!.JJ6F22\D=Y_G///6'3]1:I(=FHLIH[D,95A' MQ=:AB>>6\>@O?4_O?IR7,P4CVW6"JAXH.:!9LJW@7"F'$^;_;9D:+CAER(=V M_$_?TR?QF:-' APS'B!AI+=+&%-R\>S'E1('ECMK)(,@C/GR9U=DD3HI!$(6 M86N5Y>)+'0O9 O M'N*=#TE38>E_^/YC&U_23FIQ=6D MGE1^]3/B-$U[0;%G!.T^Z'9%I%^@;^OBL;A;0IH2CB6EI]R?]K(O+S["\; ) M*22YN $9A:5+?C\346V7%&SR,Q$58UD8+6\4#I,JF86\)H7_Y4/<4\4?\W"N M+T@5N,!]ZQ7EAH3]'MBQBO1499;M3W48R> ;1 M)?T::*]ETK.Z:M\*85>J2#'W/'[*7CXHUS].BV^)@\[H^("9O!_P2"3O1IST M:#O9GF2$!; #:5*!XT^L/!NKVXFH=(PN^0EGCIL*F) LW]52[=C3+#G4RL9A MRY^PY'4]&B&R"5X@27 \P.A=ZID]3I;:OLF1Y=TZO6FRY"U^P-5DYYINVLJ( M[)Z.1_'^[SS/^QA/,\,'*_C(7:6 V"7'\_F]<([F9KA&Z4E/N ?L%,ERKTBR M([N\D$QL$K*SE9LB$(>$R>:3'1Q1@^UCATC#RA&C=YV.=32PKM4!FCQ'4M\Q M8_YU>FF29 E4#O):TKM<5\)D2]2;2?1.]\[BMKBAY7+K8+8T:0&)0U/@%,X* MT0A-#7<]BPG67G:99D'Z2ZD#J]@\TM -S6H=-:7C":V M12.L127FP]N-I3T[H-_T6F5^3%C8,V_%Q:C>NN/YYJ^2$W X\]J6>VE!;M45 M05L88<*^AVXF\]DIX8XH0Y"#T$:O),.=@;3/CU33.(E&&A/\B,47I$($W[;+ M,8 A)4'J\W1Z(>WM:I7*L7(U!>0"*UWY U*95VB(E#PV1 JV(5+RV!!I&PV1 M#J;T\+/@JJW\\"65VZFA<-^A[M*&(F;:@P(TMVXBOJ!N8K7%G\>I[O4I?WNM M5,3\05O615 D&9G.**QSU95Z)V_-'**1BI%FA=32PY(_45:'W&=3X,)_T^F?^Q\5 >G*EO/0=^T ['R[;?]SY)5 M:_UE4^BLMP'B3]\,>!O7. "!.+6ZL>D.<5O-+$^&6W)=GQE!='J,D270=IGH M/>92<2S_XD6N,$QFRX;IZF;D5%RS;7"N?3A]AG> M.6%NA21T_R3=((C5+Q(9$IW.C4(&3;VENI3I=.]S3PVGUY^U 8[M@+.VP)$] M' @M+Q^]#)7")T+HZ> (/-"G"L MDC8SA>1U\RY[79@MZ&,< ^2:2L%6N,0'3"M.SYX"3Z( #)2,IS:Z!5(S6W0$ MF&42*/&N= 5L(0=J+<+6,G*E?ZE?%Z\ZR]X!^T'FV\FB"IW\)Q)>-J7_T/(. M/2:"QW&U/N,E"86T5+,IBRMQ7B"IM;.-A'*P+/9@/MV>Q9OI=B>]I)$@L@ZT MZP%OCPR'A;P36E^GL"^-1;3K9S/D=F$S!$S,PQ^OXOM]XF>[EEC+9C@LTE[9 MC@B'X%>V([9I/)2=IH.[OQD"J4FK668*5CNY#I;U(^W'=1!([I;5JD[444PI+3O]3\5?N="RU5NB;8S&=_G3 MQZXL+6]5' JM;P;K#W!M+)M,?_X\?D\7"P7]Y^UY2CKHD/\'S#PG-/:59"!B M0JK#"=;0='MV,K;&=[7+ULE@3=):]YUDW\JCZ4D1B87"+3AIDVGR;]61F7VY M<)QSKM-Q?H=;3TALV54P/0\[.:^-;32"R9Y3J%CL9&6H2&^.BFRY\&-<+/_^ MK:1WA(KTEE"1R,Q'!4NG=27]D"D3751H(?Y3+I8 M6_:M>EN+,H3<5?7ZL9AJUYJ[H(RI\K1%E)'(KTT9@,;5N?1L65RD \!%/_&S M5GB[&G;;.\)%>B5Z[KD"H[0S5XV4O; M HX\<(E0H)&O Z+>PGMQUT;9TV)@;T-0/_WYY.J MJM#O$B[6&[A5]]]+L-&J:CR*0-O61MPIMSA,P#5EJ]OJ/?*W3^FWOF\(5/;^,1NAE'$JC/W9R&W+48<(2JW6? MF6EWG>3/O%CI:Z].=TO+062R1982S\'O-O )9XO#P=Z)#4-1$VT@D*HYW2F= M92-(1%+L:$\ND31W&?ZP*PE=S+V^YC7XQ_:'OG] TS70JI#6EVCD@==(./=@ M3_%1[U1WR2&;F#)DN.)X8V+,D>Z9CM311. _5+_8/!_/'*4E)A;A!ZQ!1&2N MEC-%J,BY"C38ACB>E:6P013ZW.J*X,ISJO7&]<+:'(O EZK+*3R+UC2@S=9] M'E_SP_>'6G=\/VL%,Q>"PGF5%.PH537K'7%26T@N!/JRHQ@9H94;G M(U84'70.DA>Y9M4+&1"-"] %<3MP+:+JX'4G,HW"- M@@ P+J/:MN,J@A4@NE0)@0=0F]G": D?6H%,R:6D;HR2 M8$MDUB3U4ZDHU)+#JUX_/YW48#7X\UH\@5,Y-2:V!L\M$?I$HD)R3^MD)N\[ MSP6S2@W-"I?%XCCZ1J*-[3HU MK]+[UZ[4 @/S7PY@EY3>FYH)J4!E(0/.7#D8"CY+PS-9 MD7./E^45!&"0J"RLB\JPU4]?B6!A)'"9$,@PC]DRP=YWB%?I$U^\O#U_3#=6 M% SVWH*@IU1B]Z(AD)J 97 9"AZS]:I1N3NO5MY:.T5D:B>"8=G9%3-&<,ZP M5,]5K2VB4QJ=Y.)[7](<";*.[;^W=;NSJ9:!P 3JH6FVDL;3,'?\JL2,5^N-JP*G)9DL_,)OD9U+:L1;AKXEJ<"75(Q*7_;*=[C[?2>Z%S M.,0U1V=>B[BVI7]9FTK.D:^+*UGGKKH&(ZQ=S13(E-^5/(6+"IS6]1*^Q+7? MRKB:&*\J8Q[7X9.7*J>+S6.W4,X_UV_O.<0S) MOAV)9#[9644=3:0-26@N(C +R1<'QKGF1UPB274+3'J"38DDN5RDZAQ-Q259 MB/!7HHHD\^3Q#.W_;Z=2J:X*>MZ82%.U!G9,#1O2Q!Y/)SD@+R%%8_:5-<_# MF\*\<'+Q.EP_?1_"V;5&EU\L#&ZMO9>-("_VY)80C>,7;;EN^2SW^[+IJ M5OT0L *:"5$QG_D\A $O2XJOH-%]@5QG[X;0S4:80/:?8>2>(=[ MN%+NIQ+L%\^?"X=(Y.5'?QNVXU' QK:R00)],SZU@PE$1^@J% M:2CP)$7 B2CX#_?D,R<]4X]&^J:&"9R&]4Y/;4EML!')NBPAU!*[9$P+4+XU MS@@+>)8IL-MN;O<^S:]('>=7!#N_(G6<7[&-^1635T7P@Q,J"D@PL<&_GTFZ M(*NZJ) M3.HD3GC*\3]__+Y_>JA\^EZIEFK79:Y1_.WJM=_\_K%$[ >P52:K*"1"N9S! MOW-@ PPDG=@A4KLM:KI=)F7?Y$873(ZA:LHMK'HU98,^ O8#==:!(FB89%(5 M'8@&MS?[P&?@"OT+1\5;- +?PP%N1:+9*8(D2YZKW=G*YZ:HB&W)^$)F9SB[ MA<7)N#2^IYJHE;><2:O-D;,AH@_8FR+CV-HB7#N@E-.UR%;(;EV;I;OT?DW2 ML5IPN_4BT^-+<@I&R[R"7U9=]'F=5X5(;O8^;X\,> MX3*W7B3Q//YQWRJ-?G0Z9B,YLU[$-7^$"<+3\GGMMLPY8O'@!I!XSOB-6S>K MGL";VLGX$D[]6YB7;L$_72@^^XT6?/J1?^7-^VSRH;M"%&QJ)_YY[7[AG_F' M".RTA6>_P=+9A-A(O]6DM]_M4$X[E?*^X+0!EERL#*YL\!"85*FIMAV?,G% MOZV#97E-[IUIU3'*AKG5#>J6QJ31QUX[O&51OET7,N6GL>O3YHPUDRIJSBW?VAE M/-,6/:JQ)O$I@?;&BG\MQOIO++=[T AD7M?IQOM=Q7B^O9#'C\GW@9"Z'SW5BT;EO'I6+]^7[^_>SROE MPD6E+-=^Q0O5V_IIZ?;NZ>;N]:Y3O\N<->*)\\KY[>E#J:C>7MS''Q]D71B] M=GZ>GW:%WKW9NNC*K0OYY?%AV"\6GY\_?9^$6B(\J$W=>3_XJEB7%>7UH7!H M4)O?2&5SN&UW:/%NCC/5HBN8PR03/GYL?\>V-9HYW!JIY>I_/L]'0J!"/F#J M0A,&C@+8F PL9..%6"*Y87W/ER-Z-N"6V->3M101Y_/,J_DM:0PU9-FL;.Z2B*N%V",4X1310N?#ZD\CE MQ'Q6P10(S,Z)7X_P9L%U:YR?2&9C\=0ZK;E])S,>&$2#9]9$-I;+K=/1>2Z' M9A=S:*F+R0,5Y4QLBYHFMN"!HJZ+AH[!17KWH[<4\] \3*M)_.!N,*B/L\EP M; X%LE42<&;L.K#URO+7)L*EK+>): +F?E..G_82$USIYEAK//<.1 S_-#I_0XH5"1@CG)O>6[6 S(\N2*M9 M5]#8&RI>GQR7+T'8+,M^R5JL;%C]"P[B\/G-"GL]"??3653N'*H/%)]=]_JU MHA*+=2\KB6[9&$K0<9,9%7/IPMFSSR2+\:\763L=WA7-J\R.@E!+'>.0 !U_ M]AE&,*Y*B8?ZCYMK[;ZYHV#9XF.$7O)_L-BU(YTA<,D*\>U \QD;)!_<&[^? MR%#<82@_T*,Z>0&> RXFP)WPAWWU9>-_;\0K]D*+_/\!T;*3.CYSWX%_*?OW M!O?,$AL^ MH+Z/7NF9D;7L'T"CQGX^?-4^OBQ]O%VSBS-;_K1GD:9V'F:4PH MAJ5Z(EO1VV9BU#FTC(,)J.7"S-.8T/*:YH_?/5T;W162AP:U7>5I>*?2'7B6 M1GJ_LC16C"Q,N3#V,;J_+LG,<1]F8^G,XLR+X.*O!P'G=:EY-IQSV5@JG0G: M31M4ZD1*KJ5.VXKPLW?,G @G_;H8/+VFS],?J!W ]CK/ ME-1>3S)(AS6PB;!C&G"Q"()4U!?WHG&7YJVVT/-8NGHL_OB=>%1'X<[]#*4[ M36YV=YK1K^%=]S(=3W1E,&1JU]>5QG693/*LGG&E6K51J5Z4JZ7*L5_-GG*B M9ZKPD-=)($&0>;CL%0-M4O@.KS4E@W7/A-M,$$7:&+/#2XINL!'?DP$2=R]M MVO/O6C2Z:JM"9HOSVHI.[Y"EP, &*!$P2'[ M]AX7!@*6/>S_R[U@.[(2P95C%2#JJ>L-R$\U01C"@AU (N3GD=M4Y9' MG&F HCNV.@V1+1'$R+)(6W_"AP$_@"Y>T%1=Y_IPK4L ;*43BT9(J-@ 4D4T MQ,!8ZTCX]1YLE(_!?VE"%QMKZH2DE1:G8NM-^!=HUS).M*9CLK&/DNNH79'' M5HBL!VU7E%M6$ X[SJIM[M*$C:-N[7DO&G%@I!-]$%]Y4>$TG$HH!-^E)T0% M'_O'M:RVB[@:Z[GHP!V6T+#MHH;]40GZB:H)X+=VD*+H*[I> #9J$13YC?QN M\P-X!M8PABKW*H[HG''=ZAKE0OAV>SL>&R>O?H,'>)C=W4Z3E$ODDCH0Y;HA M]GS(%KN?(LDBQ5H-@JD@[VNBX6F!!IPFJ)PE7[G+>ZYHM9>>Y)IH!,2J"ELT M"0=GPQ]\8,!.PEV2@]RS@\R!"GR@+6D@37UPXOXXL:LL$#1 MI>P M=[X#.;Q$L?D;#_>"KHNZCOD+ H@UB:@AWO.22YK[/+U,-&(_],4KGHZ0!VV M&&N64#%$+DVO=*<9-I \45<6K6[=S-83TQ]V>M?C]J=Z;)\Y9HTM_ MEJK/+WS]]*K51\*+K;\Z*UA])?6YDR:FO[B]&KA8*I6,9;-^M5:$ MZF.HJZ N1& ( !Z H$)Y9O6QE$#R@P(HJ2TFNM6_/!J!SZ*ZR02IJTGER5'2[-EA=N5GJIM- MG?2G-LJH"^BS7$J>J0^SWGD>JX:FE%\:];>G<&>3A.(]RL_P'IT^CPOMP<73 MT^]!8_CI>_WNM%[^=5>N-KCR/;J0=N4P.MH9*Q^I"'J7WTV* I;\,Q?S6*2^ MJK._)T&W)+1AH I-VQ%399_4#JJF@0$5L+);((3A7?NF]KMB4YY8DN6;H5$E M4!S9]9I/6-AQN*OLP\6O17&+T3>-V>>?&6SPVD7\U:\<9)]W4V"W<9J.0*US(7 M>J)\3CCK4L]_322IUEG@^T_^^]^W1R#=#8;RZ1F:@"+E3I'MXI&",6 MQF!BV@2:A$6S P?B$HD9,RGF1%T2R>?Q:?WE(MN\OFV6/^!H*#C^O"D6Z>,4 M"[^"D_6G6*0/9XK%@0VN".<*M0LJ@]6,[LM7]4;Y.AJI5!OEVVJQ4:E5BU=< MJ79[<[(]E2?XPP6,&E;+B?D5D]6<_!*C"4&HW $U>/]4H=N]^?5ZK%:JE"R*5Z M5FFPA[C;J=V4;PE-U7V(Z1ARW>DU;.N$NAV#H1,O4(U!-=K4=<>A MI*EFIPM:+G5W@;;5@V6^_J(N:!X4'44U./B3H6IXO:&>K?#$:8M_9+YFN"AP MS-Q7655?K1$B= LGS-$IYM" M%QVX[)/H@1&,F.7'9K_E86E!ZL-"DW\!397,1HS9&V)_Z/&CR6>'DBQ/_D[O MXL24R=^BVU^9^FU3E"5QX&P!(:U+@$V>#/[61(( #/G)1A?ACSHEQ]ZR9[4( M!G,!:6(;(Y&VVT@7Y\&.)_XHQ_=/X#;Q=TGIDMP]=$B9S1=8'#5?3=)?HQ'J MM2*HZD@#Q#] 73Q M,S2AU9I, T8=J.ZZH$E-ZX@2D*Y#BDTP !@I**A"JR:&8P2@2.""'L:,D4BZ M$M*'AG 3(!L?J^!QC^0Q.'1@;3_1WH00:[AE06"9B#*:I]X.G3, MDB'3+E&&H-S3Q+ZJH:#%XC:9Q FG1^O^E8HETFD^2N5SY$?K'0+'%TY M>V E%;!VKL7$TLE8/I=QEDYD"YZE%TW#Y*RU8RAQ^[1@6!X1^=?E6QQQ6>"0 M8U+H,76T:.2O;-S^NO6P+(&IB1X1"HR_L*UTDCZETU04]SQ.KDA^>28*Q&'# MI:A3!'9$!+)W S,^PUPL$[#)%!S 9 F0)D[YH4CV0W(A'6T-"E"?)ZXSH(BV MI& N%&LKP.Y9-RO-F0(;C3B$#RI*CZ9PX70[D:HD DF<-5G@OZ.RF)H+!*3%%#?,F@+);IF M*0>R>"'CR(XX-]MR6"+VC%?MDU\R 4ON(\P M^XVH4?BNCH.'NZH,>@ZP$(^N;8 !,BG\T5H2U1V2[R8NRG:C$-+A98%ROL#W M26H;,RKZO&Y0A$I6)AG!&2\3M48J@/HG X82M8TQ)8X\3J*AL]# Z\XCR MU]>D 5'&\-ZE7EIX$31G$-6\#+H56!^HE@*RI9[9(P7'H$R!=H>/^?AMB5@G MWMUH!!-F$#--@XA$1^-F2JTEBQB0X740, P >'_H9KL-]@5YA)&H*U3+XL56 M(J,).).Y(AQ(1AI-'^73GA^IHG"HT%EXA'O'P*PMQS;AFV#AQ/RC2S9[12,] M4?22$'""QB3;M$ A28\.%)683T2\6)"S2UG_"1F@QI(ENG%]W !DL\* M/^$&D4.:: F1M%LL?S$0:"9+*)L-M+F2^@.2V@<\$J,A(#C=5\^NZ!H/\I9K M2JHAPBT@2SV)YC%99&!IXFU5,'4:6>L#?8LB24_VS\AV!>ZZ/.8NMKBN"=N- M1D#]U$:J(@GP?21M#/W84MN]/6!W6 O])7@KHG>"[R@JP$S0K0M8X_NB27Z! M"W1$Y"V!)DSV)>O'%M _&(?ZBD3O>*>(@!3V"^Y<5!U$@9ND$WU^[3"A1-E71QV:4;%I.#@*E0]2SN1+H62!0O[3+M-3 %B09?5#7V3<@P+>5AAWHXD02W2O6MZRF,Z/KE'S% U#9IO]&W;WQ,4/;K.7 MXW$WQ]UL:S>AC(99GOO]NMPQ2SP=]QU'/NFW\1>4RWQ[R=$G*R^XY#3ZE=>= M,;8^DTG$$ID9RLK&VYYWY_Y!0$YE\[%,*G$$PLS?$(Y( H.9^- MI;)'2@X5R,ED(9;)98Y #E5<9+*Q7#Z[!2#OC[6T7%=@G\XLW.>)MB5?UH5; M$(/BUC4--QD9M_HW+69VFL>L2VE!\_ ?AX//J03)2@\2!4<.6)X#LNDC!^P: M!T$+1S$+R\>P;[(+7J/X,P!V< M(K1G\/LYQ"TCS\#UKS@P43.Q1/>/N PRZ5BN<-3?/GA :\_@=B2Z(_".''M(< N7 MZ/8J=CQ+5ZA8@X:9'7%T4B]K;^9B^5G5H/O'>!\1 ;%X8H.R@"/\-X5_)I9/ M' /V.T1 /)9)!)K\>D3 2@A(QW-'Z.^2_!/Q_4S\"]'GLR 'T.,2/I+2DJ2$ M)8:)_)&7C[K<'PK_?#R6C1^S7W>'@%PFEHH?C/OK R+@J,OME/S3L7PAM OX M(!QQ5=:#FZ/C5=F8##)63[2#=OL4%3WNYKB;P]_-OMIYL\0$$1'V%!VN)QI= MM<7F>(AAF7Q[%K;YG(P5LME8.G5,,%P==MEX+),.U&WRAP .B"Z> 37EF%&] M#NQRA70LE0PT.?-/@5VR$"OD _6._"F0BV6R0'7I0"V[+WMA4TSOJ^RV%[B= MJ D?T##]G,CE8HE0*.@(_<703R6SH%@?0O'7!X3^1B-A/GU/I NQ1#R!,UF. MGK7=L5 ^#H;2(>BL'Q'X8&QECY?'KJ[N-$XD#]2K'(3R%W*C?,N/O$4Z21*< MX5176=R,4*;:@H;V/5O# .TN%[;[L*OJ(M?7)-CLB.-U733HH%Z<-*P. M%5'3NU+?Y=*46.$2SBO''=")XTH+_FV45#*['&<=FX+!*2I+C&V:NJ3@5'5X M#C:"\^CI!.08-V2CSN%931R(B@E?UF %GFU-NR>6A+( M@>_#$N^PLB'*HVCD+YRV$X_'R3)_I>!^P1_:0#\XI%J7WKF>2F:SBI[9K!R. M$R3OX&B\&))B7Q2P7%\>G7!U^+?41I-2'L7(0K E3>2!2WQVD,BGR$8+/ %5711#P8LMXT&%PPP@^V)1F?8S/$V?AM9#? :*R7XE&IIG%EA 2'4;?ATM" M4DWX+D!;;2W'3,.N)'3)/0>L^=7FS0GV]_N\M;L6V:P7\ SN;&.+(4V%!J\Y MNYU^)QIQOY2$':['R-PL/HY&+!RU?%@ZQD U[(K*A(#!_;IP-2W78K9,U,G7 MYU$/R)DI.DYD&.<0 MR33=)S))-^$ONGFGR=YY(QKQP1/7 K60$+7> \8$C5(Q>TWX+R3K/FG+R?% MSRU'*A 9H1B64/#Y)A FT!7[NR-_\$\@#]2.(N'"A"[_2J93U@&7NT?=>D.+ M&_"R*<[C0>N ^!K? PA@QR!\@?RB U2,OP#@P#. 7'B #%$?+B%S2])Q-.)#R&%(\ 6T'(ULC9BYA;0,[+_KL!?K7\Y\ MM3A.=$U RU[^?^F9'I3>=;>SX'S[H 9X'L&]<8]>'[18UO2L(WK@JD M0L%:51& B8S[K7^LU_!/CN/)U.X6XKL GTHYLPQ+GCL7EE9T(>SZ2!ZU=MDXH76W*@IC)0 MY0%1ZT$&\5I3,FAW;JJ8XB^)-XI[4240/0-XR015'R2FH5!!.R'W<9Y-:LI[ M0#45O2,XJLS?/R*+'1_GAX,X-T[I?8X' M\CDCM#>3"!S M2N6$D,C)"&A.-:G5$8?\"&&#'Z'.'3>L^0Z/+2L))C+QO_T9*,:53FY.N M- M-?ML:[@[YN6"5W77/1^S>=KR&7;Y%G$--V4;,0:29Y]'C\&([(S 690&<$"$ MD>;5'>!W,KJ3\9?3]$)=RQ0_/-?F!ZI&[E#050#=HH4?OJ>:"G-V6RHCBA:R MJJ(:>-P1>=$B+68)\Y0(+ 6-<(BE#5J.;8MZG*][=FBB3V*/=)O#=M1Y/-)= M-WIXEI ]HR>KSTV0R:QZ#5#^Q<(?B .DYP M1[*: SK6V#SO2S(;E//%_\XG[&5M@-"=--&\D,A0USWN[+8E-@U'S4"NP!5<<>>V M":JE.QZ@L$^!:(4GT?O 5!595HAZ M#BFZ"[S^2N1!4P#UFKU#\B"6VMN\FYEC9@&R@,=>FH2:]<$/12H9>E8K2_=D-#%D7#V/4F(+0^VH:(#XGO_[L_#G0K9L26)#$&H0=](&5 M,724C"?R)UP-UF#W9#325V5)&*%C!BW2?A\E Z]WJ7J.$H<&86C)YMR@- MWY[*2")NQ1XO*810);AE%<.S#_A"SVVVT*V(=#-M24'S@EHLK9ZD2&0?Z$+2 M#;[=9MF+S-#!X)Q!-? ,T4$D0G=_9&9/6#IBQ/9V $XU0/5;OJJ9,[2Y%'<)VX+^T'A#, MV++*42JQ*//10C^8(WDL]*&$Z!59**5I(-T[5,GE8!(71_R3R3;Q! MB1[MG!#C)_>DZZ(]SVON&-UR#R7\*LK56S&B*0MOXN"22Z24I>70!#36.ZEJ&DC[D&5 M>?T5:(8'"]%*#,)/G:K ?RP?$P0[1IMZU"@D42C9WA;<-ZJF@9PW^YRUFPZR MKT&='=EXW YR#%7ME=2#,+,"Y8<^%6\$$D4-3B>O6.%)L$Z1)Z,1.)R)U2.I M!#%+TS'O\[:W&.@?KD"VB_S?Z-N!S2EFSYU="!M.Q%U_(TOPK0'RK@Z\V&0* M)SY850<40HD$=>XD:;011!.H%S0^"->\+%$@3NZ3<.40UAI9-C9A;9*-Q';I MA%59K)9&#=T!2!EQH#%HS$_4 MT.'UOU)QJPJ$J+HLZ=WF'.*SS,19J,@68]2'Y/H+5P/]D]J4&'R<$ 1-3,JC M[G^+J5W\YIPM0UVASHM,2] ]P5&JG")Y-T51X=!&!#1(-!$=8([,W6J1,)(= MO65 :(/<=%(1,7V";THR\9*0),8)0>U$@6I@<]C:=Z6I.F M'!"\XUQZH\6BG!L&-XF$D7E8QUQ:Y MP%5"9^O0F@BLJ-@I*Q-9O/.2C+C/[MR$+Y2!&7Q;$MPIQ)]%+W:2IR/(O-0C MQQB(VLCZ!$,7DQQD253F&2A!OK014RQ)21Z1K :P2ZDWJ@E&OD*4[F)? SL! M;VFW74+M$7+)HN*"W^SQ & @()J*I:*)+SG96RP[B(87FT3!4)6%F3E$_]>8 M?-5%;2 1NT'2:3R;VC0H\D#8[,A8#EV,+$AWSA[3G8--=\X>TYT/\3[^&2%I"J-\C6':I<=I.("_?"ONV*U M46D4&Y7[,E>LGG'PBROKY[-*O715J]_=PI].:W<-[KIX^[/?8'N-J*;ZV6#$1MUDQ4+XC?)T.CZ]+ MM6KCMG95)SQ]M'KMTWKJV96C1RHX%]+_5![W90!T5-4GOTIP-#$&2< Q-V$;HM"1=D%4=GY]QRM5V M!0]@A(]5'\"G+'AP/4F'W1A6!3$#B;.$\T<:Z72?HR>*M!;$%;A$X\=^V2GB M !(1>:&+J*-N';HA@B;>V0W?PO(:C!W3W'5U(@8ND/G/GI33)VU&P+A0G)/ MT2N#J24^1.\($TW\RD002P!8;<_XQN+=4H$ ?V0YJ%8T$%:B<5"$AP1*?) VM\XXG%-UONBXQ M]R(DPBI1Z_M<236Q0,?I BBU)'CB\%8VT1$,DZ@->%R2V M)H_0S2=]-&_<81,N25.9(EW4SQS]S965[TJXT*PL5Z)5]?JR.D)ABM%A7:0Q M;8NN0>O$,-> %8L2D:OK+ Q&LFMY8EDR$7P4=ONS?;3W2-HKU4\KED0J,8E4 M0Z0ZUL.MA;!CZO/>\3G&1% 7450KDWF6#3;SFOG, G4T.]-UO\%*MR9<,XD4 M_S61^=S^XJH-+[^SSQ4%XPLKBJ>A,]84AT2I:/TDB>30[]%K"B/0EGC"MG5$ M 2-FG<:11^U8GRR]XA5#XDX3S\=F'S,:V;FT^4BA:!IT"50 >7UF"<=GUOQ^ M4[QM1".5RO:$3?#G^S"1A432&UE(A.>!O"I?%*^HZ[%\5JE>''V/>R=T2'0_ M&E&'V#(-; 32[]PN'27>.2LM 1X]5T&1) ):ED%>H^5!54F2A6QEX+# M?II1B$D/*M?A>^A]+#G%!':_(=K@A:Q*]4NT7TQ#U49L5S&2K2A; MV27)D321<&ZR2J7!1&N@HO26*.FX_U>7):.J%* M*7--31+;.BLP MG%:(UE.E-RJ[B(CWS+V@RZ4(!6Z3LVC=G%'R1%RLJ7(H2, M&[,D'55U^YIHV#:XP\\WK$Z+N[SGBNXV5NZ/@Y365[AA MD(+FM9E _/AP,O[-<47%N(X*2C\\!9!B7$8>2GRC'><$VK$">9"*7%JP84M2 M GFQ;Q#9AWDU-+2!A2LN4>^.?[B,$2\,K+*M2W*0>W:0V5"!]=N2UD.I.8T3 M]\?)36"!H 'RM22#;',@1^I)B5.P3RK =;R-!) /9;-LZ31'=7ZV.I^:4.>+X>GSF/3#G1=+C=KM+E3YCV2 ;WUJC=7VVQWN MIEGAO.,>:HZ8>RC9_)JTKB.W7XAJ9RS*IF']H68/)B%9S;2?)39AH%>:)=$Q M+TG:7M>,H\"8+3#27H&1#$]>W%5ORQ>5>J-\6S[CZL6K5QB-7 M+Y?N;BN-2IDF*-W5R_A'YBSX<\2+DZWMSLZ>S-Y>^=B>;.J)@:_+K^*3V;W1 MS%>VJW2^_QXB9/T&TJV\QV0ZV#U^YK\$M,&0+<>J:M#-^>6-SA@AO"N*VE,B MVM-M;=OI<"26;6_K<_,H9(YTHV2&O9KV\&F+Q MVG6E6N;JQ?-RX]%5@WKDT2./'@1J=LBC.2^/9L+CT5KC1_F6JU3/:[?7Q4:E M5CURY]YQIW)DR=VS9-[+DMGP6++\^T?EM-+XF(F6?VJH)'1P_[]4XB1Q&#;] M?WBNJXGM_WX2WU.)KXF3KM'[]+V$L'Z9:%F6/OYHT9(*6;2X MZ"-E"80 Z4-%LP_[:3HD47=*]DD".VUU?V6T3E@G"U)WS?+=%4F9-]IJ-G&$ M'>[X&/4,@=)J(@XJ=C32()-Z<.PB+3;P:=5 9XS9U2JLDIM-A2BI6O_$SDZW MFYW;)&%-KO8AAQBK;<#JB:+9@3-RB;3])Y*PR28^_SZ]O>(^B[\-H$X)3:Y3 M:Z:,73;.7?%*Q^0[XI=_N<_2%\ZAY5->)C,BZEU1Q)*MSY+GSW57'R4@YYK= M^Y4\.>-1*CQ)=3L9VN1T[[8K \ID% 8N,IBS!LZ>. ?@TY8RG^'1JFJ(M!ON M?':,<0;?Z= .(4U9%5YI^WF@FF.-T(ZVGXBG<3P(UL"3MJJ$4WC:]N>,-WC M(Y9CV!W0L>2'U6Q4%!EE)R'TEBJ0B=!;KLPXNDO"<)<0#VKXTOPP#!K:#11W M)[YWI2:6+.G6)8 S2#1%TKOP [:<0.;847+$GK3CSAW;<0?;CCMW;,=]4%>T M-X)C!R^<1M2!1BKJE8MJL3$CIO^GQJCV(69XP[P11"E&98F5>=E:-/%)8/V\ M1-J%>X;-_/^ MV1M5;UL)MG!P_/5_/R57AFG P>1J[;Y\56^4K^GF*M5&^;9*\BV*5URI=GMS MXI&@>^<&9 26(8K$/B9'.UO<^QVFP][B?I$.$VRV1DVT[2 !< :7SK]T@Q,^ M,2X@Q(5^A-,1.\#<#4\8+\UIXV4GTDWZ_H_^#]VL-=\3SB'MK33;4_D0:,X8 MVG%[MRN@#KH/))$C=>QL6PWL<;-_Y&%'W>ENK-#[AZ[V6>#/RG_C:GT26OF7 MN^+A9CLZM0)P:N77=6H=OML)]OI/4VV-D''^Z1H]^;N7 NNB80'LO?7^C:N< MD7\\Q_.GSV2>LTYZ?)%SD_?$RU'BOF"8R7'GUS^/5_EA_O3F-W\Z;/)WIZW! M=2\9ESO:Z76SWCQ]JM0Z9U>/&5WM_NQ?UE^5?]X:_Y?YE;DF]?"7550RZ7&A?B/ M\GI9^-&[^9F\T)^,JVR[T"SK]4JM;(K2S3^CL_CCQ8^F>GO:[O3.4KG\]3A7 M*&?&I>LK53B3+@JYI__+Y+6+7V^ULJH]%)^N!;FKWC](I[(I&_K-6>5W__[N M_UI/5_\\_N9+I;O!8ZO3[M:NV^5B\J+<&O7/?ANW_Z>9I\F'L5#[9Z"W\YEL M-?%VWWVZ[K_+Q,W\78NKDG73ZV&>7?^/__+=9B"\ .%!G'Y_L'D'G;RN MZH=\HPX4<^%)"3J>M:&U*O1DK1<_*2M7FE*/7T76V M.RZ@N/6P9%^O&"\608R&1X5@\--S%[;&1#23%MK;"L:\>6?W@B4;.))*ZL<-/1J[_7CC M.W6ZC_!I_"C21O:1P19#0Q+0AYH-G![T2F2O'_4].K.QF QY4ZY/WTF8B ]< M ="0 #;, [O< +'Q(-*&?"K!,0HN@JMX[7L]UC*_6/MRD8VW,M;?KJL MT+QR/^#ONA]]NZ/S#I-V(E*4=_K46WQ94X^;4+-PQC( M5MCE[2N2_$<4;J9L70 7*/08&1: M?<::CVPCDGV,*3#R&9\:E(2IN8B#M;B\T+,X$TNVE=/1C2NX;:E,$?4+XO0I M\C!AFK_E!#%U F>B;?(O&TA;6$.50IQO$2I^_7?IOCW$5N>O"\O(FX?*N/!UJ<*VB7Y9 MJ+_KF98093I X>R<\D1_X(GF@OW'/6D72D3!]C-AF!1 M"-%$*^WXF65_-VS-RL^^ZBO)]*Q'BRH7\7+!74_%?Z=SF@L['ZPL[5QRH-U5 MSF,DN-LI]^1(2YC4)^)LY>L6JR3KLFVP)H\+C)JV/Y5G$P-5#/+GDJ++H],7 M4]^M;]V' !8#,SC9H 7QHMQZKSA3Y]5P2OZ0.]0D]>97XN9'4=&92U?5X R> MK8L<8N$._V3! H\"GQRL>+WMG9U"J5Q%6?;/LV*)U,8+[,5G[8D[#YD[++S] M,]J\UE*>%KW.0B&Z__/^#U!+ P04 " Z<0Y7YT?<=1<+ "Q9 $0 M &YS=&TM,C R,S V,S N>'-D[5S=<^(X$G^_JOL??+S<[ ,A))O,))OLE@&3 M<2U?QTWU4.&UB8:HTG>7*PAQ#A3_2 MK7)U5K^9*M6J1+^/V#8=.AGJ8;\+SE?LME9[?7T]LYT7].K09W9F.$NY#D<< M<9>%O9VOS[=_\O M(_R\>'EJ?)XB^WJP.7?7_:ON9'35>1I=73!#U_PA[YBQP$ND !@VNZ\(^;;B MO5Z>.71>NS@_K]>^=3LCCZ[B$]ZN+6(_IY'7;VYN:EYM0)J@7$^I%71]61/5 M4\1PV#/4DAQZ8C..;"-&;_*P093XJN97QDA)*NFU3TH"4A/OT3%LG,V=EQI4 M /W%94#HLNHE>@]BL M075-5(LV%]7SR^IE/6C9&XV[82-09VPQCI="G;T!SJ\OA5%:>(EMWG;HLH5G MR+5 AA\NLLB,8+.B<$3GF O]9"MDX+>Z"[05_S'2&]!?R:>$9MX8V_-KZY4A;&Y M0E!X]%K>U?:)DSVY#)M]^W?O>44Q@^:>3!THV+;?DN2W-9!EN-9!37?\Y;7< ME@=04-Y E#'"TP)@S?ZKC15)3?@'S+-PA#N?<-K$-?"O;SA2_MQ(&&1@& MB(+0"\P)R)""2;Q>"J!+28"43['.?RD!RP LG$S6G_57(F"!P;<&E%$G!=2O MF4#M>E6MFD M4F!>28(9'>:?BC^0\FD[U"\EP 4!;B*V:%O.:XHY[JJD +R6!%!TJWC]EF!) M@-6#C1/%2<>94BX%TV<1\<%VRG(8M(O]WJA$(\MT MW.42T0UX.S*W82-@()NKAN&X-H?M^\"QP OAP);D:*50^[*/VFC2[:K#[P*V MD?[0T]MZ4^V-%;79[$]Z8[WWH SZ';VI:R6665CZ:T<7\X5CZO8+9MSS43YX M6952:-WLHZ7]:Z*/ORM=;?RUWU+TWJ,&&U"M-R[!R71[#L<0O&_0U,);AQUT='*J<^UBUB<5SR>J]I"305LNB>_F5=N$\%4LT]C>+>AY M!%*X7.[C JAT=7\E4-1>"WY[:[?6*Q?NW"!LRO /%V357G8K=J)4"I)?DX%5 M8P2N"B!1M,=RB3XZ%CXD)BX4&]>O#H^-E4_!4.5R=!S,8Q&6%0)YVT(*XNMC M(/8'*@$NN ^*(II/(@5A(N^0N2TF M7B&%2%8&(=P]E: 4V$9%(4D6RP!RD<@E1+=4)1C%L]@MS!&Q6 ]14?""L[+: M"3HIN!+9A[0LMWAMY'6NA+V7"&:&@<8"FZX%V#QA,E]P;*HO@-$<]]SE%-/M M^S_6G[6(Y8JIW,[M-B0\M+44VHE\QZCY56M-.A[>3YK^\'6LM13U$8!_T)3> MI-O0AE[H^%4=@O7"4TOO3,;ZHQ:J1*D($HH@K,9/AHRX8SSW5U&+30"?3RT% M="*!$@-:'0[5(),R&O>;?X*MQPV]1/6X75ZZTSZPK13B*?D9^9U?Z=X/L.K( M_B[#DE,HI+!,)FHBUAO; );F*@W7+E("Q]HF-K(-@JR!PSQ^=E!E8%FTN130 MR71-!.A(_"4<=5OOJ;VFKG; ;D>Z*(^H0JD)AV9OTCVU++$4RD4R.J4G/L"T MH^F<#/--(Y$"+WF@)&*B>^F?T@8+Y.,R]K5Y%%* )3)"Z2"5%E;$PMJ(4.^K M(K$0"A8F#")64>*)HC+F+G,W-<4[D '[,I%MBEIG6]6'RJ/:F6R74V_-G(Q$ MZ"M*O;5544<0*)>[G\(:$=F:J@:8$;"!L\#/I97".9&FBN(=AO474;"1^][B5VQ=REY46P6B11JB412 M\OU*N: >E#P0;U<:>.90'+YIR4PCY-!*H9A,#L42"MX+FH;6[@^UR.N:T@;? M"<^43^\.:2B%]!NIH[>0+C_5._X,9+HO+M) "NE$[BCWC&3IIH\X-YF5S7^# M2@K&1'(H<:[R_QXZ\8^X &*(9XIW<<2MN*W@OL*(N+JCLBU;4#R[K]B,+ZO! M70)_@=AGZZ45D(@13P00,Q[E6A$9-W MW*0-R;+(Q8.GOK*#9MR5DSMH:IL:MC@+2@YF(7JSSA$\>-T48N+MZWJRV'FK MI?>;':0$WKD%NBFB"-$FP8_#T-C=B20'1$#O@R"N23ITV .T(#EXI@IL[U+R MWX6,QMV_>OAU!,%IAYM=+$Z 53SVH#)93BQ+O#:YKW#J"I\L[LFZ!5]-''/L M+2FFZ[_"KBC^$A/>"W5K.DM$;!TZ%)0@%\2VX,U=0?U '7=U7_&[(T"2SRYO M.K"'Y#:F;)_CM*K38-J;R]0)/BE&6X1B@SL4=I#:&AO> <#F A&Z1':<>RG* M4Q I5$W]&[E .#P5'ZO[DOIU2\?&'-'-.\C9@;!_[DVFMEZ)2VU"L5)K M"D"S)X9!L?F1T6YPVUXB&K,NL1U*^$:W.::@F)Z%17M)/RJUT^:?..+)JA/P3S'L]%K8 M_Q\,VS_VRX;8P*!!P+5J+F'7#$KDJ5,;1SW"@:U/=C[$U58#1,R62\7!9X^C M-@0K4R& $2K/FV1H^Q1(6-S7^Q30"PSP'M',[LR#"%\:@)8I;A@&A^<-N_\& MW?L<:HS7O&$YQG,8^AS;RQ%+'@^Z>8?9>'+H,\QK$ZT(%V^^?.D2I2>KINF. MIH6908EWFJ4_&X#B&&2UDZY@F_^UPCY ? /+F/ MWYM+4Y\LI$% )8XB MK4GH8A/%/]FSF/S6),"IN(!AY<6G*4($%<>+\0'!L(@"* K"P Z>(TLL M6+#.QU>QIL-XB%#11B>K@7'W!_P/L04!OAE=\=^@.3CX_V#1TE2!#]K1/EI MWS<=(/+8.(TY?A#! S9_TOS*C7:$7WK'R4W<"Y$(S7(I3B3LBJ6@_WP9%281(D*#$ ]F:/"0Q MC6YV]]<7 9#X],O+VE:>D.MAXGQN79R=MQ3DF,3"SO)S:S9IJY.NKK<4SS<< MR[")@SZW'-+ZY=]__YL"?S[]H]U6^AC9UHW2(V9;=Q;DHS(TUNA&^8(3:?S_/Q\YI GXYFXW[TSDZS%&$Y\PP^\';?SE_/HSX;\DXV=[S?TK[GA M(07LY7@W+Q[^W*+WC6[[?'5&W&7G\OS\HO/[W6!BKM#::&.'VLU$K2T5Y9)& M=W%]?=T)?[L=FACY,G?M[3VN.EMQ=ISAMSAC?$P2#]]XH7@#8AI^"'ON;13N M"/I3>SNL32^U+R[;5Q=G+Y[5VAH_M*!+;#1&"X7^"^CM[@J((=OST9HBUJ&_ M[73AD@NBAG0K%RW Z3Q_#>POK\X_7)U3YO]D!OFOC^"9'J:.U5(ZQ][XUK"I ME28KA'PO3X#4P54(F81>2*I6R)!%IV* UL/=&B]$C#77PI5RC M95-5(-ID!398$=N"5*/]&6#_M8<6V,1^$4ESF50@>-?P5GV;/!-T3&_!!^<8KQ*4DT3K,:=L?TC L21&65[5Y3TQN(>(*EB[D,2H.]C!YYSL6'?$P_3BWM!"NMP).-JJV)1GRK(IG1TXA6P M, (9Q!64],(U08"V='OV#>R&4Y+4/ZD?SCS(#?1*Z*JJYP7K(S/HT:Q+5S*6 MP%43S D!AXKK(\*E['JPJT*;&[Z*"BU(7T77>%Q&R2&NH!C1%O$6+8B+=NWB M$64IGTNMHA>:Q#V!9?43#D7=Z A6%4U(%&_3Q.BSQ 5HS, .\^H ?F8HT(N/ M' M96SY4:.%U$1_[='2T5G6AM.G"5D#-#/^-1E8G2OKB!R/2)^3"HQP"X;!4Q$;YEPNG?1HX$M[>61IJI<@#C#Q9"Y:A293$UE@F2C3%Z* MEB5_\>(@%9'RK)SRT#J9WOT1FPC0'76QP#:&@NS1Q@9;V'!C2Q4QPU)2(4HY M,M"AR87%E\_7!<0&G8D97H5"^"O!CO\ PP,W%;,2G M[<_BASP[6J)$G+0_)^SY^]'D\*D>1\KTH;V] T-%FOB1/*DS?CG!C9=#CP M+7XXP\Q14B;W42TKW)EBV/<&MG2G:SQB?[\$F-(\\@B:CFEA6')4E@F=,5TE M=)"E&:Z#G:4'76^PID9%UL$.]210(K1-M_O"F(D;0B;XIBXRO,!]#=7<9(.< M;,>G$(/J7?-0Y2F= E!;AF9LNP=4L);F4S9=IT1UXW<^,L:4P#LHZ4T$EZCI MPG4D3L(OXQS7?-S!PC@!X,66^;V; 3R>(LHQ7KC,R1,K29 MO+?Y!H(-$:-::^Q@S]]L'(ODXFN02]ATG>*B<9 !"U0_4KX '+7,E0LPW_H MR+2!35>;7&OS!)>P>]OILMG..B">2"3'!TOC^TD-#KR?CYM,B R)0UB5\&80-.TVN69F@CE7M.G8K<&BO-*14F2D7)ZIWT3YH5O#_LK"2M]AA[CP(+Q5#EIC MEDOZBYR<@E>G (T%8=V*"4[UQMO\R'HGW4=EP5]Y$_-\R<\ US60G/VC(:/=!4#O*1@GY-#^1 M35^ W'N7?*$P2JWKS.05W=V#?_^$P:9*5B8QU^UI% :*8C-X3-):A[ZJQS4 M7PY.P_'46M%<$Y&J D/>D# M) YMQ >/-UX,MY_EQ2W;$+6L3M!]O:B'-O_J3O)S+.RV'$X.C&;1CF(FAN*U MA"B>HK6$#P9)5=A/P&0^].50"CZWGTN(LK"./P2D!U\E*()I@E005(EG8X3M M(U/Y3!7ZX+WY@K@FJ 6AE7N"1MA*,J'+43SZZO1)L[^I/)IZ!^[1>-TM6!#7 MSV_A,T@DG17.P"SQ)ER..:2J*J"GB9 5SGSJGA?0%QI&"[$',1%:22>'Q>$4 M-Y!,F8?J?/#AS#&B,YJFCZSHPYKLA=C(>^1B.BUZF'1-.[#"_R9 M-O%@//PP5*>SL::,^LKH7ANK4WTTG%2Z$:#8X7R,\#\?"C^9W=VIXV]4^HG^ M9:CW]:XZG"IJMSN:#:?Z\(MR/QKH75VK5*6\E41&A^M#';3_SO3I-^5.FWX= M]11]^*!-IG?:<%JIR*D?58K+>7&><)315)LH]^HW]7:@56_.K TP%Q<<([[I M:> "^K32K2QI)P(RTET>2JZ1OW4]1A M#WX.PT@;5AU#W',#&7G?)1/ [02P!WD5[:'JH#GRN$!&@_?'IS#ES99UM3NU MCCE+D-'QPRDZ;AA7JJ'8J8.,2HFRR<: M,BHFZN^D^U7KS0:ADK]I^I>O4ZVGJ ^@[1=-&<[N;K5QF)N^JF- #_[7TP>S MJ?Z@[>Q0E_9BQR RVB9J.*.M.AZKVV(^F8ZZ_P&468@E*"9BGIM2_,7+2E/^ MG'&4(J-'*G2;Z@# F^CT>DS] M>K0O>NHBHVN13J$II\PZF9%1)OG '0/NH)>H QFA0QL9#1)=1;K4M4-P_'&- MC4,.D6=0!JMM204.^*143?1O,35 MC9J%W)=9,& S3%3^[[*MLDS7=HO MC'XAWDV_-U6*0QQAS1_ 1_K0">"EPV2S'EZ BO",A[,^N'XTPZ9?P"K%&T3M M)M6J^"EG;C-=8<[T3%Y76.:B8.V]O>CYW8Q.B5F9Q,(A M7X_(9^E?<\-#<.5_4$L#!!0 ( #IQ#E>.D2BZ9!P #;= 0 5 ;G-T M;2TR,#(S,#8S,%]D968N>&UL[5U;<]NXDG[?JOT/7&_55N;!<10GF4GF9$_1 MLIQ1'5O22'(R>5+1)"1Q0Q$>7GPYOWX!4A=2Q(T2"8 .YR%C20VPN[\F+MV- MQC_^^;3RC <0A"[T/Y]T7K\Y,8!O0\?U%Y]/;B>GYJ3;[Y\8863YCN5!'WP^ M\>')/__W/__#0/_]X[].3XTK%WC.)^,2VJ=]?PY_-P;6"GPRO@ ?!%8$@]^- MKY87XV_@E>N!P.C"U;T'(H!^2!_\R7C_NO/QSC@]%>CW*_ =&-R.^]M^EU%T M'WXZ.WM\?'SMPP?K$08_PMK/^+VW^#\_U?WS"_]Q9 M(3"0OOSPTU/H?C[!SUT_]O'\-0P69V_?O.F<_75S/;&78&6=NC[6FPU.-JUP M+Z1VG8\?/YXEOVY("Y1/=X&W><;YV8:=;<_H5R?:-L@2OS]+?\R2NHRN,TR' M[J0:VE:46 B7(X-*@3^=;LA.\5>GG;>GYYW73Z%SLL$I478 /3 &
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end